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Abstract 
Obstructive lung diseases such as chronic-obstructive-lung-disease (COPD), bronchiectasis, 
and asthma are characterized by airflow obstruction.  They affect over six million Canadians 
costing the economy $12 billion/year.  Despite decades of research, therapies that modify 
obstructive-lung-disease progression and control are lacking because patient diagnosis, 
monitoring, and response to therapy are currently made using airflow measurements that may 
conceal the independent contributions of underlying pathologies.  One goal of obstructive-
lung-disease research is to develop ways to identify patients with specific underlying 
pathological phenotypes to improve patient care and outcomes.  Thoracic computed-
tomography (CT) and magnetic-resonance-imaging (MRI) provide ways to regionally identify 
the underlying pathologies associated with obstructive-lung-disease, and offer quantitative 
biomarkers of obstructive-lung-disease (e.g. lung-density, airway dimensions, ventilation 
abnormalities, and lung microstructure).  As the first step to identify patients with specific 
underlying pathological phenotypes, it is important to understand the physiological and clinical 
consequences of these imaging derived measurements.  Accordingly, our objective was to 
evaluate lung structure and function using multi-nuclear pulmonary MRI in aging and 
obstructive-lung-disease to provide a better understanding of MR-derived biomarkers.  In older 
never-smokers, the majority of subjects had 3He MR ventilation abnormalities that were not 
responsive to bronchodilation.  3He ventilation abnormalities were related to airflow 
obstruction and airways resistance, but not occupational exposure or exercise limitation.  We 
then developed and evaluated ultra-short-echo-time MRI in COPD subjects with and without 
bronchiectasis.  This work demonstrated that ultra-short-echo-time MR-derived measurements 
were reproducible and significantly related to CT tissue-density measurements.  In the COPD 
subjects with bronchiectasis, ultra-short-echo-time signal-intensity was related to airway 
measurements.  In COPD subjects without bronchiectasis, ultra-short-echo-time signal-
intensity was related to the severity of emphysema.  Finally, based on the ultra-short-echo-time 
MR biomarkers developed in patients with COPD and bronchiectasis, patients that share some 
of the airway and inflammatory features common in asthmatics, we produced ultra-short-echo-
time MR measurements in asthma.  These measurements not only provided similar information 
as CT, but also information about regional ventilation deficits.  These results demonstrated that 
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ultra-short-echo-time MR biomarkers may reflect ventilation heterogeneity and/or gas-
trapping in asthma.  These important findings indicate that multi-nuclear pulmonary MRI has 
the potential to quantitatively evaluate the different pathologies of obstructive-lung-disease. 
Keywords 
Aging, Obstructive Lung Disease, Chronic Obstructive Pulmonary Disease, Asthma, 
Bronchiectasis, X-ray Computed Tomography, Magnetic Resonance Imaging, Hyperpolarized 
3He, Hyperpolarized 129Xe, Ultra-short echo time, Pulmonary Imaging, Imaging Biomarkers 
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CHAPTER 1 
1 INTRODUCTION 
Obstructive Lung Diseases are chronic and heterogeneous diseases characterized by the 
obstruction of the airways resulting from inflammatory processes. Chronic obstructive 
pulmonary disease (COPD) and asthma are the most common obstructive lung diseases.  
COPD is characterized by persistent airflow limitation that is usually progressive and 
associated with an enhanced response of the lungs due to noxious particles or gases,1 
whereas asthma is a chronic inflammatory disorder characterized by airway hyper-
responsiveness and inflammation.2  
1.1 The Burden of Obstructive Lung Disease 
According to the World Health Organization’s estimates, 300 million people suffer from 
obstructive lung disease (i.e. chronic obstructive pulmonary disease [COPD]: n=64 
million3 and asthma: n=235 million4).  All respiratory diseases including asthma and 
COPD accounted for the 4th leading cause of death worldwide (Figure 1-1).5  However, 
looking at all diseases individually, COPD was the 3rd leading cause of death worldwide 
(n=3.1 million), behind ischaemic heart disease (n=7.4 million) and stroke (n=6.7 million), 
but just above lower respiratory infections (n=3.0 million).  Unfortunately, asthma also 
accounted for 386,318 deaths.   
 
Figure 1-1 Proportion of deaths due to respiratory disease 
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Above: Number of disease specific deaths. Below: Left-Top five leading causes of death. 
Right-proportion of causes of death due to respiratory diseases: 1) COPD (n= 3,104,330), 
2) Other respiratory diseases (n=551,425), and, 3) Asthma (n=386,318). 
In 2014, Statistics Canada reported that over 3 million people were affected by COPD 
(n=804,043) and asthma (n=2,448,817).6  Obstructive lung disease also accounted for the 
most number of hospitalizations, surpassing the number of hospitalizations due to angina, 
heart failure, and diabetes in 2007 (as shown in Figure 1-2).  Although, COPD accounted 
for the number one reason for hospitalizations (and remained the leading cause of 
emergency department visits in 2014), asthma was the most common cause of 
hospitalizations among children.7-9   
 
Figure 1-2 Repeat Hospitalizations by Condition at First Admission 
This graph shows the number of patients (outside Quebec) with a single hospitalization, 
one repeat hospitalization, and two or more repeat hospitalizations by Ambulatory Care 
Sensitive Condition at first admission. Adapted from the Canadian Institute for Health 
Information’s (CIHI) publication.10 
In Ontario, from the years 2002 to 2011, 722,494 individuals were identified as having 
COPD.  The prevalence rate for COPD in Southwestern Ontario was significantly higher 
than the provincial average of 103 per 1000 population aged 35 years and older.11  In 2015, 
asthma statistics reported by the Ontario Asthma Surveillance Information System, and 
data provided by the Institute for Clinical Evaluative Sciences demonstrated that there were 
about 2 million individuals living with asthma in Ontario.12,13  In terms of healthcare 
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service use, in Southwestern Ontario, from 2003-2013 the average emergency department 
visit rate was greater than 2.4 per 1000 asthma prevalence.14  Evidently, obstructive lung 
disease is a health and economic challenge in Ontario.  To give some perspective, in 2011 
the total projected expenses for the Government of Ontario was $124 billion and the direct 
and indirect costs for COPD and asthma were over $5 billion.15   
Despite these alarming statistics, therapies that modify obstructive lung disease outcomes 
are still lacking and perhaps it is because of our reliance on pulmonary function test 
measurements.1  While these measurements provide a reproducible and easy method to 
evaluate lung function, they can hide the different underlying components of obstructive 
lung disease and do not provide any regional information.  Accordingly, one goal of 
obstructive lung disease research is to develop methods to identify obstructive lung disease 
patients with specific underlying pathological phenotypes with the hope that this will 
improve patient care and outcomes. 
Pulmonary magnetic resonance imaging (MRI), with and without the use of inhaled 
contrast agents, is an emerging technique that not only provides a way to quantify lung 
structure and function in-vivo, but also provides spatial information.  However, before these 
methods can be translated to clinic, a strong understanding of the different MR imaging 
biomarkers is needed, more specifically, their clinical consequences and structural 
determinants.  Equipped with such knowledge, there is potential to use these measurements 
to phenotype patients with obstructive lung disease to better guide and individualize 
therapies.  This thesis focuses on the development and application of novel quantitative 
measurements of lung structure and function derived from hyperpolarized noble gas MRI 
and non-contrast enhanced ultra-short echo time (UTE) MRI.  These measurements were 
evaluated in older never-smokers and subjects with obstructive lung disease (COPD and 
asthma).  In order to validate and understand imaging biomarkers aimed at quantifying lung 
function in obstructive lung disease, imaging measurements must first be understood in 
healthy lung aging.  These measurements can then be extended to evaluate lung function 
in the context of obstructive lung disease, and more specifically, COPD and asthma. 
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In this Chapter, the relevant background knowledge necessary to understand and motivate 
the original research presented in Chapters 2 to 4 will be summarized.  It will begin with a 
general overview of the respiratory system’s structural and functional responsibilities while 
addressing the current understanding of normal lung aging (1.2).  The pathophysiology and 
underlying disease mechanisms of obstructive lung disease (i.e. COPD and asthma) will 
be addressed next (1.3) and followed by the standard clinical measurements of obstructive 
lung disease (1.4).  The benefits and limitations of currently available imaging methods 
will then be discussed with respect to imaging biomarkers and the different 
pathophysiology they probe (1.5).  Novel multi-nuclear MRI methods for pulmonary 
imaging will then be discussed (1.6).  Finally, the specific hypotheses and objectives of 
this thesis will be introduced (1.7). 
1.2 Lung Structure and Function 
The respiratory system is responsible for the exchange of oxygen and carbon dioxide 
between the cells of the body and the external environment.  In humans, the respiratory 
system includes the oral and nasal cavities, two lungs, the conducting airways, the chest 
wall structures, diaphragm, and the central nervous system responsible for controlling the 
muscles of respiration.16  The primary function of this system is to move oxygen from the 
environment into the blood and to move carbon dioxide out of the blood and back into the 
environment.  The oxygen is used for cellular metabolism and the carbon dioxide waste 
that is produced by cellular metabolism is eliminated.  This process is called “gas 
exchange”.16  This section will begin with a discussion on the process by which air moves 
from the environment into our body through the conducting and respiratory zones.   
1.2.1 The Airways: Conducting and Respiratory Zones 
The conducting zone is responsible for leading air from the external environment to the 
exchange surface of the lung.  During inspiration, air enters the upper respiratory tract 
through the oral or nasal cavities and passes through the pharynx, larynx, and then into the 
trachea.   The trachea is a hollow tube held open by cartilage rings and extends down into 
the thorax where it branches into the primary bronchi.17  Each bronchus feeds into the left 
and right lung.  Within the lung, the bronchi continue to divide while progressively 
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decreasing in diameter (Figure 1-3).  Similar to the trachea, the bronchi are supported by 
cartilage. The smallest bronchi branch to become bronchioles, which are small collapsible 
airways with smooth muscle walls.  The bronchioles are histologically different from the 
bronchi because they are not supported by cartilage. 
As shown in Figure 1-3, the last seven generations of the airway tree make up the 
respiratory zone.16  The respiratory zone contains air passages with alveoli which facilitate 
gas exchange.  The bronchioles continue to branch until the respiratory bronchioles form a 
transition between the airways and the exchange epithelium of the lung.  The diameter of 
the bronchioles decreases progressively the further they are from the trachea and 
consequently their number and the total cross section increases.16,17  The respiratory zone 
makes up most of the volume in the lung, accounting for 2.5 to 3 liters at rest. 
The upper airways and bronchi are involved in conditioning the air before it reaches the 
alveoli.  There are three main components to air conditioning:  the air is heated to body 
temperature, water vapour is added to ensure the air reaches 100% humidity, and foreign 
material is filtered out.17  The air entering the human body needs to be heated to body 
temperature (37°C) and moistened to ensure that the core body temperature does not 
change and the cold air does not damage or dry out the alveoli.  The air is heated and 
moistened by the water evaporating from the mucosal lining of the airways.  The trachea 
and bronchi are lined with ciliated epithelium.  A sticky layer of mucus floats over cilia to 
trap particles larger than 2μm.  The cilia beat upward to move mucus toward the pharynx 
and once the mucus reaches the pharynx, it can be expectorated or swallowed.17   
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Figure 1-3 Schematic of the human airways 
Generations 0 to 16 make up the conducting zone and the last 7 make up the respiratory 
zone. The conducting zone is responsible for guiding air into the gas exchanging regions 
of the lung.  The respiratory zone is where gas exchange occurs.  Adapted from West, JB, 
Respiratory Physiology: The Essentials, Ninth Edition.16 
1.2.2 The Alveoli: Site of Gas Exchange 
The alveoli line the respiratory bronchioles, alveolar ducts, and alveolar sacs, thus making 
up the majority of lung tissue.  The average adult lung has 480 million alveoli18 with each 
alveolus being about 1/3mm in diameter.16  Their main function is to exchange gas between 
themselves and the blood via simple diffusion (i.e. from high partial pressure to low partial 
pressure).  Two cells make up the epithelium of the alveoli (Type I: thin alveolar cells to 
allow for gas diffusion, and, Type II: thicker alveolar cells that produce surfactant to aid 
the lungs in expanding).  The walls of the alveoli are thin (approximately 0.2μm)19 without 
any muscle and surrounded by capillaries to ensure rapid gas exchange.  The surface area 
of the alveoli in contact with capillaries is approximately 70m2.
20 
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1.2.3 Ventilation and Diffusion 
Ventilation is the bulk flow exchange of air between the environment and the alveoli.17  
During a normal breath, about 500mL of air is inspired (at a rate of 1L/s) and the volume 
of the thoracic cavity increases while the pressure decreases, thus drawing air in.  The 
mechanism for this is partly due to the diaphragm contracting and descending and the 
intercostal muscles raising the ribs and increasing the cross-sectional area of the thorax.17  
The rate and force of inspiration and expiration depends on the respiratory system 
compliance.  Compliance is the change in volume relative to the change in pressure.  Once 
air reaches the terminal bronchioles, the air is drawn in by bulk flow (i.e. due to a pressure 
gradient).  Finally, when air is in the respiratory bronchioles, the forward velocity of the 
air decreases and the mechanism of ventilation becomes diffusion.   
Expiration is a passive process during quiet breathing.  The average healthy adult exhales 
500mL of air at 15 breaths/min—meaning that each minute 7500mL of air has been 
exhaled.  This is known as total ventilation.16  The amount of air that is inhaled is slightly 
more than what is exhaled because more oxygen is taken in than carbon dioxide is given 
out.  It should also be noted that not all of the 500mL of gas that is inhaled reaches the 
alveoli.  About 150mL of the 500mL of gas that is inhaled comprises “dead space” and is 
the same volume as that of the conducting airways.  The volume of new gas that enters the 
respiratory zone each minute is thus 5250mL and this is called alveolar ventilation.16  
Once air has entered the alveoli from the atmosphere, the gas is transferred across the 
blood-gas barrier by a process called diffusion.  The process of diffusion through tissues 
can be described by Fick’s law: the rate of transfer of gas through a sheet of tissue is 
proportional to the tissue area and the difference in gas partial pressure between the two 
sides, and inversely proportional to the tissue thickness.21   
The pulmonary arteries follow the airways as far as the terminal bronchioles and then 
supply the capillary bed in the walls of the alveoli.  The partial pressure of oxygen (PO2) in 
a red blood cell entering a capillary is normally 40 mmHg and across the blood-gas barrier 
the pressure increases to 100 mmHg.16  Blood takes in oxygen from the alveolar air space 
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provided that the oxygen there is greater than in the blood.  Oxygen then diffuses across 
the alveolar walls into the blood down the concentration gradient.   
1.3 Pathophysiology of Obstructive Lung Disease 
Obstructive lung disease is characterized by persistent airflow limitation.  Increased 
resistance to airflow can be caused by conditions inside the lumen, the airway wall, or the 
peribronchial region (i.e. the region outside the airway).  The airway lumen may be 
partially occluded by excessive secretions (as in chronic bronchitis), acutely due to 
pulmonary edema, or localized due to the inhalation of foreign particles.  The airway wall 
may be contracted due to the airway smooth muscle (as in asthma), or inflamed (as in 
bronchitis and asthma).  There may be hyperinflation due to gas-trapping (i.e. abnormal 
retention of air) caused by mucus plugging of the segmental, subsegmental, and smaller 
conducting airways.  In the peribronchial region, the lung parenchyma may become 
destroyed (i.e. emphysema), the bronchus may become compressed locally by an enlarged 
lymph node, and peribronchial edema could case narrowing.  Before addressing the 
pathophysiology of obstructive lung disease, the physiology of aging will be briefly 
discussed.  
1.3.1 The Aging Lung 
Aging is a progressive phenomenon that occurs in each and every individual.  In order to 
appreciate and recognize obstructive lung disease, it is essential to understand the age-
related changes involving the lung in the absence of disease.  Physiological and 
immunological changes with aging influence the presentation of disease, responses to 
treatment, and possible complications. 
Aging of the lung can be classified into a growth phase, maturation phase, a plateau phase, 
and a decline phase.  The major physiological changes of the aging lung during the decline 
phase are: 1) loss of elastic recoil, 2) decrease of chest wall compliance, 3) change in the 
shape and structure of the lung, and, 4) decrease in respiratory muscle strength.22  
Similar to an elastic band, the lungs experience elastic recoil during inspiration and 
expiration.  Elastic recoil is the rebound of the lungs after being stretched during 
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inspiration.  The lungs have elastic fibers (elastin), collagen, smooth muscle, pulmonary 
blood, and bronchial mucus which all have elastic properties and contribute to elastic 
recoil.  As the lung increases in volume, the elastic recoil also increases.  Although the 
decrease in elastic recoil in the lung is not completely understood, some studies have 
demonstrated that reduced elastic recoil and diffusing capacity of the lung (a measure of 
the transfer of gas from the lungs to the surrounding blood vessels) is a result of stress 
relaxation of elastin-fibers as evidenced by an apparent increase in thickness along with 
the appearance of more loosely associated fibers.23  A disruption in collagen fibers leading 
to an increase in intermolecular crosslinks has also been hypothesized to explain 
diminished elastic recoil with age.24  Currently, there is limited and conflicting evidence to 
support this theory.  
The chest wall also stiffens with age leading to a decrease in chest wall compliance.  This 
is due to structural changes of the lung such as the decalcification of the ribs, calcification 
of the costal cartilage, changes in rib-vertebral articulations, changes in the shape of the 
chest, and narrowing of the intervertebral disk space.25  Other structural changes that 
contribute to decreased chest wall compliance are kyphotic curvature of the spine and 
deformation of the diaphragm leading to a reduction in its force generating capabilities.26  
Taken together, all these structural changes lead to the decreased respiratory system 
compliance which ultimately increase the work of breathing.   
The fine structures of the lung also undergo changes with age.  The degeneration of the 
elastic fibers around the alveolar duct results in airspace enlargement which leads to a 
reduction of airspace wall surface per unit volume of lung tissue.22,27  Reduction in 
supporting tissue results in premature closure of small airways during normal breathing.  
There is also calcification of bronchial cartilage. These changes result in an increase in 
anatomic dead space, gas-trapping, and hyperinflation.28   
Lastly, muscle strength and endurance decrease with age.  The thoracic diaphragm, a sheet 
of internal skeletal muscle extending across the bottom of the thoracic cavity, is the most 
important respiratory muscle and plays a vital role in inspiration.  Maximum inspiratory 
pressure is an index of diaphragm muscle strength and is measured using a mechanical 
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pressure gauge with a closed valve at the mouth during an inspiration.  A decline in this 
measurement is indicative of impaired ventilation and impaired clearance of airway 
secretions.  Studies have demonstrated that maximum inspiratory pressure is higher in men 
than in women and decreases with age.29,30  Reduced maximum inspiratory pressure and 
decreased diaphragm muscle strength may be due to age-related muscle atrophy and 
decrease in fast twitch muscle fibers that are responsible for generating higher peak 
tensions.  The age related changes to the lungs are reflected in clinical measurements of 
lung function which will be discussed in Chapter 1.4. 
1.3.2 Obstructive Lung Disease: Airways Disease in Asthma and COPD 
Airway disease in obstructive lung disease (i.e. asthma and COPD) is characterized by an 
inflammatory process of the airways that can lead to airflow limitation.  Airflow limitation 
is mostly reversible in asthma and is mostly irreversible in COPD.  The natural progression 
of asthma and COPD are different.  Asthma begins in childhood31,32 and has been 
associated with allergic diathesis and environmental factors in modern affluent 
countries.33,34  The onset of COPD is attributed to the total burden of toxic gases and 
particles that a person inhales during his or her lifetime.35,36  The smoking of tobacco 
products is the major risk factor for the development of COPD.37,38   
Asthma 
Asthma is a chronic disease confined to the airways characterized by airway hyper-
responsiveness (i.e. increased responsiveness of the airways to stimuli), airway 
inflammation and narrowing.  Histopathological studies have demonstrated that asthma 
affects the central and peripheral airways.39  This process involves cellular changes 
(infiltration of inflammatory cells such as eosinophils and lymphocytes) and structural 
changes (such as thickened airway walls).  Figure 1-4 shows a bronchiole of a subject who 
died during an asthma attack.  There is a luminal occlusion caused by muscle constriction, 
airway wall thickening, increased smooth muscle mass, and a marked inflammatory 
response in the airway wall which is characterized by eosinophils.40 
Airway inflammation is a multi-cellular process which involves eosinophils, CD4 T-
lymphocytes, and mast cells.  Eosinophils are the most striking cellular feature of asthma.  
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Distribution of eosinophils varies between the small and large airways.  In the small 
airways, most eosinophils are in the outer section of the airway wall (between the smooth 
muscle and the alveolar attachments).  The increased density of eosinophils in the outer 
airway promotes airway constriction by decreasing the tethering forces of the parenchyma 
in the airway wall.  In the larger airways, eosinophils are mostly located in the inner section 
of the airway wall (between the smooth muscle and the basement membrane).41  The 
increased density of eosinophils in the inner airway wall promotes constriction by 
increasing the effect of bronchial smooth muscle shortening. 
The structural changes that accompany asthmatic airways are increased smooth muscle 
mass, mucous gland hypertrophy, and bronchial wall edema.  These all lead to a thickened 
airway wall which contribute to airflow limitation resulting from the increased airways 
resistance. The increase in smooth muscle mass is induced by inflammatory mediators, 
cytokines, and growth factors.  Further enhancing this flow limitation is the increased 
amount of mucous and inflammatory exudate.  They not only block airways, but can 
increase surface tension which can lead to airway closure. The excess production of 
mucous is not only due to the hypertrophy of mucous glands, but also resultant of 
hyperplasia of goblet cells.   
Taken together, these cellular and structural changes of the airways can obstruct airflow in 
the large and small airways, thus affecting ventilation or leading to an abnormal retention 
of air at expiration (i.e. gas-trapping). 
Chronic Obstructive Pulmonary Disease 
In COPD, airways disease can present itself as chronic bronchitis.  This is characterized by 
airway inflammation and excessive mucous production.  The inflammation associated with 
chronic bronchitis is located in the epithelium of the central airways (airways with a 
diameter larger than 4mm) and extends along the gland ducts into the mucous-producing 
glands.42-44  There is hypertrophy of the mucous glands in the large bronchi and chronic 
inflammation in the small airways.  Excessive mucous is found in the airways and can 
obstruct them.  
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The major site of obstruction in COPD is found in the smaller conducting airways (less 
than 2mm in diameter).  The small airways are spread out between the fourth and 14th 
generation of airway branching.  The increase in the number of airways with respect to the 
branching increases their total cross sectional area and decreases their resistance.  In the 
healthy lung, about three quarters of the total airway resistance is from the large airways 
(i.e. diameter greater than 2mm) and the rest is from the small airways.  The airways below 
the larynx account for half of the total resistance measured at the mouth, and the smaller 
conducting airways only account for 10–15% of total airway resistance.  For this reason, 
the smaller conducting airways are the lungs’ silent zone.45  This means that the disease 
may accumulate for many years without being detected. 
The structural and physiological components responsible for the increase in peripheral 
airway (small conducting airway) resistance include: the destruction of alveolar support of 
the peripheral airways,46 loss of elastic recoil in the parenchyma that support the airways,47 
a decrease in the elastic force available to drive flow out of the lung,48 and structural 
narrowing of the airway lumen because of inflammatory processes.49  Figure 1-4 shows a 
representative small airway of a subject with COPD.  The airway is inflamed with a 
thickened wall in which the lumen is partly filled with an inflammatory exudate of mucous 
and cells.  Similar to asthma, these changes can lead to ventilation abnormalities and the 
retention of air, i.e. gas-trapping. 
 
Figure 1-4 Small airway pathology in health, asthma, and COPD 
From left to right: Healthy: normal small airway, Asthma: luminal occlusion resulting from 
muscle constriction, thickening of the airway wall, increased smooth muscle mass, and an 
increased inflammatory process in the airway wall (mainly characterized by eosinophils), 
COPD: inflamed airway with thickened wall in which lumen is partly filled with an 
inflammatory exudate. 
Adapted from Hogg JC, Lancet (2004)43 and Saetta M et al. Eur Respir J (2001).40 
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1.3.3 Obstructive Lung Disease: Emphysema 
Emphysema is defined as “the enlargement of air spaces distal to the terminal bronchiole, 
accompanied by the destruction of their walls and without obvious fibrosis.”50,51  This 
destruction reduces the expiratory flow because of the reduced elastic recoil force available 
to expire the air out of the lung.  Figure 1-5 shows a typical appearance of histology of a 
healthy subject and a subject with emphysema.  The emphysematous lung has loss of 
alveolar walls and the small airways are reduced in number in comparison to the healthy 
subject.  
 
Figure 1-5  Parenchymal pathology in healthy and COPD subject.  
Adapted from Wood et al. 
There are two major types of emphysema: centriacinar and panacinar.  These classifications 
are based on where the destruction occurs in the acinus.  Centriacinar emphysema is more 
prominent in smokers and is confined to the destruction of the central part of the lobule 
and does not affect the peripheral alveolar ducts or alveoli.  It initially affects the upper 
lobes and spreads down the lung as the disease progresses.  Panacinar emphysema affects 
the entire lobule and is more common in the lower lobes.52   
It is interesting to note that only 40% of smokers develop emphysema and only 15% 
develop airflow limitation.43  Smokers who develop emphysema have an increased number 
of macrophages, neutrophils, T-lymphocytes, and eosinophils in their lungs compared to 
those smokers who do not develop emphysema.44,53-55   
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1.4 Clinical Measurements of Lung Function 
There are several methods that can be used to evaluate lung function in patients with 
obstructive lung disease.  Here, two clinically available methods for testing lung function 
are discussed: pulmonary function testing and cardiopulmonary exercise testing (CPET).  
Pulmonary function testing is the first method of choice to evaluate lung function at a 
physician’s clinic.  These measurements are made at the mouth that provide global lung 
function and lung volume measurements.  These tests can be used to evaluate forced 
expiration, lung volumes, diffusion, and airways resistance.  CPET is another method that 
can be used to test exercise responses that involve the respiratory, cardiovascular, skeletal 
muscle, and neuropsychological systems that cannot be adequately reflected by evaluating 
one organ system.  The use of CPET stems from the fact that resting pulmonary and cardiac 
testing cannot reliably predict exercise performance and functional capacity.  Although 
pulmonary function testing is more commonly used clinically, CPET should be considered 
when specific questions remain unanswered. 
1.4.1 Pulmonary Function Testing 
Pulmonary function testing can be divided into spirometry, plethysmography, and single 
breath carbon monoxide diffusing capacity.  Spirometry measures the volume of air that is 
inhaled or exhaled as a function of time.  The primary signal measured using spirometry is 
volume or flow.  Plethysmography allows for the measurement of lung volumes (i.e. the 
volume of air in the lungs). 
Figure 1-6 shows a spirometer which is a mouthpiece attached to a small machine that 
allows for the measurement of volume inhaled or exhaled. The plot beside the spirometer 
is the volume of air inspired as a function of time.  The two most important measurements 
obtained from spirometry are the forced expiratory volume (FEV) and the forced vital 
capacity (FVC). FEV1 is maximum volume of air expired in one second after a full 
inspiration.  FVC is the maximum volume of air that can be expired when the patient 
exhales as forcefully and quickly as possible after a maximum inspiration.56   
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Figure 1-6 Pulmonary Function Testing: Spirometry 
Shown above is a hand held spirometer and a sample airflow curve measured by the 
spirometer.   
 
Figure 1-7 shows a plethysmograph which is an air-tight box that patients sit in to perform 
lung function tests.  The plot shown on the right is an example airflow curve of volume 
inspired as a function of time.  The main measurements obtained using plethysmography 
are: functional residual capacity (FRC), residual volume (RV), tidal volume (VT), 
inspiratory capacity (IC), vital capacity (VC), and total lung capacity (TLC).57  The FRC 
is the volume of air present in the lung at the end of a passive expiration.  The maximum 
volume of gas that can be inspired from FRC is the IC.  RV is the volume of air remaining 
in the lung after a maximum expiration.  The volume of gas displaced between passive and 
inhalation and expiration during the respiratory cycle is the VT.  The VC is the volume 
change at the mouth between the positions of full inspiration and complete expiration.  
Finally, TLC is the volume of gas in the lungs after a maximum inspiration.57 
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Figure 1-7 Pulmonary Function Testing: Plethysmography 
Above: a whole body plethysmograph and a sample airflow curve used to determine lung 
volumes. 
 
The diffusing capacity of the lung for carbon monoxide (DLCO) can also be determined 
using pulmonary function tests and provides an indirect measure of diffusion of gases 
across the alveolar membrane into the blood.58  DLCO is measured when the subject exhales 
to RV and then performs a maximum inhalation to TLC.  The subject inhales a gas mixture 
that contains a very low concentration of carbon monoxide (CO) (0.3%) and helium (10%) 
with air.  The subject then holds his/her breath for 8 seconds before exhalation.  The 
exhaled gas is collected and analyzed.  The gas first exhaled is discarded as it represents 
the anatomic dead space volume and is defined as the product of 2.2ml and the body weight 
in kilograms.  The remaining volume is analyzed by comparing the exhaled concentrations 
of CO and helium to the inspired concentrations to determine the amount of CO diffusing 
across the alveolar membrane.  The capacity of the lung to exchange gas across the 
alveolar-capillary interface is determined by its structural (e.g. lung gas volume, path 
length for diffusion, thickness and area of the alveolar capillary membrane, etc.) and 
functional (e.g. levels of ventilation, composition of the alveolar gas, diffusion 
characteristics of the membrane, the concentration and binding properties of haemoglobin 
in the alveolar capillaries, etc.) properties.  Flow rates, lung volumes, and DLCO are 
expressed as a percent of predicted value (%pred).  These measurements are dependent on 
age, sex, height, and ethnicity.59 
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Aging 
The underlying structural changes that occur in the aging lung lead to changes in lung 
function, including dynamic flow rates, static lung volumes, and alveolar gas exchange 
rates.  The current understanding of lung function decline over age stems from work done 
by Fletcher et al. in 1977. This work showed a continuous decline in FEV1 at a rate of 
roughly 42 ml/year beginning between the ages of 25 and 30 (Figure 1-8).38  FVC has also 
been shown to steadily decrease to approximately 75% of the corresponding peak-value. 
Together, with the age-related changes in FEV1, this results in an overall decrease in the 
FEV1/FVC ratio (approximately 70-75% of peak value) by the age of 70, as FEV1 declines 
more rapidly than FVC. In terms of lung volumes, RV, RV/TLC, and FRC (due to 
increased lung compliance) decrease, while TLC shows no change with age.26,28  The 
increase in RV that occurs with age is likely due to the decreased strength of the expiratory 
muscles and the tendency of the small airways to collapse.  There is also an increase in 
anatomic dead space that occurs during aging and this is thought to be due to calcification 
of the bronchial cartilage.28  Finally, studies have also suggested that there is a decline in 
DLCO with age, corrected for alveolar volume.  The reported decrease in DLCO correlates 
well with the decrease in internal surface area of the lung.60 
It should be noted that although elderly subjects have sufficient lung function for their 
normal day-to-day lives,61 these age-related changes increase the risk of breathlessness and 
respiratory failure when compromised.  And although the changes associated with aging 
are histologically different from COPD-related changes to the lung parenchyma, they result 
in similar changes in lung compliance and function.  A consequence of the reduction in 
supporting tissues (as mentioned above) around the airways is the tendency of the smaller 
airways to collapse. 
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Figure 1-8  Pulmonary function decline in aging in health and disease. 
Plot of FEV1 over time in non-smokers and smokers not susceptible to smoke and smokers 
that are susceptible to effects of smoking (with the risk of smokers developing airflow 
obstruction being 25%62). Adapted from Fletcher et al.38 
Obstructive Lung Disease 
Most of the pulmonary function features of obstructive lung disease stem from the 
pathologic features discussed above.  In asthma, especially during a lung attack, 
measurements of expiratory flow are reduced (i.e. FEV1 and FEV1/FVC).  The FVC is also 
reduced because the airways prematurely close during forced expiration.  Static lung 
volumes are also increased (such as FRC and TLC) during asthma attacks.  The increase 
in RV is caused by premature airway closure during a full expiration which can be a result 
of increased smooth muscle, edema, or inflammation of airways.  This may be indicative 
of gas-trapping.  In COPD, FEV1, FVC, and FEV1/FVC are all reduced.  These 
measurements reflect airway obstruction, whether it is caused by excessive mucous in the 
lumen, thickening of the airway wall by inflammation, or by the loss of radial traction.  
FVC is reduced because the airways close prematurely during expiration at an abnormally 
high lung volume and this can also increase RV.  In patients with emphysema, TLC, 
RV/TLC, and FRC are also increased resulting from the loss of elastic recoil.  A decrease 
in IC can be indicative of hyperinflation.  A decline in DLCO is measured in patients with 
COPD, reflective of the loss in alveolar surface area.63  
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Pulmonary function test measurements remain the gold standard for the diagnosis and 
monitoring treatment of obstructive lung disease.  These measurements evaluate the lung 
on a global basis and lack the ability to detect functional changes in the distal lung.45  These 
measurements are also dependent on patient effort.56 
1.4.2 Cardiopulmonary Exercise Testing 
Cardiopulmonary exercise testing (CPET) is used to evaluate a combination of exercise 
responses involving multiple body systems (i.e. respiratory, cardiovascular, 
neuropsychological, and skeletal muscle systems).  CPET allows for the evaluation of 
submaximal and peak exercise responses while providing an objective measurement of 
functional capacity and impairment.64  Studies have shown that measurements of exercise 
intolerance, functional capacity and impairment65 correlate better with overall health status 
than resting lung function measurements.64  CPET can be performed using two methods 
involving either a treadmill or a cycle ergometer.  In addition to measuring respiratory gas 
exchange (e.g. respiratory exchange ratio [RER]), oxygen uptake (VO2), carbon dioxide 
output (VCO2), minute ventilation (VE), heart rate, and blood pressure can also be 
evaluated.  Two different types of gas analyzers can be used to determine the O2 and CO2 
concentrations: a mass spectrometer (this is considered the “gold standard”) which 
analyzes all gases (CO2, O2, N2), and separate mass spectroscopy analyzers for CO2 and 
O2.  Exercise testing in patients with obstructive lung disease is clinically useful in relating 
symptoms to exercise limitation, especially when exertional symptoms are 
disproportionate to resting pulmonary function test measurements. 
1.5 Imaging Measurements of Lung Structure and Function 
While pulmonary function testing and CPET measurements provide global measurements 
of lung function, they do not expose underlying pathologies of lung disease, have been 
shown to be poor predictors of mortality66 and are insensitive to disease onset, progression, 
and treatment response.67  These limitations have motivated researchers to investigate 
methods that provide biomarkers sensitive to regional structural and functional changes, 
and sensitive to the heterogeneity of lung disease.  Thoracic imaging is a potential method 
that allows for the regional evaluation of obstructive lung disease and provides quantitative 
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measurements of lung disease.  Thus far, imaging methods such as chest x-ray, thoracic 
computed tomography (CT), single photon emission computed tomography (SPECT), and 
positron emission tomography (PET), have played a role in the visualization of pulmonary 
structure and function in obstructive lung disease and will be discussed in this section.  
1.5.1 Chest X-ray  
The discovery of x-rays was made in 1895 by a German physicist, Wilhelm Rӧntgen.  
Today, x-rays are widely used in for diagnostics because of the short acquisition time, low 
cost, and low radiation dose.  A typical dose associated with a chest radiograph is 
approximately 0.01mSv68 which is less than a percent of the annual background radiation 
(2-3mSv/year).68  Radiographs (or x-ray images) are shadows created when all or part of a 
beam of x-rays are attenuated by part of the body.  The x-rays that are not absorbed by the 
body are absorbed by a detector and this results in a projection of the objects in the path of 
the x-ray beam.  Essentially, the resulting image is an overlap or superposition of all 
structures in the path of the x-ray leading to a loss of depth information.   
Image contrast is thus dependent on the mass attenuation coefficient of the tissue which 
varies with photon energy, atomic number, and mass density of the absorbing material.  
Thus, a bony structure, is highly attenuating (i.e. absorbs many x-rays) and appears white 
on an x-ray image.  On the other hand, a low attenuating structure, such as the lung, absorbs 
fewer x-rays and thus appears black on a radiograph.  Figure 1-9 shows a chest radiograph 
of a healthy volunteer.  The lungs appear dark and the ribs, scapula, and spine appear white, 
which is consistent with the notion that bony structures attenuate x-rays more than soft 
tissues such as the lung. 
Radiographic abnormalities in patients with obstructive lung disease have previously been 
studied.  In asthma, the most common radiographic findings include: hyperinflation and 
abnormalities of the airways.69,70  On a frontal radiograph, similar to what is shown in 
Figure 1-9, hyperinflation is seen as an increase in the length of the lung, a depression of 
the diaphragm, and a decrease in the transverse cardiac diameter.  Airway abnormalities of 
the large airways are also visible on a frontal radiograph, more specifically, bronchial wall 
thickening.  In patients with emphysema, a chest radiograph is mostly useful at detecting 
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moderate-to-severe emphysema.52  The key features on a radiograph in a patient with 
emphysema are hyperinflation and abnormalities of the small vessels.71  The radiographic 
signs of hyperinflation in emphysema (Figure 1-9) are no different than what is observed 
in asthma (i.e. elongated lung, depressed diaphragm, and change in the cardiac silhouette).  
Radiographic findings in asthma, such as bronchial wall thickening have been shown to be 
signs of an asthmatic exacerbation.72,73  Bronchial wall thickening in asthma has also been 
qualitatively evaluated in asthma using chest radiographs and compared with healthy 
controls.74  This work has demonstrated that wall thickening measured using chest x-rays 
is greater in asthmatics than in healthy volunteers.74  In patients with COPD, as stated 
before, only moderate-to-severe emphysema is detectable on radiographs.  The limited 
work that has been done in COPD using planar x-rays, has demonstrated that emphysema 
severity (evaluated using chest x-rays) is related to pulmonary function test 
measurements.75   
 
Figure 1-9 Representative posterior-anterior chest radiograph of a healthy volunteer, an 
asthmatic subject, and subject with COPD. 
In asthma, the lungs appear hyperlucent, the diaphragm is flattened indicative of 
hyperinflation, and more than six anterior ribs are in the mid-clavicular line at the lung 
diaphragm level.  In COPD, the lungs are hyperinflated (consistent with a flat diaphragm 
and secondary to emphysema), the retrosternal airspace is enlarged, and the pulmonary 
arteries are protruding (consistent with pulmonary hypertension). 
Healthy case courtesy of Dr. Frank Gaillard, Radiopaedia.org, rID: 8090.  Asthma case 
courtesy of Dr. Ian Bickle, Radiopaedia.org, rID: 33470. COPD case courtesy of Dr. Mai-
Lan Ho, Radiopaedia.org, rID: 6452. 
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1.5.2 X-ray Computed Tomography 
The limitations of a planar chest x-ray, including the loss of depth information and poor 
contrast, for the evaluation of obstructive lung disease has been recognized for some while.  
In the 1970s, radiography (the science of medical x-ray images) was revolutionized with 
the introduction of x-ray CT.  Over the past few years, CT has become the imaging 
modality of choice for the lung because it provides subtle differences in lung parenchymal 
density and eliminates the anatomical superposition present in chest x-rays.76,77  
Furthermore, high resolution CT allows for the assessment of emphysema and airways 
disease using quantitative indices.78   
During a CT scan, a series of x-ray projections are collected from different regions of the 
body.  These projections are created by an x-ray source which is detected by a series of 
detectors that lie opposite to one another.  Each voxel in a CT image represents a relative 
measurement of tissue density based on the attenuation coefficient of water: 
Equation 1-1 
𝐻𝑜𝑢𝑛𝑠𝑓𝑖𝑒𝑙𝑑 𝑈𝑛𝑖𝑡 = (
𝜇𝑡𝑖𝑠𝑠𝑢𝑒 − 𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟
) 1000 [𝐻𝑈] 
where μwater and μtissue  are the linear attenuation coefficients of water and tissue, respectively. 
The Hounsfield Unit (HU) scale is a standard scale that represents densities within the 
tissue being scanned.  The scale is based off of water which has a Hounsfield value of 0HU.  
Tissues or substances with higher densities have higher Hounsfield numbers compared to 
those with lower densities.  A soft tissue such as the liver would have a Hounsfield value 
between 30-50HU, blood around 80HU, and bone around 1500-4000HU.79  A tissue with 
low density such as the lung would have a Hounsfield value between -1000HU to -525HU.  
The dose associated with a typical chest CT is approximately 7-8mSv.80  Depending on 
where an individual lives, this is equivalent to about 4 years of natural background radiation 
or 400 chest x-rays.  It should be noted, low dose and ultra-low-dose CT acquisitions81 are 
becoming achievable with new image reconstruction techniques where doses on the order 
of 0.1mSv have been observed.  These methods have yet to be implemented in clinic.82  
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Airway Disease 
Airway disease in patients with obstructive lung disease presents with varying diagnoses 
and symptoms as discussed above.  The key features of airways disease seen on CT include: 
mosaic attenuation patterns, mucous plugging, atelectasis, bronchiectasis, and bronchial 
wall thickening.  The small airways (diameter less than 2mm) cannot be directly evaluated 
using CT because of spatial resolution limitations.  As a result the small airways, as shown 
in Figure 1-10, in obstructive lung disease are reflected by gas-trapping, more specifically 
the mosaic attenuation pattern.  A typical mosaic pattern results when the distribution of 
these areas of decreased attenuation is patchy, which is often the case in gas-trapping, and 
when the surrounding normal lung areas show increased lung density resulting from 
compensatory hyper-perfusion.  Gas-trapping is best visualized on expiratory CT.  The 
extent of gas-trapping can be estimated using computerized and automated analysis.  In 
this analysis the CT density histogram of all Hounsfield unit values is evaluated using a 
number of HU threshold to generate the relative area of the lung occupied by attenuation 
values lower than specific threshold (e.g. relative area under -856HU [RA856] at full 
expiration to evaluate gas-trapping83).  
Large airway abnormalities, such as bronchiectasis and bronchial wall thickening, are 
frequent findings in patients with obstructive lung disease.  Bronchiectasis is reflected by 
bronchial dilation where the diameter of the bronchus is approximately 1.5 times greater 
than the corresponding artery.  In Figure 1-10, the yellow arrows in the axial slice indicate 
cylindrical bronchiectasis, whereas the arrows in the coronal view show a signet ring and 
varicose bronchiectasis.  Bronchial wall thickening appears like a donut, where the edge of 
the airway wall is thicker and the centre contains air.   
Airway dimensions can be quantified using CT and this is helpful in obstructive lung 
disease to provide an understanding of bronchial inflammation and remodeling.  Currently, 
there is software available (e.g. Pulmonary Workstation V.2.0 [VIDA Diagnostics, 
Coralville, Iowa, USA]) for the reconstruction of airways from volumetric datasets.  These 
software allow for the quantification of luminal diameter and wall thickness to the fifth-
sixth airway generation.  Indices for evaluating airway dimensions include: bronchial 
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luminal area (LA), bronchial wall thickness and area (or percent, where the wall area in 
normalized to the outer wall area [WA%]), and total bronchial area.   
In patients with asthma, CT bronchial wall thickness measurements are greater than healthy 
controls84 and have been shown to be associated with airflow obstruction.85,86  Decreased 
lung density has been shown to be related to pulmonary function test measurements of gas-
trapping (e.g. RV) and airflow obstruction (e.g. FEV1).
87,88  Furthermore, CT 
measurements of gas-trapping have been shown to be associated with increased number of 
asthma related hospitalizations and intensive care unit visits.83   
Airway wall measurements in patients with COPD have been associated with histology,89 
frequency of exacerbation,90 and dyspnea.91  Wall area measurements have also been 
shown to be correlated with the FEV1/FVC, and RV/TLC, but not DLCO.
92  COPD patients 
with a clinical diagnosis of chronic bronchitis have also been shown to have thicker airway 
walls (measured using CT) than those without chronic bronchitis.93  Recent work showed 
that quantitative CT measures of airway thickness in COPD patients were greater in those 
with bronchodilator responsiveness.94      
 
Figure 1-10  Axial and coronal x-ray CT images of representative subjects.  
Subjects shown in health, with small airways disease, and large airways disease. 
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Emphysema 
The evaluation of emphysema using CT has been done for the past three decades.  The 
earliest studies evaluating emphysema noted the key feature of emphysema was the 
decrease of lung density.95  Other radiological signs of emphysema include focal areas of 
low attenuation, no definable wall, upper zone predominance, no obvious fibrosis, vascular 
pruning and distortion, and bullae.96   
The CT image is essentially a densitometric map of the lung, where each pixel corresponds 
to a Hounsfield Unit value representing tissue density.  The evaluation of emphysema has 
evolved from visual scoring systems which are subject to high inter- and intra-user 
variability97 to less biased quantitative methods.  Emphysema can now be estimated using 
computerized and automated analysis.  In this analysis the CT density histogram of all 
Hounsfield unit values is evaluated using a number of HU threshold to generate the relative 
area of the lung occupied by attenuation values lower than specific threshold (Figure 1-
11) and percentiles (e.g. relative area under -950HU [RA950] or the lowest 15
th percentile 
[HU15] at inspiration to evaluate emphysema).  These values have been shown to correlate 
well with manual radiologists' emphysema scores,98 pulmonary function test 
measurements,99 and with histology.100  Limitations with single threshold methods include 
the over or under-estimation of emphysema, where a lower threshold differentiates more 
severe emphysematous regions101 disregarding regions with mild tissue destruction and a 
higher threshold identifies mild emphysematous regions.102  Consequently, methods that 
diverge from single threshold measurements have emerged.  An example of this is an 
automated evaluation of the CT density histogram using principal component analysis that 
has been used to generate a principal component score based on each frequency–HU pair.  
This measurement was strongly related to pulmonary function tests and expert radiologist 
emphysema scores.103  
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Figure 1-11 Representative CT images and corresponding frequency distribution of 
radiodensity shown below for healthy and emphysematous lungs.   
The regions below -950HU are shown in yellow. 
Another commonly used measurement of emphysema is the percentage of lower 
attenuation areas (LAA%).  The LAA% expresses the emphysema volume as a proportion 
of total lung volume measured by CT and has been shown to be associated with pulmonary 
function test measurements,104 frequency of COPD exacerbations,90 and quality of life 
scores.105   
It should be noted that the use of CT for pulmonary applications, especially for serial and/or 
longitudinal studies or pediatric applications, is limited due to the potential risks related to 
radiation doses stemming from the ionizing x-ray radiation (the radiation that displaces 
electrons from atoms or molecules and produces ions).106  However, thoracic x-ray CT 
provides a wealth of structural pulmonary information, where each voxel in the resulting 
CT image provides a physical unit of tissue density.  
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1.5.3 Nuclear Medicine 
In comparison to CT imaging methods that are based on the relative absorbance of x-rays, 
nuclear medicine techniques utilise tracers that emit radiation.  These methods involve 
intravenous injection of radioisotopes to the pulmonary vasculature or inhalation to the 
peripheral airspaces, thus giving functional images of ventilation and perfusion. 
Single Photon Emission Computed Tomography 
Three-dimensional SPECT has been clinically available for 30 years, having mainly been 
used for myocardium, brain, and liver imaging.  The technique has also been applied in 
lung scintigraphy, especially for the assessment of pulmonary embolisms.  SPECT 
radioisotopes emit a single gamma beam as they decay.  Every point on the gamma camera 
image corresponds to an entire line within the person being imaged.  These projections can 
be reassembled to provide three-dimensional information about the distribution of 
radionuclides within the body.  For pulmonary imaging, SPECT has been used to provide 
information about pulmonary physiology, i.e. ventilation and perfusion.  Perfusion 
scanning is typically performed using 99m-technecium labelled macro-aggregated albumin 
(99mTc-MAA), which lodges in the pulmonary circulation after peripheral injection.  
Ventilation scanning requires the inhalation of gaseous radioisotopes (e.g. 81mKr and 133Xe) 
and the gas distributes throughout the whole lung, and the differences in its regional 
distribution reflect differences in regional ventilation.  These isotopes have been used to 
produce both perfusion107 and ventilation108,109 maps in subjects with obstructive lung 
disease.  These studies have quantified perfusion defects and ventilation defects as the 
extent that is not perfused or ventilated, respectively.  
In patients with asthma, the disease heterogeneity has been established using SPECT 
imaging.110  Changes in regional perfusion and ventilation during 
bronchoconstriction,111,112 bronchodilation,113 exercise,114 antigen challenge,115 and 
histamine inhalation116 have been evaluated in asthmatics using 99mTc-MAA and 81mKr.  In 
patients with COPD, previous work has investigated the effects of baseline lobar perfusion 
on outcomes following endobronchial valve placement.107  This study demonstrated that 
pulmonary function test measurements did not change pre- and post-endobronchial valve 
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placement.  However, the patients with high baseline perfusion had significant shifts in 
perfusion with endobronchial valve placement, in comparison to patients with low baseline 
perfusion.    Although SPECT has been used to assess the severity of airflow limitation in 
subjects with COPD,117,118 intrabullous ventilation in patients with emphysema,119 and 
ventilation-perfusion mismatch in COPD subjects,120,121 it is limited by the risk of 
cumulative radiation exposure for longitudinal monitoring and offers poor spatial 
resolution.  As a result so far there have been no published studies using SPECT to assess 
treatment responses aimed at improving ventilation patterns in asthma or COPD. 
Positron Emission Tomography  
PET utilises radioisotopes that emit positrons as they decay through the process of beta 
decay.  As the positron is ejected from the nucleus and encounters an electron, these 
particles annihilate resulting in two photons emitted at approximately 180 degrees.  These 
photons are detected at or very near the same time and are considered to be “coincident” 
and the location of the source particle can therefore be determined geometrically from the 
coincident beams—being located on the straight line between the two detectors.  Flourine-
18 (18F) is the most commonly used radioisotope in PET and when it is bound to 
fluorodeoxyglucose (FDG) it can be taken up by metabolically active tissue.  In COPD, 
18F-FDG has been used to assess inflammation.  Studies have highlighted the challenges 
of quantifying inflammation given the variability of lung density in diseased patients.122  
For example, visually, a patient with emphysema would unlikely show an increased signal 
even when there is a high degree of inflammation, simply because there is so little tissue 
in each image voxel.  However, the finding that COPD patients have greater 18F-FDG 
uptake than healthy controls,122,123 paves the road for future work that may assess treatment 
response with 18F-FDG uptake as an endpoint.  Regional ventilation has also been assessed 
using PET by using the 13N isotope.124  This marker is injected and enters the lung via 
pulmonary arterial circulation.  Due to its low tissue solubility, the 13N diffuses across the 
alveolar membrane and allows for the measurement of ventilation and perfusion.  As such, 
unventilated lung regions, termed ventilation defects, retain the tracer due to gas-trapping 
whereas the tracer is quickly washed out of ventilated lung regions.  
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In patients with asthma, 18F-FDG PET has been used to evaluate inflammation125 and 13N 
PET has been used to evaluate bronchoconstriction.126 Studies have evaluated perfusion 
and ventilation using 13N PET as a vascular biomarker in COPD, demonstrating that 
perfusion is significantly heterogeneous in COPD patients compared to healthy 
volunteers127 and this may suggest that regional changes in pulmonary blood flow may 
precede lung parenchymal changes in COPD.  Ventilation-perfusion ratios have also been 
assessed in COPD patients, where emphysema dominant COPD patients had higher 
ventilation-perfusion ratios compared to COPD patients with airways disease.128 
PET has evolved over the years to allow for the measurement of ventilation and perfusion 
in patients with lung disease.  However, the limitations that accompany PET include the 
need for a cyclotron for the production of isotopes, for short term repeated studies time is 
required for the radioisotope to decay enough to avoid signal contamination, cumulative 
radiation exposure limits longitudinal monitoring of patients, and low spatial resolution 
(due to physical effects) does not allow imaging of individual gas exchange units. 
1.6 Pulmonary Magnetic Resonance Imaging 
Unlike x-ray and nuclear imaging methods, magnetic resonance imaging (MRI) uses 
radiofrequency (RF) waves to manipulate nuclear spins (typically of hydrogen atoms) to 
generate images. The MRI signal is generated from the protons in water molecules and 
unfortunately, the lung contains only 800g of tissue which is distributed over 4-6L.129  The 
resulting signal-intensity of the lung is low compared to the rest of the body. Although 
pulmonary MRI remains clinically challenging due to the unique characteristics of lung 
tissue, in the last several decades, MRI using hyperpolarized noble gases and conventional 
methods has revolutionized the field of pulmonary imaging.  There have been a series of 
new technologies developed to qualitatively and quantitatively evaluate lung 
abnormalities.  These techniques provide unique biomarkers and insights into the 
pathophysiology of obstructive pulmonary diseases.  Before these biomarkers can be used 
in clinic, their structural determinants and clinical consequences must first be better 
understood. 
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1.6.1 Inhaled Noble Gas Magnetic Resonance Imaging 
The development of inhaled gas contrast MRI has allowed for the visualization of lung 
function and structure.  The first lung ventilation images acquired using hyperpolarized 
129Xe were captured in 1994.130  Shortly after the first lung ventilation images were 
acquired using 129Xe MRI, the field shifted towards hyperpolarized 3He.  The main reason 
for this stems from the inherent properties of these two gases.  The gyromagnetic ratio of 
129Xe (𝞬=-11.8MHz/T) is three times smaller than that of 3He (𝞬=-32.3MHz/T) and the 
achievable polarization of 129Xe is lower (129Xe: 8-25%; 3He: 30-40%)131—which 
consequently leads to a lower signal-to-noise ratio.  With improvements in hardware, 
however, similar signal-to-noise ratio is becoming more attainable.132   
Unlike clinically available MR methods, hyperpolarized inhaled gas MRI requires 
specialized equipment and personnel to prepare and image the gas.  This is because both 
129Xe and 3He have low spin density in the gaseous state.  The spin densities of these gases 
are typically about four orders of magnitude less than the density of protons in water.133  
Since MR signal is determined by the difference in the number of spins aligned in either 
direction, the most ideal case to produce signal would involve spins being aligned 
completely in one direction (i.e. 100% polarized).   In practice, not all spins will align in 
one direction and this is determined by the Boltzmann distribution, therefore, there is a 
reduction in the polarization which is proportional to the signal.  The polarization of dilute 
gases like 3He and 129Xe is not sufficient for imaging and results in a very low signal for 
in-vivo imaging.  Angular momentum can be added to the system to align all nuclear spins 
in one direction and overcome the lack of polarization.   
Classically, hyperpolarization involves the addition of angular momentum to the system.  
Optical pumping and spin exchange are typically used to polarize the gas.  A circularly 
polarized laser serves as the carrier of the angular momentum.  This laser (where the 
wavelength of laser photons matches the electronic orbital transmission of the alkali atom) 
is used to excite the electrons of an alkali metal (e.g. rubidium).  The angular momentum 
that the electrons obtain from the laser is transferred to the noble gas nuclei through 
collisions.  Once there is enough rubidium vapour (at temperatures >>40°C which is the 
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melting point of rubidium) for the gas to interact with, the temperature has a minimal effect 
on the spin exchange.  It should be noted, that the pressure is well controlled in this system.  
This method increases the nuclear polarization of the unpaired nuclear proton in these 
atoms up to five orders of magnitude compared to thermal polarization.134  This increase 
in polarization is needed to compensate for the low density of noble gas nuclei within the 
lung (compared to the protons from the lung tissue) and provides ventilation images with 
resolution on the order of millimetres.  The polarization for 3He and 129Xe lasts up to days 
if there are no external sources of relaxation (such as oxygen, magnetic field gradients, and 
surface-to-volume relaxation).131 
Ventilation Imaging 
Hyperpolarized noble gas MRI using 3He and 129Xe provides a method to visualize those 
regions of the lung that are ventilated and those that are not.  This type of imaging is based 
on the spin density of the hyperpolarized gas.  In a healthy young subject, as shown in cyan 
in Figure 1-12, the hyperpolarized gas is distributed homogeneously in the lung.  In older 
never-smokers or patients with obstructive lung disease (Figure 1-12), the distribution of 
the hyperpolarized gas is more heterogeneous.  There are apparent regions of signal void 
known as ventilation defects.  These regions of signal void can be quantified as the 
ventilation defect percent (VDP) by normalizing the ventilation defect volume (VDV) to 
the thoracic cavity volume (TCV).135  The imaging biomarker, VDP, has been shown to be 
reproducible,136 related to lung function,137 and sensitive to disease severity and treatment 
response.138,139 
 
Figure 1-12 Representative coronal centre slice of healthy young and older never-smokers 
and patients with OLD.  
 32 
 
Hyperpolarized 3He MRI gas distribution (in cyan) registered to the 1H MRI of the thorax 
(in grey-scale). Unlike the representative healthy young never-smoker, the older never-
smoker and obstructive lung disease subjects have visually obvious ventilation defects. 
Studies using ventilation MR imaging have revealed that COPD and asthma are regionally 
heterogeneous diseases140,141 and that there are significant ventilation improvements post-
therapy even in the absence of pulmonary function test measurement improvements.138  As 
can be seen in Figure 1-12, the distribution of ventilation defects varies for those subjects 
who are older never-smokers or have asthma or COPD.  Although the aged subject and 
subjects with obstructive lung disease have ventilation defects, they are distributed in 
different patterns.  This suggests that there are different looks to ventilation patterns in 
obstructive lung disease patients and this information could potentially be used for 
phenotyping.  But before these biomarkers can be used for phenotyping, as stated before, 
their structural determinants and clinical consequences need to be better understood. 
In order to better understand the clinical consequences of this imaging biomarker in 
patients with obstructive lung disease, studies have evaluated aging,142 asthma,139,143-145 
and patients with COPD.138,140,146  Ventilation defects have been shown to correlate with 
age.142  The clinical consequences of ventilation defects in aging have yet to be determined.  
In asthma, ventilation defects have been shown to be related to worse airflow obstruction, 
greater airways resistance, and airway inflammation.145  Ventilation defects in severe 
asthmatics have also been reported to be related to asthma control.147  In COPD, ventilation 
defects have been shown to represent a mixed airways disease-emphysema phenotype148 
and have been shown to be correlated with COPD exacerbations.146  
Collectively, these studies suggest that in obstructive lung disease the biomarker VDP is 
related to airways disease and emphysema, these defects are heterogeneously distributed, 
and are responsive to therapy.  Hyperpolarized noble gas MRI for evaluating lung 
ventilation has thus become an accepted tool for visualizing lung function.  With the 
increased costs related to noble gas ventilation MR imaging, the field’s future transition 
appears to be geared towards non-contrast enhanced MR methods, such as proton MRI.  
However, obstructive lung disease has yet to be evaluated using these more clinically 
available approaches.  Although it can be hypothesized that the knowledge gained from 
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pulmonary non-contrast enhanced MRI studies will be complementary, direct comparisons 
with noble gas MRI are required. 
Diffusion Weighted Imaging 
In addition to the visualization of gas distribution, there is the potential to evaluate lung 
microstructure using hyperpolarized noble gas MRI.  3He is a highly diffusive gas due to 
its low atomic weight (self-diffusion coefficient of 2cm2/s at 37°C).131  The diffusion 
coefficient can be measured using diffusion-weighted MR methods that are sensitive to the 
gas’ self-diffusion based on the random Brownian motion of the atoms, as opposed to 
transmembrane gas diffusion.  The 3He apparent diffusion coefficient (ADC) reflects 
diffusion of the gas when restricted by the airways and airspaces.  129Xe also provides 
measurements of lung structure, but 3He ADC measurements have been more extensively 
reported.  An increased ADC value reflects a greater mean square displacement of the gas 
molecule which is consistent with an increased measure of lung microstructure.   
In healthy volunteers, diffusion weighted 3He MRI has been used to demonstrate that 
structural changes occur with an annual increase in ADC of 0.0015cm2/s for subjects 
between the ages of 20 and 70 years.149  The limited work that has used 3He ADC to 
evaluate asthma has revealed to be inconsistent.  Some work has shown that 3He ADC 
values are elevated in asthma (suggesting gas-trapping),150 while others have reported no 
differences in ADC values between asthmatics and healthy volunteers.151,152  In terms of 
evaluating treatment response, 3He ADC values are elevated after bronchoconstriction 
(suggesting gas-trapping) and decreased following the administration of a 
bronchodilator.153  In patients with COPD, 3He and 129Xe ADC values are elevated 
compared to age matched healthy volunteers.154  Previous work has revealed the 
association of 3He ADC measurements with pulmonary function test measurements,155 
histology,156 age,149 smoking history,149 and gas-trapping.148  3He ADC has also been 
evaluated pre- and post-bronchodilator administration and the newly ventilated regions of 
the lung did not have elevated ADC compared to the regions participating in ventilation 
before bronchodilator administration.157  
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Hyperpolarized noble gas MRI has yet to find wide-ranging acceptance in the clinic. 
Advances in CT, limited availability of the necessary hardware for polarizing and imaging 
hyperpolarized noble gases, and the identification of clinical applications that will benefit 
from this have made clinical translation difficult.  With this, there has been growing 
motivation for the development and implementation of non-contrast enhanced pulmonary 
MRI to overcome the challenges of ionization radiation and resource accessibility. 
1.6.2 Non-Contrast Enhanced 1H Magnetic Resonance Imaging 
As mentioned above, the lung is more challenging to image using conventional proton (1H) 
MR pulse sequences than MRI of most other organs due the combined effects of low proton 
density, magnetic susceptibility, and to a lesser extent because of the effects of cardiac and 
respiratory motion.158,159  Because the alveolar ducts and sacs make up most of the lung 
volume and are air-filled, there is very little lung tissue and consequently the mass density 
of the lung is lower than any other organ in the body, and is approximately 0.15g/mL.159  
Since MR signal is proportional to the proton density of the tissue, the resulting signal from 
the lung is much lower than all other body tissues.   
The lung parenchyma also has a short transverse magnetization relaxation time (arising 
from natural interactions at the atomic or molecular levels), known as T2.  This is the time 
it takes the excited protons to lose phase coherence due to the interaction between spins 
resulting in a reduction in transverse magnetization.  The decay of the MR signal due to T2 
is because of the natural interactions of spins at the atomic and molecular levels within the 
tissue.  The resulting T2* at 3T, which is the sum of T2 and the relaxation due to the field 
inhomogeneities across a voxel (γΔB0), of the lung is also short (i.e. 0.4-0.9ms):160,161   
Equation 1-2 
1
𝑇2 ∗
=
1
𝑇2
+ 𝛥𝐵0𝛾 
Taken together, these MR properties of the lung result in a much faster MR signal decay 
for the lung parenchyma in comparison to other tissues.  In addition to the short T2, another 
problem for MRI of the lung relates to the fact that air and tissue have very different 
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magnetic susceptibilities.  The adult human lung is composed of approximately 480 million 
alveoli and it is the co-distribution of airspaces/tissue/gas/blood that leads to local magnetic 
field inhomogeneities158,159 that are problematic for high spatial resolution MRI.  The 
differences in the magnetic susceptibilities between different materials (i.e. air and alveolar 
wall tissue) lead to variations in the local magnetic field and this leads to faster spin 
dephasing (i.e. shorter T2*).  With an increased voxel size, there is a greater number of air-
tissue interfaces and this may result in a greater T2* decay.  A larger voxel size is also 
susceptible to the main magnetic field inhomogeneities.  Furthermore, since the local 
magnetic field determines the angular speed of magnetic spin rotation, the magnetic field 
inhomogeneity at the interface causes the spins to precess at different angular velocities 
and this leads to an increased dephasing of the measureable magnetization.  The dephasing 
effect leads to a signal loss or field inhomogeneity artifacts which further degrade the 1H 
signal and distort the image.  Consequently, as shown in Figure 1-13, the lungs appear as 
black holes with no information that can be obtained about lung structure.  Furthermore, 
the lungs of health and disease in these cases are indistinguishable.  
 
Figure 1-13 Representative coronal centre slice of healthy young never-smoker and 
patients with obstructive lung disease.  
Due to low 1H and tissue density within the lung there is no signal inside the lung and thus 
structural abnormalities are not visually apparent. Coronal 1H MRI acquired using the 
whole-body RF coil and 1H fast-spoiled, gradient-recalled echo sequence using a partial 
echo (16s total data acquisition, repetition time (TR)/echo time (TE)/flip angle = 
4.7ms/1.2ms/30°, field-of-view (FOV)=40×40cm, bandwidth=24.4 kHz, matrix=128×80, 
15-17 slices, 15mm slice thickness, 0 gap). 
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Making this situation even more complex is the respiratory motion that occurs during tidal 
breathing because the change in lung volume causes blurring of pulmonary structures.  To 
overcome this limitation, the lung can be imaged under rapid breath hold conditions or 
using prospective or retrospective respiratory gating.  The periodic motion of the heart also 
causes motion artifacts in MR images making the visualization of the lung parenchyma 
near the heart more complex.   
Several techniques have been proposed to overcome these challenges and have been 
discussed above (i.e. hyperpolarized noble gas MRI).  It should be noted, however, that 
these techniques require a certain amount of additional hardware such as special RF coils 
tuned to the Larmor frequency of the gas being imaged and hardware to prepare the 
hyperpolarized gases.  Alternative methods that are based on the visualization of the 
enhanced proton signal of the lung tissue have been developed and will be discussed. 
Ultra-Short Echo Time MRI 
Although hampered by low signal-intensity due to low 1H density and the multitude of lung 
air-tissue interfaces, 1H MRI of the lung can be performed on every scanner without 
additional hardware (such as a polarizer or an MR system with multi-nuclear imaging 
capabilities). To maximize the potential to provide high spatial resolution quantitative 
images of lung parenchyma in MR images, pulse sequences need to provide maximal signal 
and minimal degradation in the presence of susceptibility dephasing.  This can be achieved 
by minimizing the echo time (TE) which is the time between excitation and acquisition of 
the signal.159  With recent technical advancements, MRI using ultra-short echo time (UTE) 
acquisition methods have emerged.  These methods were first proposed as a way to address 
the inherent challenges of pulmonary imaging stemming from low tissue and 1H density.162  
UTE MRI combines fast RF excitation pulses and efficient k-space sampling trajectories 
to minimize MR signal decay and motion artefacts.162 The length of TE, however, depends 
on how quickly the RF electronics (hardware) can switch from transmit to receive.163   
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Figure 1-14 Conventional two-dimensional UTE pulse sequence diagram. 
The half radiofrequency (RF) pulses are applied with a negative slice-selection gradient 
(Gz) in the first half and a positive gradient in the second half. The RF pulse is truncated 
and followed by a radial acquisition which is when Gx and Gy are applied. These gradients 
ramp up to a plateau during data acquisition.  
Briefly, as shown in Figure 1-14, a typical two-dimensional UTE sequence starts with a 
half-sinc pulse RF excitation followed by a centre out radial acquisition, where the free 
induction decay will be acquired. To remove the out-of-slice signal and correct the phase 
resulting from the half-pulse excitation, a second excitation will be implemented 
simultaneously with the inverted slice select gradient. This acquisition will be added to the 
first acquisition to remove the phase variation across the slice and out-of-slice signal.   
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Figure 1-15 shows UTE MR images of a healthy never-smoker and patients with 
obstructive lung disease.  There are visually apparent regions of low signal-intensity in the 
patients with obstructive lung disease which may reflect regions of low tissue density due 
to gas-trapping or emphysema.  As can be seen when comparing Figure 1-14 and Figure 
1-15, UTE MRI methods result in higher pulmonary signal intensities than clinically 
available MR methods.  The biomarkers stemming from UTE MRI include mean whole 
lung T2*, mean whole lung signal-intensity, and threshold based indices quantifying 
volumes of low signal-intensity164 which have been all used to evaluate lung parenchyma.  
It should be noted that the resulting MR signal is not only influenced by T1, T2*, and proton 
density, but also hardware factors such as the positioning of the RF coils, which introduce 
inter-scan variability.  Because of this, it is difficult to ascertain the physiological meaning 
of 1H MR signal-intensity and thus translate across multiple sites. 
Thus far, in asthma, limited work has been done using UTE MR methods.  However, 
conventional and clinically available 1H MRI pulse sequences have been used to monitor 
inflammatory responses to allergen challenges in animal models165 and asthmatics.166  With 
recent advancements in pulmonary 1H MRI, the first studies employing UTE methods 
imaged mice and reported that the MR signal and T2* of the lung parenchyma were higher 
at end-expiratory phase than at end-inspiratory phase.167  This work also reported that these 
values were reduced in the mouse model of emphysematous lungs compared to normal 
mouse lungs at end-expiratory phase suggesting that higher signal-intensity and T2* values 
are related to increased lung density.  More recently, UTE MRI measurements, 
implemented in a mouse model of emphysematous lungs, were correlated with histology 
measurements of the mean chord length of the alveoli.168  These results are consistent with 
the notion that smoking exposure results in alveolar enlargement and increases the air-
tissue ratio and susceptibility driven local field inhomogeneity. 
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Figure 1-15 Representative coronal centre slices of healthy young never-smoker and 
patients with obstructive lung disease acquired using UTE MRI.  
Regions of low signal-intensity are visually obvious in the obstructive lung disease subjects 
compared to the healthy never-smoker. Images of healthy volunteer and COPD subject 
acquired using a 2D UTE MR method using a 32-channel torso coil (GEHC) (13s 
acquisition time, TR/TE/flip angle=13.0ms/0.05ms/10°, FOV=40×40cm, matrix 256×511, 
NEX=2, 15mm slice thickness). Image of asthmatic acquired using a 3D UTE MR method 
using a 32-channel torso coil (GEHC) (15s acquisition time, TE/TR/flip 
angle=0.03ms/3.5ms/5°, FOV=40×40cm, matrix=200×200, NEX=1, and reconstructed to 
a 10mm slice thickness). 
Fourier Decomposition MRI 
Fourier decomposition (FD) MRI has also been proposed for non-contrast enhanced 
functional lung MRI to obtain regional ventilation and perfusion information about the 
lung.   This approach exploits fast MRI acquisition of the lung with respiratory motion 
compensation using non-rigid image registration.  Spectral analysis of the images allows 
for identification of peaks of the respiratory and cardiac frequencies; these peaks are related 
to 1H density change caused by compression and expansion of the lung parenchyma and 
pulmonary blood flow.169,170  Ventilation and perfusion maps of the lung can then be 
created using this information.  Currently, FD techniques utilize a short echo dynamic 
steady state free precession lung image acquisition.170  The limited work that has 
investigated the use of FDMRI in patients with asthma has shown similar information to 
hyperpolarized noble gas MRI after a bronchoconstriction challenge.171  The first study to 
have used FDMRI to quantify pulmonary abnormalities in subjects with COPD 
demonstrated that the FDMRI derived ventilation measurements were associated with 
noble gas MRI ventilation abnormalities and CT derived measurements of emphysema.172  
Although FDMRI requires sophisticated post-processing methods, it is a promising method 
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for serial lung function measurements without the dependence of inhaled gases.   Non-
contrast enhanced 1H MR methods such as UTE and FDMRI open up the opportunity for 
structural and functional lung imaging on clinically available MR systems for longitudinal 
monitoring of subjects with obstructive lung disease.  
1.7 Thesis Hypotheses and Objectives 
Pulmonary function tests are clinically used for the diagnosis, monitoring, and evaluation 
of response to therapy in patients with obstructive lung disease.  These measurements, 
while important, conceal the regional contributions of underlying pathologies.  
Accordingly, a necessary goal of obstructive lung disease research is to develop ways to 
identify patients with specific underlying pathological phenotypes to further personalize 
medicine with the hopes to improve patient care and outcomes.  Imaging methods such as 
thoracic CT and MRI have the potential to provide regional and quantitative biomarkers of 
obstructive lung disease.  Before identifying patients with specific underlying pathological 
phenotypes, it is important to understand the physiological and clinical consequences of 
MR-derived measurements.  Thus, the overarching objective of this thesis was to develop 
and evaluate lung structure and function measurements using multi-nuclear pulmonary 
MRI in older never-smokers and obstructive lung disease to provide an understanding of 
the physiological and clinical etiology of these MR-derived measurements.  In Chapter 2, 
an understanding of healthy aging was first developed using hyperpolarized noble gas MRI.  
Following this, a non-contrast enhanced UTE MR method was developed and its 
reproducibility was evaluated.  This method was then used to evaluate patients with COPD 
(Chapter 3) and asthma (Chapter 4) to determine the physiological and clinical 
consequences of UTE-derived measurements.  The objectives and hypotheses specific to 
each chapter are described below. 
In Chapter 2, our objective was to determine the physiological consequences and potential 
relevance of ventilation abnormalities in older never-smokers.  We evaluated the response 
of bronchodilation (i.e. deep inspiration and salbutamol) on these defects and the 
relationship of ventilation defects with occupational exposures, pulmonary function, and 
exercise capacity.  Based on previous work in young healthy volunteers where ventilation 
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defects resolved after deep inspiration, we hypothesized that in older never-smokers, 
narrowed or collapsed airways were responsible for persistent ventilation defects, and these 
would be responsive to and improve following deep inspiration.   
In Chapter 3, our objective was to develop a UTE MR method, evaluate its reproducibility, 
and use this method to evaluate pulmonary abnormalities in COPD patients with and 
without bronchiectasis. We also evaluated the relationship between UTE-derived 
measurements with CT scan measurements and pulmonary function tests to better 
understand the underlying determinants of signal-intensity measurements in COPD and 
bronchiectasis.  We hypothesized that pulmonary UTE MRI signal-intensity would have 
high short-term reproducibility and be related to CT radiodensity and pulmonary function 
test measurements in COPD patients with and without bronchiectasis. 
In Chapter 4, our objective was to determine the underlying structural and clinical 
determinants of UTE-derived signal-intensity measurements in asthma by evaluating well-
established clinical and emerging imaging (hyperpolarized noble gas MRI and CT) 
measurements in asthmatics.  These patients shared some airway and inflammatory 
features common in COPD and bronchiectasis.  We hypothesized that UTE-derived 
biomarkers that merge information acquired at different lung volumes could be generated 
to capture evidence of regional ventilation heterogeneity and these measurements would 
be related to gas-trapping and/or airway flow obstruction in patients with asthma.  
In Chapter 5, an overview and summary of the important findings and conclusions of 
Chapters 2-4 is provided.  The study specific and general limitations of these studies will 
be discussed and some potential solutions.  The thesis concludes with an outline of future 
studies that can build on the work presented in this thesis. 
  
 42 
 
1.8 References 
 (1) Vestbo, J. et al. Global strategy for the diagnosis, management, and prevention of 
chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir 
Crit Care Med 2013; 187: 347-365. 
(2) Global Initiative for Asthma. Global Initiative for Asthma: Global Strategy for 
Asthma Management and Prevention, <http://www.ginasthma.org/> (2015). 
(3) World Health Organization. Global Burden of Disease: Disease Incidence, 
Prevalence, and Disability.  (2004). 
<http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update
_part3.pdf>. 
(4) Global Alliance against Chronic Respiratory Diseases. World Health Organization 
Asthma Fact Sheet N 307, <http://www.who.int/mediacentre/factsheets/fs307/en/> 
(2013). 
(5) World Health Organization. Global Health Estimates 2014 Summary Tables: Death 
by Cause, Age and Sex, 2000-2012.  (2014). 
<http://www.who.int/healthinfo/global_burden_disease/en/>. 
(6) Statistics Canada.    (ed CANSIM) (Statistics Canada, Ottawa, Ontario, 2015). 
(7) Gershon, A. S., Wang, C., Wilton, A. S., Raut, R. & To, T. Trends in chronic 
obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, 
Canada, 1996 to 2007: a population-based study. Archives of internal medicine 
2010; 170: 560-565. 
(8) Gershon, A. S., Warner, L., Cascagnette, P., Victor, J. C. & To, T. Lifetime risk of 
developing chronic obstructive pulmonary disease: a longitudinal population study. 
The Lancet 2011; 378: 991-996. 
 43 
 
(9) Canadian Institute for Health Information. Emergency Department Visits in 2014-
2015.  (2015). 
<https://secure.cihi.ca/free_products/NACRS_ED_QuickStats_Infosheet_2014-
15_ENweb.pdf>. 
(10) Canadian Institute for Health Information. Health Indicators 2008. (CIHI, Ottawa, 
2008). 
(11) Crighton, E. J., Ragetlie, R., Luo, J., To, T. & Gershon, A. A spatial analysis of 
COPD prevalence, incidence, mortality and health service use in Ontario. Health 
Rep 2015; 26: 10-18. 
(12) OASIS. OASIS: Asthma Infographic, <http://lab.research.sickkids.ca/oasis/oasis-
statistics/> (2015). 
(13) To, T. et al. Progression from Asthma to Chronic Obstructive Pulmonary Disease. 
Is Air Pollution a Risk Factor? Am J Respir Crit Care Med 2016; 194: 429-438. 
(14) Larsen, K. et al. The Annual September Peak in Asthma Exacerbation Rates. Still 
a Reality? Ann Am Thorac Soc 2016; 13: 231-239. 
(15) Smetanin, P. et al. Life and economic impact of lung disease in Ontario: 2011 to 
2041. Risk Analytica on Behalf of the Ontario Lung Association 2011. 
(16) West, J. B. Respiratory Physiology the Essentials. Ninth edn,  (Lippincott Williams 
& Wilkins, 2012). 
(17) Silverthorn, D. U. Human Physiology An Integrated Approach 6th Edition.  
(Pearson, 2013). 
(18) Ochs, M. et al. The number of alveoli in the human lung. Am J Respir Crit Care 
Med 2004; 169: 120-124. 
(19) Eric P. Widmaier, H. R., and Kevin T. Strang. Human Physiology The Mechanisms 
of Body Function. Ninth edn,  (McGraw Hill, 2004). 
 44 
 
(20) Weibel, E. R. Geometry and dimensions of airways of conductive and transitory 
zones.  (Springer, 1963). 
(21) Fick, A. V. On liquid diffusion. The London, Edinburgh, and Dublin Philosophical 
Magazine and Journal of Science 1855; 10: 30-39. 
(22) Verbeken, E. et al. The senile lung. Comparison with normal and emphysematous 
lungs. 1. Structural aspects. CHEST Journal 1992; 101: 793-799. 
(23) Sobin, S. S., Fung, Y. C. & Tremer, H. M. Collagen and elastin fibers in human 
pulmonary alveolar walls. J Appl Physiol (1985) 1988; 64: 1659-1675. 
(24) Toshima, M., Ohtani, Y. & Ohtani, O. Three-dimensional architecture of elastin 
and collagen fiber networks in the human and rat lung. Arch Histol Cytol 2004; 67: 
31-40. 
(25) Mahler, D. A., Rosiello, R. A. & Loke, J. The aging lung. Clin Geriatr Med 1986; 
2: 215-225. 
(26) Janssens, J. P., Pache, J. C. & Nicod, L. P. Physiological changes in respiratory 
function associated with ageing. Eur Respir J 1999; 13: 197-205. 
(27) Gillooly, M. & Lamb, D. Airspace size in lungs of lifelong non-smokers: effect of 
age and sex. Thorax 1993; 48: 39-43. 
(28) Sharma, G. & Goodwin, J. Effect of aging on respiratory system physiology and 
immunology. Clin Interv Aging 2006; 1: 253-260. 
(29) Enright, P. L., Kronmal, R. A., Manolio, T. A., Schenker, M. B. & Hyatt, R. E. 
Respiratory muscle strength in the elderly. Correlates and reference values. 
Cardiovascular Health Study Research Group. Am J Respir Crit Care Med 1994; 
149: 430-438. 
 45 
 
(30) Tolep, K., Higgins, N., Muza, S., Criner, G. & Kelsen, S. G. Comparison of 
diaphragm strength between healthy adult elderly and young men. Am J Respir Crit 
Care Med 1995; 152: 677-682. 
(31) Yunginger, J. W. et al. A community-based study of the epidemiology of asthma. 
Incidence rates, 1964-1983. Am Rev Respir Dis 1992; 146: 888-894. 
(32) Anderson, H. R., Pottier, A. C. & Strachan, D. P. Asthma from birth to age 23: 
incidence and relation to prior and concurrent atopic disease. Thorax 1992; 47: 537-
542. 
(33) Martinez, F. D. & Vercelli, D. Asthma. Lancet 2013; 382: 1360-1372. 
(34) Mallol, J. et al. Heightened bronchial hyperresponsiveness in the absence of 
heightened atopy in children with current wheezing and low income status. Thorax 
2008; 63: 167-171. 
(35) Becklake, M. R. Occupational exposures: evidence for a causal association with 
chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: S85-91. 
(36) Higgins, M. W. et al. An index of risk for obstructive airways disease. Am Rev 
Respir Dis 1982; 125: 144-151. 
(37) Health, U. D. o. & Services, H. The health consequences of smoking: a report of 
the Surgeon General. Atlanta, GA: US Department of Health and Human Services, 
Centers for Disease Control and Prevention, National Center for Chronic Disease 
Prevention and Health Promotion, Office on Smoking and Health 2004; 62. 
(38) Fletcher, C. & Peto, R. The natural history of chronic airflow obstruction. Br Med 
J 1977; 1: 1645-1648. 
(39) Hamid, Q. et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 
1997; 100: 44-51. 
 46 
 
(40) Saetta, M. & Turato, G. Airway pathology in asthma. Eur Respir J Suppl 2001; 34: 
18s-23s. 
(41) Tulic, M. K., Christodoulopoulos, P. & Hamid, Q. Small airway inflammation in 
asthma. Respir Res 2001; 2: 333-339. 
(42) Mullen, J. B., Wright, J. L., Wiggs, B. R., Pare, P. D. & Hogg, J. C. Reassessment 
of inflammation of airways in chronic bronchitis. Br Med J (Clin Res Ed) 1985; 
291: 1235-1239. 
(43) Hogg, J. C. Pathophysiology of airflow limitation in chronic obstructive pulmonary 
disease. Lancet 2004; 364: 709-721. 
(44) Saetta, M. et al. Inflammatory cells in the bronchial glands of smokers with chronic 
bronchitis. Am J Respir Crit Care Med 1997; 156: 1633-1639. 
(45) Mead, J. The lung's "quiet zone". N Engl J Med 1970; 282: 1318-1319. 
(46) Dayman, H. Mechanics of airflow in health and in emphysema. J Clin Invest 1951; 
30: 1175-1190. 
(47) Butler, J., Caro, C. G., Alcala, R. & Dubois, A. B. Physiological factors affecting 
airway resistance in normal subjects and in patients with obstructive respiratory 
disease. J Clin Invest 1960; 39: 584-591. 
(48) Mead, J., Turner, J. M., Macklem, P. T. & Little, J. B. Significance of the 
relationship between lung recoil and maximum expiratory flow. J Appl Physiol 
1967; 22: 95-108. 
(49) Matsuba, K. & Thurlbeck, W. M. The number and dimensions of small airways in 
emphysematous lungs. Am J Pathol 1972; 67: 265-275. 
(50) Snider, G. The definition of emphysema; report of a National Heart, Lung and 
Blood Institute. Division of Lung Diseases. Workshop. Am Rev Respir Dis 1985; 
132: 182-185. 
 47 
 
(51) Thurlbeck, W. M. & Muller, N. L. Emphysema: definition, imaging, and 
quantification. AJR Am J Roentgenol 1994; 163: 1017-1025. 
(52) Thurlbeck, W. M. & Simon, G. Radiographic appearance of the chest in 
emphysema. AJR Am J Roentgenol 1978; 130: 429-440. 
(53) Tetley, T. D. Inflammatory cells and chronic obstructive pulmonary disease. Curr 
Drug Targets Inflamm Allergy 2005; 4: 607-618. 
(54) Saetta, M. Airway inflammation in chronic obstructive pulmonary disease. Am J 
Respir Crit Care Med 1999; 160: S17-20. 
(55) Saetta, M. et al. CD8+ T-lymphocytes in peripheral airways of smokers with 
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 822-
826. 
(56) Miller, M. R. et al. Standardisation of spirometry. Eur respir J 2005; 26: 319-338. 
(57) Wanger, J. et al. Standardisation of the measurement of lung volumes. European 
Respiratory Journal 2005; 26: 511. 
(58) Macintyre, N. et al. Standardisation of the single-breath determination of carbon 
monoxide uptake in the lung. European Respiratory Journal 2005; 26: 720-735. 
(59) Clayton, N. Review Series: Lung function made easy: Assessing lung size. Chronic 
respiratory disease 2007; 4: 151-157. 
(60) Turner, J. M., Mead, J. & Wohl, M. E. Elasticity of human lungs in relation to age. 
J Appl Physiol 1968; 25: 664-671. 
(61) Mayer, E., Blazsik, C. & Rappaport, I. Emphysema and the lungs of the aged: a 
clinical study; preliminary report. Dis Chest 1958; 34: 247-256. 
(62) Lokke, A., Lange, P., Scharling, H., Fabricius, P. & Vestbo, J. Developing COPD: 
a 25 year follow up study of the general population. Thorax 2006; 61: 935-939. 
 48 
 
(63) West, J. B. Pulmonary pathophysiology: the essentials.  (Lippincott Williams & 
Wilkins, 2011). 
(64) ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care 
Med 2003; 167: 211-277. 
(65) Albouaini, K., Egred, M., Alahmar, A. & Wright, D. J. Cardiopulmonary exercise 
testing and its application. Postgrad Med J 2007; 83: 675-682. 
(66) Celli, B. R. et al. The body-mass index, airflow obstruction, dyspnea, and exercise 
capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 
1005-1012. 
(67) Vestbo, J. et al. Evaluation of COPD Longitudinally to Identify Predictive 
Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31: 869-873. 
(68) Brenner, D. J. & Hall, E. J. Computed tomography--an increasing source of 
radiation exposure. N Engl J Med 2007; 357: 2277-2284. 
(69) Hodson, M. E., Simon, G. & Batten, J. C. Radiology of uncomplicated asthma. 
Thorax 1974; 29: 296-303. 
(70) Rebuck, A. S. Radiological aspects of severe asthma. Australas Radiol 1970; 14: 
264-268. 
(71) Kerley, P. Emphysema: (Section of Radiology). Proc R Soc Med 1936; 29: 1307-
1324. 
(72) Petheram, I. S., Kerr, I. & Collins, J. Value of chest radiographs in severe acute 
asthma. Clinical radiology 1981; 32: 281-282. 
(73) Hodson, C. & Trickey, S. Bronchial wall thickening in asthma. Clinical Radiology 
1960; 11: 182-191. 
 49 
 
(74) DiMango, E. A., Lubetsky, H. & Austin, J. H. Assessment of bronchial wall 
thickening on posteroanterior chest radiographs in acute asthma. J Asthma 2002; 
39: 255-261. 
(75) Andersen, P. E., Jr., Andersen, L. H. & Jest, P. The chest radiograph in chronic 
obstructive lung disease compared with measurements of single-breath nitrogen 
washout and spirometry. Clin Radiol 1982; 33: 51-55. 
(76) Rosenblum, L. J. et al. Density patterns in the normal lung as determined by 
computed tomography. Radiology 1980; 137: 409-416. 
(77) Haaga, J. R. & Boll, D. Computed tomography & magnetic resonance imaging of 
the whole body.  (Elsevier Health Sciences, 2008). 
(78) Litmanovich, D. E., Hartwick, K., Silva, M. & Bankier, A. A. Multidetector 
computed tomographic imaging in chronic obstructive pulmonary disease: 
emphysema and airways assessment. Radiol Clin North Am 2014; 52: 137-154. 
(79) Dendy, P. P. & Heaton, B. Physics for diagnostic radiology.  (CRC Press, 2011). 
(80) Mettler, F. A., Jr., Huda, W., Yoshizumi, T. T. & Mahesh, M. Effective doses in 
radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248: 254-
263. 
(81) Lambert, L., Banerjee, R., Votruba, J., El-Lababidi, N. & Zeman, J. Ultra-low-dose 
CT Imaging of the Thorax: Decreasing the Radiation Dose by One Order of 
Magnitude. Indian J Pediatr 2016. 
(82) Willemink, M. J. et al. Iterative reconstruction techniques for computed 
tomography part 2: initial results in dose reduction and image quality. Eur Radiol 
2013; 23: 1632-1642. 
(83) Busacker, A. et al. A multivariate analysis of risk factors for the air-trapping 
asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135: 48-
56. 
 50 
 
(84) Okazawa, M. et al. Human airway narrowing measured using high resolution 
computed tomography. Am J Respir Crit Care Med 1996; 154: 1557-1562. 
(85) Little, S. A. et al. High resolution computed tomographic assessment of airway wall 
thickness in chronic asthma: reproducibility and relationship with lung function and 
severity. Thorax 2002; 57: 247-253. 
(86) Awadh, N., Muller, N. L., Park, C. S., Abboud, R. T. & FitzGerald, J. M. Airway 
wall thickness in patients with near fatal asthma and control groups: assessment 
with high resolution computed tomographic scanning. Thorax 1998; 53: 248-253. 
(87) Mitsunobu, F. et al. Decreased computed tomographic lung density during 
exacerbation of asthma. Eur Respir J 2003; 22: 106-112. 
(88) Gono, H., Fujimoto, K., Kawakami, S. & Kubo, K. Evaluation of airway wall 
thickness and air trapping by HRCT in asymptomatic asthma. Eur Respir J 2003; 
22: 965-971. 
(89) Nakano, Y. et al. The prediction of small airway dimensions using computed 
tomography. Am J Respir Crit Care Med 2005; 171: 142-146. 
(90) Han, M. K. et al. Chronic obstructive pulmonary disease exacerbations in the 
COPDGene study: associated radiologic phenotypes. Radiology 2011; 261: 274-
282. 
(91) Grydeland, T. B. et al. Quantitative computed tomography measures of emphysema 
and airway wall thickness are related to respiratory symptoms. Am J Respir Crit 
Care Med 2010; 181: 353-359. 
(92) Nakano, Y. et al. Computed tomographic measurements of airway dimensions and 
emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 
2000; 162: 1102-1108. 
 51 
 
(93) Orlandi, I. et al. Chronic obstructive pulmonary disease: thin-section CT 
measurement of airway wall thickness and lung attenuation. Radiology 2005; 234: 
604-610. 
(94) Kim, V. et al. Airway wall thickness is increased in COPD patients with 
bronchodilator responsiveness. Respir Res 2014; 15: 84. 
(95) Hayhurst, M. D. et al. Diagnosis of pulmonary emphysema by computerised 
tomography. Lancet 1984; 2: 320-322. 
(96) Barnes, P. J., Drazen, J. M., Rennard, S. I. & Thomson, N. C. Asthma and COPD: 
basic mechanisms and clinical management.  (Elsevier, 2009). 
(97) Sakai, N., Mishima, M., Nishimura, K., Itoh, H. & Kuno, K. An automated method 
to assess the distribution of low attenuation areas on chest CT scans in chronic 
pulmonary emphysema patients. Chest 1994; 106: 1319-1325. 
(98) Bankier, A. A., De Maertelaer, V., Keyzer, C. & Gevenois, P. A. Pulmonary 
emphysema: subjective visual grading versus objective quantification with 
macroscopic morphometry and thin-section CT densitometry. Radiology 1999; 
211: 851-858. 
(99) Park, K. J., Bergin, C. J. & Clausen, J. L. Quantitation of emphysema with three-
dimensional CT densitometry: comparison with two-dimensional analysis, visual 
emphysema scores, and pulmonary function test results. Radiology 1999; 211: 541-
547. 
(100) Gevenois, P. A., de Maertelaer, V., De Vuyst, P., Zanen, J. & Yernault, J. C. 
Comparison of computed density and macroscopic morphometry in pulmonary 
emphysema. Am J Respir Crit Care Med 1995; 152: 653-657. 
(101) Muller, N. L., Staples, C. A., Miller, R. R. & Abboud, R. T. "Density mask". An 
objective method to quantitate emphysema using computed tomography. Chest 
1988; 94: 782-787. 
 52 
 
(102) Coxson, H. O. et al. A quantification of the lung surface area in emphysema using 
computed tomography. Am J Respir Crit Care Med 1999; 159: 851-856. 
(103) Owrangi, A. M., Etemad-Rezai, R., McCormack, D. G., Cunningham, I. A. & 
Parraga, G. Computed tomography density histogram analysis to evaluate 
pulmonary emphysema in ex-smokers. Acad Radiol 2013; 20: 537-545. 
(104) Cerveri, I. et al. Assessment of emphysema in COPD: a functional and radiologic 
study. Chest 2004; 125: 1714-1718. 
(105) Martinez, C. H. et al. Relationship between quantitative CT metrics and health 
status and BODE in chronic obstructive pulmonary disease. Thorax 2012; 67: 399-
406. 
(106) Smith-Bindman, R. et al. Use of diagnostic imaging studies and associated 
radiation exposure for patients enrolled in large integrated health care systems, 
1996-2010. JAMA 2012; 307: 2400-2409. 
(107) Argula, R. G., Strange, C., Ramakrishnan, V. & Goldin, J. Baseline regional 
perfusion impacts exercise response to endobronchial valve therapy in advanced 
pulmonary emphysema. Chest 2013; 144: 1578-1586. 
(108) Stavngaard, T. et al. Hyperpolarized 3He MRI and 81mKr SPECT in chronic 
obstructive pulmonary disease. Eur J Nucl Med Mol Imaging 2005; 32: 448-457. 
(109) Suga, K. et al. Dynamic pulmonary SPECT of xenon-133 gas washout. J Nucl Med 
1996; 37: 807-814. 
(110) King, G. G., Eberl, S., Salome, C. M., Meikle, S. R. & Woolcock, A. J. Airway 
closure measured by a technegas bolus and SPECT. Am J Respir Crit Care Med 
1997; 155: 682-688. 
(111) Mishkin, F. & Wagner, H. N., Jr. Regional abnormalities in pulmonary arterial 
blood flow during acute asthmatic attacks. Radiology 1967; 88: 142-144. 
 53 
 
(112) Farrow, C. E. et al. Airway closure on imaging relates to airway 
hyperresponsiveness and peripheral airway disease in asthma. J Appl Physiol 
(1985) 2012; 113: 958-966. 
(113) Sovijarvi, A. R., Poyhonen, L., Kellomaki, L. & Muittari, A. Effects of acute and 
long-term bronchodilator treatment on regional lung function in asthma assessed 
with krypton-81m and technetium-99m-labelled macroaggregates. Thorax 1982; 
37: 516-520. 
(114) Munkner, T. & Bundgaard, A. Regional V/Q changes in asthmatics after exercise. 
Eur J Respir Dis Suppl 1986; 143: 62-66. 
(115) Munkner, T. & Bundgaard, A. Regional V/Q changes in asthmatics after antigen 
inhalation. Eur J Respir Dis Suppl 1986; 143: 44-47. 
(116) Munkner, T. & Bundgaard, A. Regional V/Q changes in asthmatics after histamine 
inhalation. Eur J Respir Dis Suppl 1986; 143: 22-27. 
(117) Bajc, M. et al. Grading obstructive lung disease using tomographic pulmonary 
scintigraphy in patients with chronic obstructive pulmonary disease (COPD) and 
long-term smokers. Ann Nucl Med 2015; 29: 91-99. 
(118) Norberg, P. et al. Quantitative lung SPECT applied on simulated early COPD and 
humans with advanced COPD. EJNMMI Res 2013; 3: 28. 
(119) Suga, K., Iwanaga, H., Tokuda, O., Okada, M. & Matsunaga, N. Intrabullous 
ventilation in pulmonary emphysema: assessment with dynamic xenon-133 gas 
SPECT. Nucl Med Commun 2012; 33: 371-378. 
(120) Jogi, J., Ekberg, M., Jonson, B., Bozovic, G. & Bajc, M. Ventilation/perfusion 
SPECT in chronic obstructive pulmonary disease: an evaluation by reference to 
symptoms, spirometric lung function and emphysema, as assessed with HRCT. Eur 
J Nucl Med Mol Imaging 2011; 38: 1344-1352. 
 54 
 
(121) Suga, K. et al. Lung ventilation-perfusion imbalance in pulmonary emphysema: 
assessment with automated V/Q quotient SPECT. Ann Nucl Med 2010; 24: 269-
277. 
(122) Jones, H. A., Marino, P. S., Shakur, B. H. & Morrell, N. W. In vivo assessment of 
lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J 
2003; 21: 567-573. 
(123) Jones, H. A. et al. In vivo measurement of neutrophil activity in experimental lung 
inflammation. Am J Respir Crit Care Med 1994; 149: 1635-1639. 
(124) Senda, M., Murata, K., Itoh, H., Yonekura, Y. & Torizuka, K. Quantitative 
evaluation of regional pulmonary ventilation using PET and nitrogen-13 gas. J Nucl 
Med 1986; 27: 268-273. 
(125) Harris, R. S. et al. 18F-FDG uptake rate is a biomarker of eosinophilic 
inflammation and airway response in asthma. J Nucl Med 2011; 52: 1713-1720. 
(126) Venegas, J. G. et al. Self-organized patchiness in asthma as a prelude to 
catastrophic shifts. Nature 2005; 434: 777-782. 
(127) Vidal Melo, M. F. et al. Spatial heterogeneity of lung perfusion assessed with (13)N 
PET as a vascular biomarker in chronic obstructive pulmonary disease. J Nucl Med 
2010; 51: 57-65. 
(128) Brudin, L. H. et al. Regional structure-function correlations in chronic obstructive 
lung disease measured with positron emission tomography. Thorax 1992; 47: 914-
921. 
(129) Albertine, K. Structural organization and quantitative morphology of the lung. 
Application of magnetic resonance to the study of lung. Futura, Armonk, New York, 
USA 1996; 73-114. 
(130) Albert, M. S. et al. Biological magnetic resonance imaging using laser-polarized 
129Xe. Nature 1994; 370: 199-201. 
 55 
 
(131) Kauczor, H.-U. MRI of the Lung.  (2009). 
(132) Neil James Stewart, H.-F. C., Guilhem Jean Collier, Felix Clemens Horn, Graham 
Norquay, Juan Parra-Robles, Denise Yates, Paul Collini, Rod Lawson, Helen 
Marshall, and Jim Michael Wild. in International Society of Magnetic Resonance 
in Medicine 24th Annual Meeting. 
(133) Roos, J. E., McAdams, H. P., Kaushik, S. S. & Driehuys, B. Hyperpolarized Gas 
MR Imaging: Technique and Applications. Magn Reson Imaging Clin N Am 2015; 
23: 217-229. 
(134) Saam, B. T. Magnetic resonance imaging with laser-polarized noble gases. Nat Med 
1996; 2: 358-359. 
(135) Kirby, M. et al. Hyperpolarized 3He magnetic resonance functional imaging 
semiautomated segmentation. Acad Radiol 2012; 19: 141-152. 
(136) Mathew, L. et al. Hyperpolarized 3He magnetic resonance imaging of chronic 
obstructive pulmonary disease: reproducibility at 3.0 tesla. Acad Radiol 2008; 15: 
1298-1311. 
(137) Kirby, M. et al. Quantitative evaluation of hyperpolarized helium-3 magnetic 
resonance imaging of lung function variability in cystic fibrosis. Acad Radiol 2011; 
18: 1006-1013. 
(138) Kirby, M. et al. Chronic obstructive pulmonary disease: quantification of 
bronchodilator effects by using hyperpolarized (3)He MR imaging. Radiology 
2011; 261: 283-292. 
(139) Svenningsen, S. et al. Hyperpolarized He and Xe MRI: Differences in asthma 
before bronchodilation. J Magn Reson Imaging 2013. 
(140) Kirby, M. et al. Chronic obstructive pulmonary disease: longitudinal 
hyperpolarized (3)He MR imaging. Radiology 2010; 256: 280-289. 
 56 
 
(141) Svenningsen, S. et al. Pulmonary functional magnetic resonance imaging: asthma 
temporal-spatial maps. Acad Radiol 2014; 21: 1402-1410. 
(142) Parraga, G., Mathew, L., Etemad-Rezai, R., McCormack, D. G. & Santyr, G. E. 
Hyperpolarized 3He magnetic resonance imaging of ventilation defects in healthy 
elderly volunteers: initial findings at 3.0 Tesla. Acad Radiol 2008; 15: 776-785. 
(143) Aysola, R., de Lange, E. E., Castro, M. & Altes, T. A. Demonstration of the 
heterogeneous distribution of asthma in the lungs using CT and hyperpolarized 
helium-3 MRI. J Magn Reson Imaging 2010; 32: 1379-1387. 
(144) de Lange, E. E. et al. Evaluation of asthma with hyperpolarized helium-3 MRI: 
correlation with clinical severity and spirometry. Chest 2006; 130: 1055-1062. 
(145) Svenningsen, S. et al. What are ventilation defects in asthma? Thorax 2014; 69: 63-
71. 
(146) Kirby, M., Kanhere, N., Etemad-Rezai, R., McCormack, D. G. & Parraga, G. 
Hyperpolarized helium-3 magnetic resonance imaging of chronic obstructive 
pulmonary disease exacerbation. J Magn Reson Imaging 2013; 37: 1223-1227. 
(147) Svenningsen, S., Nair, P., Guo, F., McCormack, D. G. & Parraga, G. Is ventilation 
heterogeneity related to asthma control? Eur Respir J 2016. 
(148) Capaldi, D. P. et al. Pulmonary Imaging Biomarkers of Gas Trapping and 
Emphysema in COPD: (3)He MR Imaging and CT Parametric Response Maps. 
Radiology 2016; 279: 597-608. 
(149) Fain, S. B. et al. Detection of age-dependent changes in healthy adult lungs with 
diffusion-weighted 3He MRI. Acad Radiol 2005; 12: 1385-1393. 
(150) Wang, C. et al. Assessment of the lung microstructure in patients with asthma using 
hyperpolarized 3He diffusion MRI at two time scales: comparison with healthy 
subjects and patients with COPD. J Magn Reson Imaging 2008; 28: 80-88. 
 57 
 
(151) Trampel, R. et al. Diffusional kurtosis imaging in the lung using hyperpolarized 
3He. Magn Reson Med 2006; 56: 733-737. 
(152) Fain, S. et al. in Proc Intl Soc Mag Reson Med.  335. 
(153) Costella, S. et al. Regional pulmonary response to a methacholine challenge using 
hyperpolarized (3)He magnetic resonance imaging. Respirology 2012; 17: 1237-
1246. 
(154) Kirby, M. et al. Hyperpolarized 3He and 129Xe MR imaging in healthy volunteers 
and patients with chronic obstructive pulmonary disease. Radiology 2012; 265: 
600-610. 
(155) Salerno, M. et al. Emphysema: Hyperpolarized Helium 3 Diffusion MR Imaging 
of the Lungs Compared with Spirometric Indexes—Initial Experience 1. Radiology 
2002; 222: 252-260. 
(156) Woods, J. C. et al. Hyperpolarized 3He diffusion MRI and histology in pulmonary 
emphysema. Magn Reson Med 2006; 56: 1293-1300. 
(157) Kirby, M., Heydarian, M., Wheatley, A., McCormack, D. G. & Parraga, G. 
Evaluating bronchodilator effects in chronic obstructive pulmonary disease using 
diffusion-weighted hyperpolarized helium-3 magnetic resonance imaging. J Appl 
Physiol 2012; 112: 651-657. 
(158) Bergin, C. J., Noll, D. C., Pauly, J. M., Glover, G. H. & Macovski, A. MR imaging 
of lung parenchyma: a solution to susceptibility. Radiology 1992; 183: 673-676. 
(159) Bergin, C. J., Glover, G. M. & Pauly, J. Magnetic resonance imaging of lung 
parenchyma. J Thorac Imaging 1993; 8: 12-17. 
(160) Ohno, Y. et al. T2* measurements of 3-T MRI with ultrashort TEs: capabilities of 
pulmonary function assessment and clinical stage classification in smokers. AJR 
Am J Roentgenol 2011; 197: W279-285. 
 58 
 
(161) Ohno, Y. et al. Pulmonary MR imaging with ultra-short TEs: utility for disease 
severity assessment of connective tissue disease patients. Eur J Radiol 2013; 82: 
1359-1365. 
(162) Bergin, C. J., Pauly, J. M. & Macovski, A. Lung parenchyma: projection 
reconstruction MR imaging. Radiology 1991; 179: 777-781. 
(163) Gatehouse, P. D. & Bydder, G. M. Magnetic Resonance Imaging of Short T2 
Components in Tissue. Clinical Radiology 2003; 58: 1-19. 
(164) Roach, D. J. et al. Morphological and quantitative evaluation of emphysema in 
chronic obstructive pulmonary disease patients: A comparative study of MRI with 
CT. J Magn Reson Imaging 2016. 
(165) Ble, F. X. et al. Allergen-induced lung inflammation in actively sensitized mice 
assessed with MR imaging. Radiology 2008; 248: 834-843. 
(166) Vogel-Claussen, J. et al. Quantification of pulmonary inflammation after segmental 
allergen challenge using turbo-inversion recovery-magnitude magnetic resonance 
imaging. Am J Respir Crit Care Med 2014; 189: 650-657. 
(167) Takahashi, M. et al. Ultra-short echo time (UTE) MR imaging of the lung: 
comparison between normal and emphysematous lungs in mutant mice. J Magn 
Reson Imaging 2010; 32: 326-333. 
(168) Zurek, M., Boyer, L., Caramelle, P., Boczkowski, J. & Crémillieux, Y. 
Longitudinal and noninvasive assessment of emphysema evolution in a murine 
model using proton MRI. Magnetic Resonance in Medicine 2012; 68: 898-904. 
(169) Bauman, G. et al. Non-contrast-enhanced perfusion and ventilation assessment of 
the human lung by means of fourier decomposition in proton MRI. Magn Reson 
Med 2009; 62: 656-664. 
 59 
 
(170) Lederlin, M. et al. Functional MRI using Fourier decomposition of lung signal: 
reproducibility of ventilation- and perfusion-weighted imaging in healthy 
volunteers. Eur J Radiol 2013; 82: 1015-1022. 
(171) Capaldi, D. P. et al. in A19. GETTING POLARIZED: MR IMAGING IN 
OBSTRUCTIVE LUNG DISEASE     A1055-A1055 (Am Thoracic Soc, 2016). 
(172) Capaldi, D. P. et al. Free-breathing pulmonary 1H and Hyperpolarized 3He MRI: 
comparison in COPD and bronchiectasis. Acad Radiol 2015; 22: 320-329. 
 
 60 
 
CHAPTER 2 
2 PULMONARY VENTILATION DEFECTS IN OLDER 
NEVER-SMOKERS 
To better understand the physiological consequences and potential relevance of 3He MRI 
ventilation defects in aging, we evaluated 3He MRI ventilation defects in older never-
smokers before and after bronchodilation administration.  To identify the potential 
determinants of ventilation defects, we also evaluated dyspnea, pulmonary function, and 
exercise test measurements.  
The contents of this chapter were previously published in the Journal of Applied 
Physiology: K Sheikh, GA Paulin, S Svenningsen, M Kirby, NAM Paterson, DG 
McCormack, and G Parraga.  Pulmonary Ventilation Defects in Older Never-Smokers.  J 
Appl Physiol 2014; 117(3):297-306.  Permission to reproduce this article was granted by 
The American Physiological Society and is provided in Appendix A.   
2.1 Introduction 
Pulmonary aging is concomitant with changes in elastic recoil,1-3 chest wall compliance,1,3 
and respiratory muscle strength.4,5  In concert with these physiological changes, functional 
residual capacity (FRC), residual volume (RV), and airways resistance (Raw) also 
increase,4 whereas the forced expiratory volume in one second (FEV1), forced vital 
capacity (FVC)6 and inspiratory capacity (IC) decrease.7 
Healthy older adults may experience breathlessness during everyday activities8-12 and this 
is related to mortality risk.8,9,12  In addition, in older adults, cardiopulmonary exercise test 
(CPET) measurements13 correlate more strongly with overall health status than do 
measurements of resting lung function.14-16  Moreover, CPET measurements show that in 
“normal” healthy aging, there is lower exercise-related oxygen uptake (VO2) as well as 
greater minute ventilation (VE), and increased respiratory exchange ratio (RER).
17-19  
Recent studies have also shown that during exercise, significant ventilatory impairment is 
possible without increased dyspnea or premature exercise limitation.20 
The role of occupational and second-hand tobacco smoke exposure is important to 
acknowledge and understand in both normal and accelerated lung aging.  In this context, 
the Burden of Obstructive Lung Disease (BOLD) study21 showed that in never-smokers, 
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the prevalence of airflow limitation consistent with chronic obstructive pulmonary disease 
(COPD) was as high as 30%.  The BOLD study also revealed the critical relationships in 
never-smokers between airflow limitation and age, history of occupational exposure and 
childhood respiratory disease.22   
3He ventilation magnetic resonance imaging (MRI) provides high resolution, non-invasive 
measurements of lung function,23,24 and identifies those regions of the lung that participate 
in ventilation and those that do not.24,25  In healthy young subjects, a single inhalation of 
hyperpolarized 3He gas results in homogeneous lung filling, but in older never-smokers, 
characteristic “focal” ventilation defects are observed, corresponding to poorly ventilated 
lung regions.23,25  In older never-smokers, ventilation defects are commonly observed on 
the lung periphery and the dependent lung regions, and this is in contrast with COPD and 
asthma, where numerous and large defects are heterogeneously distributed throughout the 
lung.23,24,26 
The finding of spatially and temporally-persistent 3He MRI ventilation defects in older 
never-smokers with normal spirometry23,25 raises questions about the physiological 
meaning of ventilation defects in all subjects.  For example, as previously shown, 3He MRI 
ventilation abnormalities induced by methacholine challenge in young healthy volunteers 
were reversed by deep inspiration (DI).27  In young asthmatics, salbutamol inhalation 
reduced ventilation defects observed with 3He MRI after methacholine challenge,28 but the 
effect of DI was not investigated.  Airway resistance measurements determined that 
asthmatic subjects cannot maximally dilate their airways and that the dilation that does 
occur after DI constricts back to baseline much faster than in healthy subjects.29  This 
suggested that in asthma, ventilation defects were related to salbutamol-responsive airway 
abnormalities, whereas in healthy volunteers, ventilation defects may reflect “normal” 
airway smooth muscle behaviour that is reversible using DI. 
We hypothesized that in older never-smokers, narrowed or collapsed airways were 
responsible for the persistent ventilation defects observed and these would be responsive 
to, and improve following DI.  To test this hypothesis, we evaluated the effect of both DI 
and salbutamol on 3He ventilation defects in a relatively large group of older never-smokers 
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with no history of respiratory disease.  We also evaluated the relationship of ventilation 
defects with occupational exposures, pulmonary function and cardiopulmonary exercise 
test measurements. 
2.2 Materials and Methods 
2.2.1 Study Subjects and Logistics 
All subjects provided written informed consent to a study protocol approved by a local 
research ethics board and Health Canada.  Subjects were enrolled between the ages of 60 
and 90 years with a smoking history of < 0.5 pack-years and no history of chronic 
respiratory or cardiovascular disease.  After providing consent, all subjects made a single 
2-3 hour visit and underwent the following evaluations in the same order: 1) Burden of 
Obstructive Lung Disease (BOLD) occupational questionnaire,5 2) spirometry, 3) 
plethysmography and the diffusing capacity of carbon monoxide (DLCO), 4) CPET 
including dyspnea score, and, 5) MRI.  Pulmonary function tests were completed in 
approximately 45 minutes followed by CPET that was completed in 10-15 minutes.  MRI 
was performed following CPET and for subjects who did not have ventilation defects and 
those with defects that responded to DI, MRI was completed within 10-15 minutes.  For 
subjects who were administered salbutamol, MRI was performed 25-30 minutes post 
salbutamol inhalation.  
2.2.2 Questionnaires 
All subjects completed the BOLD occupational questionnaire21 with exposures defined as 
previously described22 including: 1) organic dust (farming; flour, feed or grain milling and 
cotton or jute processing), 2) inorganic dust (working with asbestos; hard-rock mining; 
coal mining; sandblasting and foundry or steel milling), and, 3) irritant gases (welding; 
firefighting; chemical or plastics manufacturing).  We also directly queried subjects about 
spousal and/or life-partner smoking history and recorded potential household 2nd hand-
smoke exposure. 
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2.2.3 Pulmonary Function and Cardiopulmonary Exercise Tests 
Spirometry was performed using an ndd EasyOne spirometer (ndd Medizintechnik, Zurich) 
according to American Thoracic Society (ATS) guidelines.  Body plethysmography was 
performed for the measurement of lung volumes and DLCO was measured using the gas 
analyser (Medgraphics Corporation, St. Paul, MN). Inspiratory capacity (IC), defined as 
the volume change recorded at the mouth when taking a slow full inspiration from a 
position of passive end-expiration, was measured using body plethysmography31 as was 
airways resistance (Raw), defined as the pressure difference per unit flow.  Post-DI 
pulmonary function tests were not performed but for subjects administered salbutamol, 
FEV1 and FVC were recorded 35-40 minutes post-inhalation and upon completion of MRI. 
After completion of pulmonary function tests, all subjects performed CPET using a cycle 
ergometer (MedGraphics Ultima PFX, MedGraphics Corporation) according to ATS 
guidelines 14 with a two minute warm-up with no resistance, followed by a 20 watt 
incremental increase in work rate.  Subjects were required to pedal at a frequency of 60 
rpm with increasing work rate until the ventilatory anaerobic threshold was reached.  
Ventilatory anaerobic threshold was defined as the time when CO2 production increased 
disproportionately in relation to O2 consumption.  The ventilatory anaerobic threshold was 
determined by onboard software for the CPET unit which used an iterative regression and 
analysis of slope.  Subjects continued exercise until fatigue was reported.  Oxygen uptake 
(VO2), respiratory exchange ratio (RER), work rate (i.e. power) as well as minute 
ventilation (VE) were measured at rest, at the ventilatory anaerobic threshold, and when 
maximum pulmonary O2 uptake was reached.  The time taken to reach VO2max was also 
recorded.  CPET measurements including VO2, power, and VE were adjusted for age, sex, 
and height using percent predicted values previously reported.17,18,30  Borg dyspnea and leg 
discomfort scales were used before and after exercise. 
2.2.4 Image Acquisition 
MRI was performed after completion of all pulmonary function and cardiopulmonary 
exercise tests on a 3.0 Tesla MR750 (General Electric Health Care (GEHC), Milwaukee, 
WI) system as previously described23 using a whole-body gradient set with maximum 
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gradient amplitude of 1.94 G/cm and a single-channel rigid elliptical transmit/receive chest 
coil (Rapid Biomedical GmbH, Germany).  For both 1H and 3He MRI, subjects were 
instructed to inhale a gas mixture from a 1.0-liter Tedlar bag (Jensen Inert Products, Coral 
Springs, FL) from FRC, and image acquisition was performed during a 16 second breath-
hold.  Coronal (anatomical) 1H MRI was performed using the whole-body RF coil and 1H 
fast-spoiled, gradient-recalled echo sequence using a partial echo (16s total data 
acquisition, repetition time (TR)/echo time (TE)/flip angle = 4.7ms/1.2ms/30°, field-of-
view (FOV)=40×40cm, bandwidth=24.4 kHz, matrix=128×80, 15-17 slices, 15mm slice 
thickness, 0 gap), as previously described.23  3He MRI static ventilation images were 
acquired using a fast gradient-echo method using a partial echo (14s total data acquisition; 
TR/TE/flip angle = 4.3ms/1.4ms/7°, FOV = 40×40cm, bandwidth=48.8 kHz, matrix= 
128×80, 15-17 slices, 15mm slice thickness, 0 gap).   
Immediately after image acquisition, at the scanner while the subject was still in position, 
3He static ventilation images were qualitatively evaluated for ventilation abnormalities by 
a single trained observer.  If 3He gas was homogeneously distributed throughout the lung 
and there were no visible ventilation defects, the subjects were classified as belonging to 
the no defect group and the session was deemed complete.  In contrast, if 3He gas was 
heterogeneously distributed throughout the lung and/or there were visually obvious 
ventilation defects, the subject was classified as having ventilation defect(s).  Upon 
qualitative inspection, subjects with visually obvious ventilation defects were instructed to 
perform DI.   They were instructed to sit up whilst remaining on the scanner bed and take 
four deep breaths in through their nose and out through their mouth.  Imaging was 
performed immediately following DI.  If defects persisted following DI, the subject inhaled 
four puffs (400 µg) of salbutamol while seated upright, and 25 minutes later imaging was 
performed on a final occasion.  
2.2.5 Image Analysis 
Based on visual inspection at the scanner, subjects were classified as: 1) no defects—those 
subjects without visually obvious ventilation defects, 2) subjects with ventilation defects 
that responded to DI or salbutamol, and, 3) subjects with ventilation defects that did not 
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respond to DI or salbutamol.  3He MRI semi-automated segmentation was performed, as 
previously described,31 to generate ventilation defect percent (VDP) – the ventilation defect 
volume (VDV) normalized to 1H MRI thoracic cavity volume (TCV).  Briefly, 3He static 
ventilation images were segmented using a k-means approach that classified voxel intensity 
values into five clusters ranging from signal void (cluster 1[C1] or VDV) and hypo-intense 
(cluster 2 [C2]) to hyper-intense signal (cluster 5 [C5]),  therefore, generating a gas 
distribution cluster-map.  For delineation of the ventilation defect boundaries, a seeded 
region-growing algorithm was used to segment the 1H MRI thoracic cavity for registration 
to the cluster-map, as previously described.31 
Ventilation heterogeneity was estimated according to a previously described method27 
using the coefficient of variation (COV).  A local COV, rather than a global COV, was 
generated27 to ensure local ventilation heterogeneity was not ignored.  Briefly, for each 
voxel in a region of interest (ROI) a local ventilation heterogeneity value was calculated 
by computing the COV of the signal intensity in a 5×5 voxel neighbourhood which 
corresponded to a 244 mm2 area centred on that voxel.  To ensure that the 5×5 voxel 
neighbourhood did not include voxels that were outside of the lungs, a signal-to-noise 
threshold of five was established.  For example, any voxels that were in a neighbourhood 
with an overall signal-to-noise ratio of less than five were excluded from the COV 
computation. COV of the lung was calculated for each subject as in Equation 2-1: 
Equation 2-1 
𝐶𝑂𝑉 =  
√∑
𝜎𝑖
2
𝑁
𝑖=𝑁
𝑖=1
∑ 𝜇𝑖
𝑖=𝑁
𝑖=1
𝑁
 
where 𝜎𝑖
 is the standard deviation of the signal intensity of the 5×5 voxel neighbourhood, 
𝜇𝑖
 is the mean signal intensity of the 5×5 voxel neighbourhood, and 𝑁 is the number of 
ventilation ROIs in the lung.  The ventilated lung ROI was defined as gas distribution 
cluster-map clusters C2-C5.   
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We also measured regional differences in VDP for the centre nine 15mm thick slices using 
several different measurements as shown in Figure 2-1.  The VDP gradient in the posterior-
anterior direction was defined as the slope of the line that described the change in VDP 
from the most posterior slice in centimeters over the nine central slices (with a slice 
thickness of 15mm each).  The centre nine slices were used to ensure the static ventilation 
slices across subjects had adequate signal-to-noise ratios (i.e. SNR>10) for VDP 
calculations as well as to maintain an equal number of slices among all subjects.  To 
calculate the gradient in the superior-inferior (SI) direction, the centre nine coronal slices 
were reformatted into 15mm axial slices.  The VDP SI gradient was defined as the slope 
of the line that described the change in VDP over the axial superior-inferior slices.  In 
addition, the VDP difference between the most posterior and anterior slices (VDP ∆PA) 
was calculated as was the VDP difference between the most superior and inferior slices 
(VDP ∆SI) of the central nine slices.  The ventilation defect percent located on the 
peripheral boundary of the lung (relative peripheral VDP) was estimated as the ratio of the 
ventilation defect volume for the outermost 10 voxels of each slice (not including boundary 
voxels defined as SNR <2) to the 1H MRI thoracic cavity volume.  The proportion of 
ventilation defects located on the peripheral boundary was quantified as the ratio of 
peripheral lung VDV to whole lung VDV (i.e. VDVPer/VDVWL). 
 
Figure 2-1 Schematic for regional evaluation of 3He MRI ventilation-defect percent (VDP) 
The central coronal static ventilation image slices (9 × 15 mm) were evaluated. The lung 
was also divided into 15-mm slices in the axial direction. The VDP ΔSI was defined as the 
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difference between the most superior slice and the most inferior slice. The VDP ΔPA was 
defined as the difference between the most posterior slice and the most anterior slice. 
2.2.6 Statistical Analysis 
Analysis of variance (ANOVA), multivariate regression and post-hoc analysis using the 
Holm Bonferroni correction 32 were performed using SPSS 20.0 (IBM, Armonk, NY).  
Paired sample t-tests were performed to determine the differences in VDP ΔPA and VDP 
ΔSI using SPSS 20.0.  We used the NHANES III reference standards33 for percent 
predicted values.  Univariate relationships were determined using regression (r2) and 
Pearson correlation coefficients (r) for all subjects with GraphPad Prism V.6.00 (GraphPad 
Software Inc, La Jolla, CA).  Stepwise multivariate regression was used to identify the 
predictors of VDP.  The variables considered for modelling were chosen based on 
statistically significant univariate relationships with VDP.  Results were considered 
statistically significant when the probability of making a Type I error was less than 5% 
(p<0.05). 
2.3 Results 
2.3.1 Subject Data 
As summarized in Table 2-1 (and a detailed subject listing in Table 2-2), 52 never-smokers 
(71±6 years) completed all measurements during a single visit.  In total there were 13/52 
(25%) subjects without 3He MRI ventilation defects and 39/52 (75%) with ventilation 
defects.  Of those subjects with ventilation defects, six (6/39, 15%) showed a VDP response 
(i.e. visually obvious and quantitative decrease in VDP) to DI (n=4) or salbutamol (n=2).  
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Table 2-1 Baseline subject demographic and other measurements. 
  
Ventilation Defects  
(n = 39) 
Significance 
of Difference 
 
No Defects 
Imaging 
Response 
No 
Imaging 
Response 
(p-value)* 
  (n=13) (n=6) (n=33) ND-IR-NIR 
Demographics     
Age yrs (±SD) 71 (8) 72 (4) 71 (6) 0.90 
Male n 6 3 12  
BMI kg/m2 (±SD) 26 (4) 27 (3) 26 (3) 0.90 
Occupational Exposures     
Organic Dust n 3 1 4  
Inorganic Dust n 0 2 2  
Irritant Gases n 0 0 1  
Pulmonary Function     
FEV1 %pred (±SD) 113 (11) 93 (29) 106 (20) 0.09 
FVC %pred (±SD) 107 (15) 96 (26) 103 (17) 0.40 
FEV1/FVC % (±SD) 80 (5) 71 (4) ** 77 (5) 0.004 
FRC %pred (±SD) 105 (24) 114 (15) 107 (17) 0.60 
IC %pred (±SD) 112 (20) 94 (26) 106 (19) 0.20 
RV/TLC % (±SD) 41 (7) 43 (15) 41 (7) 0.50 
DLCO %pred (±SD) 96 (7) 75 (13) 92 (19) 0.07 
Raw %pred (±SD) 71 (25) 100 (82) 72 (31) 0.20 
CPET      
VO2max %pred (±SD) 83 (18) 86 (11) 87 (19) 0.80 
RER (±SD) 1.17 (0.15) 1.19 (0.11) 1.21 (0.12) 0.90 
Power %pred (±SD) 126 (38) 118 (9) 121 (31) 0.70 
VEmax %pred (±SD) 50 (17) 54 (19) 51 (16) 0.90 
Post Exercise Dyspnea (±SD) 2.1 (1.4) 2.0 (1.0) 2.3 (1.6) 0.80 
Post Exercise Leg discomfort 
(±SD) 
11.5 (2.4) 11.0 (3.7) 10.9 (3.3) 0.90 
Time to VO2max s (±SD) 478 (89) 532 (111) 494 (82) 0.50 
MRI     
VDP % (±SD) 1.6 (0.7) 5.8 (3.8) ** 2.6 (1.2) <0.001 
3He COV (±SD) 0.19 (0.01) 
0.24 (0.04) 
** 
0.21 (0.02) 0.001 
VDP ∆PA % (±SD) 0.7 (2.7) 
11.2 (13.5) 
** 
1.5 (4.0) 0.001 
PA VDP Gradient %/cm (±SD) 
-0.02 
(0.17) 
-0.69 (0.93) 
** 
-0.05 (0.21) <0.001 
VDP ∆SI % (±SD) -1.9 (1.3) -3.4 (9.6) -2.8 (2.3) 0.67 
SI VDP Gradient %/cm (±SD) 0.14 (0.1) 0.26 (0.72) 0.21 (0.17) 0.67 
Relative Peripheral VDP % (±SD) 1.3 (0.6) 3.3 (1.8) ** 1.9 (0.8) 0.001 
VDVPer/VDVWL % (±SD) 80 (10) 68 (13) 78 (10) 0.05 
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Imaging response refers to subjects with change in VDP after DI or salbutamol.  No 
Imaging Response refers to subjects with no VDP change after salbutamol; IR=imaging 
response; NIR=imaging non-responders; NR=non responders. *Significance of difference 
(p<.05) determined using multivariate analysis of variance. **Post-hoc analysis conducted 
using Holm-Bonferroni demonstrating significant difference between groups.  
SD=standard deviation; BMI=body mass index; FEV1=forced expiratory in 1 s; 
FVC=forced vital capacity; FRC=functional residual capacity; IC=inspiratory capacity; 
TLC=total lung capacity; DLCO=diffusing capacity of carbon monoxide; Raw=airways 
resistance; RV=residual volume; VO2max=maximal oxygen capacity; RER=respiratory 
exchange ratio at VO2max; VEmax=minute ventilation at VO2max;VCO2=volume of carbon 
dioxide at VO2max; Time to VO2max is time taken to reach VO2max during CPET; 
VDP=ventilation defect percent; 3He COV=ventilation coefficient of variation; PA 
∆VDP=change in posterior and anterior VDP; SI ∆VDP=change in superior and inferior 
VDP; VDVPer=ventilation defect volume in the periphery of the lung; VDVWL=ventilation 
defect volume in the whole lung.
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Table 2-2 Subject listing and demographics, pulmonary function tests, cardiopulmonary exercise testing, and imaging measurements  
Subject Age 
(yrs) 
Sex BMI 
kg2/
m 
FEV1 
%pred 
FVC 
%pred 
FEV1
/FVC 
% 
FRC 
%pred 
IC 
%pr
ed 
TLC 
%pred 
RV 
%pred 
RV/T
LC 
% 
DLCO 
%pred 
Raw 
%pred 
VO2
max 
%pred 
RER Power 
%pred 
VE 
%pred 
Post 
Dyspnea 
Post 
Exertion 
VDP 
% 
3He 
COV 
Occupation
al Exposure 
001 74 F 22 89 91 73 92 112 95 95 43 99 130 103 1.22 159 64 3 11 1.37 0.200  
002 68 F 27 101 97 79 102 125 112 124 47 79 81 86 1.39 123 56 4 12 2.39 0.206  
003** 76 F 27 70 78 67 127 92 112 149 62 52 181 66 1.14 109 38 2 11 9.17 0.274  
004 69 M 25 94 84 83 86 111 98 109 38 116 84 87 1.27 96 56 3 13 4.70 0.238  
005 77 M 24 133 128 74 135 83 110 107 37 153 62 113 1.25 136 83 0.5 7 1.34 0.200  
006 66 M 23 88 94 70 90 92 91 90 33 90 99 67 1.25 85 43 2 11 2.96 0.227 Construction 
007 65 F 31 86 76 86 81 90 85 87 43 78 52 72 1.11 97 34 0.5 7 1.45 0.201  
012 71 M 29 84 83 75 134 72 105 131 44 80 80 100 1.68 49 108 3 11 3.91 0.230  
013 83 M 27 151 141 75 92 125 107 64 23 62 58 122 1.24 148 87 0.5 7 2.05 0.203  
015 65 F 20 91 86 81 136 76 110 121 45 81 56 82 1.17 110 45 7 12 2.69 0.195  
016 67 F 30 120 116 77 123 124 123 132 37 114 39 49 1.29 105 28 0.5 12 2.22 0.205  
017** 69 F 27 59 65 68 107 81 96 134 61 68 216 84 1.07 129 34 1 14 10.6 0.294  
018 61 F 22 111 107 80 102 112 106 83 31 95 62 98 1.27 128 46 3 13 5.55 0.223  
019 67 M 26 131 129 75 118 138 128 122 33 84 44 86 1.36 107 83 2 13 1.08 0.199 Organic dust 
020* 78 M 23 101 105 68 133 60 99 100 38 78 30 99 1.22 121 63 2 6 7.49 0.235 Inorganic 
021 74 M 34 82 85 70 102 90 96 109 42 97 189 95 1.38 124 68 2 15 5.99 0.260 Welding 
022 81 F 20 123 116 78 122 143 131 134 50 75 69 83 1.14 129 41 0.5 13 3.01 0.221  
023 68 F 30 93 90 79 92 99 95 95 43 90 102 115 1.18 116 55 3 9 1.60 0.215  
024 62 F 21 121 109 86 108 97 103 78 31 78 64 83 1.24 120 48 2 9 1.17 0.195  
025 66 M 24 95 98 72 139 88 115 160 46 114 29 92 1.16 102 54 2 11 3.10 0.234 Farming 
029 84 M 24 102 80 87 79 114 67 58 35 92 65 53 1.03 64 36 5 14 2.74 0.229  
030 77 M 32 98 91 77 87 104 95 98 38 89 73 80 1.00 109 42 0 7 2.70 0.221  
031* 71 M 30 103 109 69 107 90 99 80 29 77 45 94 1.20 56 71 0.5 12 2.22 0.216 Fire Fighting 
032 69 F 29 106 103 78 91 130 108 99 39 81 39 107 1.17 169 49 2 13 1.83 0.215  
033* 80 M 26 89 94 68 93 93 93 101 40 74 82 82 1.11 113 40 3 12 4.63 0.222  
034 69 M 28 122 120 75 113 103 108 92 29 78 28 93 1.26 118 63 4 15 2.46 0.196  
035 74 F 31 107 103 77 152 137 145 179 56 76 107 96 1.06 179 44 3 13 1.67 0.187  
036* 78 M 24 106 109 69 124 77 103 106 39 75 51 92 1.30 122 67 1 8 2.73 0.206 Farming 
038 79 F 29 108 111 71 116 102 110 96 43 73 106 81 1.00 145 52 2 11 1.25 0.196 Farming 
039 71 F 32 122 115 80 86 153 115 101 39 89 102 96 1.25 161 56 3 14 0.65 0.210  
041 71 F 31 89 87 78 110 116 112 134 51 101 99 99 1.18 184 56 3 13 3.62 0.216  
042 61 F 26 98 94 81 123 103 114 137 47 87 64 89 1.07 117 39 3 15 1.38 0.200  
044 65 F 28 95 88 82 92 109 99 105 44 81 61 68 1.15 110 30 4 13 1.82 0.194  
045 77 F 31 116 109 80 98 135 113 110 45 90 82 100 1.25 140 65 4 13 1.49 0.194  
046 73 F 27 102 90 85 92 93 92 81 40 81 73 100 1.00 80 100 0 6 2.29 0.218  
047 63 F 23 114 109 80 111 120 115 104 37 99 78 69 1.14 94 37 1 8 2.68 0.203 Farming 
049 63 F 23 126 137 71 88 71 123 87 29 96 92 71 1.48 114 47 0.5 11 0.85 0.183  
050 66 F 22 123 117 80 132 105 121 2 38 91 48 68 1.29 101 39 0.5 7 0.72 0.188  
052 68 F 30 122 110 84 108 128 117 116 43 119 63 120 1.12 177 59 3 9 1.83 0.197  
053 75 F 33 111 107 78 73 128 96 78 37 86 41 103 1.14 181 51 1 9 1.58 0.243 Farming 
054 65 F 27 102 111 70 98 121 108 86 33 119 44 68 1.07 98 34 3 13 2.30 0.192  
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055 66 M 24 114 96 88 92 121 106 127 41 90 34 55 1.11 66 35 0.5 13 2.08 0.190  
056 61 F 25 108 102 81 105 127 115 122 41 72 58 76 1.20 105 41 6 18 2.10 0.206  
057 78 F 29 114 117 72 84 134 105 98 44 87 79 82 1.07 159 40 3 15 1.60 0.205  
059 79 M 26 116 98 83 78 91 84 87 41 74 85 62 1.06 93 40 0 9 2.83 0.221 Farming 
060 77 F 24 120 112 80 104 107 105 106 47 91 89 84 1.14 135 47 2 14 1.27 0.195  
061# 74 F 24 72 71 77 126 83 108 153 64 90 34 65 1.03 92 30 3 7 3.26 0.231  
062 82 M 26 164 135 84 127 101 115 110 39 91 51 101 1.20 125 74 3 9 3.48 0.209  
063# 67 M 31 72 77 70 90 87 88 93 36 89 100 90 1.10 125 41 1 7 4.17 0.232 
Foundry and 
Steel Milling 
064 69 M 25 130 123 78 134 111 123 134 37 90 50 96 1.30 120 61 2 10 1.79 0.193 Farming 
065 69 F 26 109 113 73 127 99 115 111 41 80 68 59 1.24 79 37 2 13 1.59 0.193  
066 73 M 28 110 104 76 101 112 106 99 34 82 55 111 1.34 156 99 3 12 2.10 0.207  
#: GOLD-Unclassified, *: Stage I COPD, **:Stage II COPD 
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Figure 2-2 3He MRI for four representative subjects 
3He MRI ventilation (in blue) co-registered with anatomical 1H MRI (grey-scale) of the 
centre coronal slice.  Subject 64 (S64) is a 69 year old male: FEV1=130%, 
FEV1/FVC=78%, slice number shown: 7.  Subject 19 (S19) is a 67 year old male: 
FEV1=131%, FEV1/FVC=75%, slice number shown: 8.  Subject 20 (S20) is a 78 year old 
male: FEV1=101%, FEV1/FVC=68%, slice number shown: 9.  Subject 15 (S15) is a 65 
year old female: FEV1=91%, FEV1/FVC=81%, slice number shown: 8. Yellow arrows 
identify the position of ventilation defects. DI = Deep Inspiration. 
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Figure 2-2 shows 3He MRI coronal slices at baseline, post-DI, and post-salbutamol for 
four representative subjects.  For the subject shown without ventilation defects, there was 
homogeneous signal intensity over the entire lung with no obvious ventilation defects in 
the centre MR slice or any of the anterior to posterior slices.  For two representative 
subjects that showed an imaging response to DI or salbutamol, there were ventilation 
defects peripherally located in the central and posterior slices that resolved (arrows) in 
response to DI or bronchodilation.  For the representative subject with ventilation defects 
that did not appear to respond to DI or salbutamol, a number of small peripheral ventilation 
defects (arrows) remained spatially persistent post-DI and 25 minutes after salbutamol 
inhalation.   
For the three comparator groups (Table 2-1) there was no significant difference for age, 
sex or BMI.  However, there was a significant difference for FEV1/FVC (p=0.004), VDP, 
3He COV, VDP ∆PA and PA gradient (p<0.001) as well as relative peripheral VDP 
(p=0.001).  There was no significant difference for any CPET or other pulmonary function 
measurements for the three subgroups.  Post-hoc analysis showed that the imaging 
responder group had significantly lower FEV1/FVC and significantly higher VDP, 
3He 
COV, PA ∆VDP, and relative peripheral VDP than the no defect and no imaging response 
groups.  Figure 2-3 shows scatter plots for VDP, relative peripheral VDP, VDP ∆PA, VDP 
∆SI, PA VDP gradient, SI VDP gradient and 3He COV.  
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Figure 2-3 Scatter plots of MRI metrics 
Plots showing all MRI metrics for three subgroups (non-imaging responders, imaging 
responders, and no defects). A) VDP and relative peripheral VDP, B) VDP ∆PA and VDP 
∆SI, C) PA and SI gradients, and, D) 3He COV. Error bars are the standard deviation of 
the mean. 
Table 2-2 shows that 13 subjects reported significant exposure, 10 of whom (77%) had 
ventilation defects.  Of those 10 subjects, three showed an imaging response to DI or 
salbutamol.  Table 2-2 also shows that eight never-smokers had spirometry evidence of 
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airway obstruction34 (GOLD Unclassified (U) (n=2), GOLD 1 (n=4), GOLD 2 (n=2)).  Five 
of these eight subjects reported second-hand smoke or occupational exposures and two 
subjects responded to salbutamol.  In addition, 10 never-smokers had 0.70≤ FEV1/FVC 
≤0.73, where the 0.73 threshold was used to compensate for the variability in FEV1 and 
FVC.35,36  The eight never-smokers with spirometry evidence of COPD had significantly 
greater VDP (5.5±3.1%, p<0.001) than the never smokers with (VDP=2.5±1.2%) or 
without (VDP=1.6±0.7%) ventilation defects.  When the subjects with spirometry evidence 
of COPD (n=8) were removed in a sub analysis, only VDP remained significantly different 
across all three subgroups (p=0.03).  Post-hoc analysis showed that the no imaging 
response group had greater baseline VDP than the no defect group, but was not 
significantly different from the imaging response group. 
2.3.2 Pre- and Post-DI/Salbutamol Analysis 
Table 2-3 shows a subject listing for pre- and post-salbutamol FEV1, VDP, and 
3He COV 
for all subjects administered salbutamol (n=35).  Three subgroups were identified for those 
subjects administered salbutamol: imaging-responders, FEV1-responders, and non-
responders.  Twenty-eight of 35 subjects did not show an imaging response or an FEV1 
response to salbutamol.  There were five subjects who responded to salbutamol 
(ΔFEV1>200ml), but did not have an imaging (VDP or cluster 1) response to salbutamol.  
In addition, for these five subjects, there was no significant change in any of ventilation 
clusters 2-5 or any combination of ventilation clusters (i.e. C1+C2) post-salbutamol.  It is 
worth noting that one of the five FEV1-responders reported 30 years of occupational 
exposure working in the steel mill industry (S63) while two were lifelong farmers (S25 and 
S59).  Finally, for those subjects administered salbutamol, there were no relationships for 
the change in FEV1 post-salbutamol with change in VDP (r
2=0.04, p=0.50) or change in 
3He COV (r2=0.08, p=0.10).  
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Table 2-3 Subject Listing for FEV1, VDP and 
3He COV for all subjects administered 
salbutamol (n=35) 
Table 2-4 shows VDP and 3He COV measurements for all three time points for imaging 
responders (DI or salbutamol responders).  There were no statistically significant 
differences in 3He COV or VDP across time points for the imaging responders. 
  
Subject  Pre-Salbutamol Post-Salbutamol 
 Age 
(yrs) 
FEV1 
(L) 
FEV1 
(%pred) 
VDP 
(%) 
3He 
COV 
FEV1 
(L) 
FEV1 
%pred 
VDP 
(%) 
3He 
COV 
Δ 
FEV1 
(L) 
Δ 
FEV1 
%pred 
Δ 
VDP 
% 
001 74 1.68 89 1.35 0.20 1.70 91 0.84 0.20 0.02 2 -0.51 
002# 68 2.52 101 2.34 0.21 2.72 109 1.65 0.20 0.20 8 -0.69 
003 76 1.30 70 9.17 0.27 1.34 72 8.15 0.28 0.04 2 -1.02 
004 69 3.33 94 4.49 0.24 3.31 94 4.02 0.24 -0.02 0 -0.47 
005 77 3.36 133 1.32 0.20 3.06 122 1.55 0.21 -0.30 -11 0.23 
006 66 3.30 88 2.87 0.23 3.29 88 2.73 0.22 -0.01 0 -0.14 
007 65 2.01 86 1.43 0.20 2.08 89 2.11 0.22 0.07 3 0.68 
012 71 2.78 84 3.76 0.23 2.66 81 2.87 0.23 -0.12 -3 -0.90 
015 65 2.38 91 2.61 0.20 2.52 96 2.29 0.21 0.14 5 -0.33 
016 67 3.80 120 2.22 0.21 3.88 123 1.65 0.22 0.08 3 -0.57 
017* 69 1.24 59 10.6 0.29 1.35 64 7.91 0.27 0.11 5 -2.70 
018 61 3.06 111 5.26 0.22 3.14 114 5.62 0.24 0.08 3 0.36 
020* 78 2.76 101 7.49 0.24 3.02 110 3.47 0.24 0.26 9 -4.02 
021 74 2.32 82 5.65 0.26 2.41 85 3.25 0.25 0.09 3 -2.40 
022# 81 2.18 123 2.92 0.22 2.43 137 5.37 0.23 0.25 14 2.45 
023 68 1.96 93 1.57 0.22 2.09 99 1.25 0.21 0.13 6 -0.32 
025# 66 3.54 95 3.01 0.23 3.78 102 2.33 0.22 0.24 7 -0.68 
031 71 3.14 103 2.17 0.22 3.15 103 1.93 0.22 0.01 0 -0.24 
032 69 2.75 106 1.79 0.22 2.82 109 1.56 0.21 0.07 3 -0.24 
033 80 2.86 89 4.42 0.22 2.76 86 6.13 0.23 -0.10 -3 1.71 
036 78 2.88 106 2.73 0.21 3.06 112 1.92 0.20 0.18 6 -0.81 
041 71 2.19 89 3.49 0.22 2.31 94 3.38 0.22 0.12 5 -0.11 
044 65 2.24 95 1.79 0.19 2.14 90 1.84 0.22 -0.10 -5 0.05 
045 77 2.44 116 1.46 0.19 2.31 109 2.02 0.21 -0.13 -7 0.55 
046 73 2.06 102 2.35 0.22 1.90 94 2.14 0.22 -0.16 -8 -0.21 
047 63 2.52 114 2.61 0.20 2.53 116 3.09 0.20 0.01 2 0.48 
052 68 2.55 122 1.83 0.20 2.63 125 1.58 0.19 0.08 3 -0.25 
054 65 2.42 102 2.24 0.19 2.49 105 3.33 0.20 0.07 3 1.08 
056 61 3.12 108 2.10 0.21 3.19 110 1.90 0.21 0.07 2 -0.20 
057 78 2.23 114 1.58 0.21 2.27 116 1.29 0.21 0.04 2 -0.28 
059# 79 2.53 116 2.83 0.22 2.73 125 2.90 0.22 0.20 9 0.07 
060 77 2.36 120 1.26 0.20 2.37 121 1.55 0.20 0.01 1 0.29 
061 74 1.53 72 3.15 0.23 1.59 75 5.21 0.24 0.06 3 2.03 
063# 67 2.46 72 4.00 0.23 2.94 86 3.72 0.22 0.48 14 -0.28 
065 69 2.57 109 1.59 0.19 2.70 114 1.79 0.20 0.13 5 0.20 
Imaging Responders* 
Mean (SD) n=2 
74 
(6) 
2.0 
(1.1) 
80  
(30) 
9.0 
(2.2) 
0.27 
(0.04) 
2.2 
(1.2) 
87 
(33) 
5.7 
(3.0) 
0.26 
(0.02) 
0.2  
(0.1) 
7.0  
(2.8) 
-3.4 
(0.9) 
FEV1 Responders# 
Mean (SD) n=5 
74 
(7) 
2.7 
(0.5) 
102 
(20) 
3.1 
(0.5) 
0.22 
(0.01) 
3.0 
(0.5) 
112 
(20) 
3.3 
(1.3) 
0.22 
(0.01) 
0.3 
(0.1) 
10.0 
(3.8) 
0.2 
(1.3) 
Non-responders 
Mean (SD) n=28 
71 
(5) 
2.5 
(0.6) 
100 
(16) 
2.8 
(1.7) 
0.21 
(0.02) 
2.5 
(0.6) 
101 
(15) 
2.7 
(1.7) 
0.22 
(0.02) 
0.00 
(0.1) 
1.0 
(4.4) 
-0.04 
(0.8) 
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Table 2-4 VDP and 3He COV measurements for imaging responders 
 Baseline Post-DI Post-Salbutamol 
Imaging Responders (n=6) 
VDP % (±SD) 5.8 (3.8) 4.7 (2.6) 5.7 (3.1) 
3He COV (±SD) 0.24 (0.04) 0.24 (0.04) 0.25 (0.02) 
DI Responders (n=4) 
VDP % (±SD) 4.2 (3.5) 3.5 (2.3) -- 
3He COV (±SD) 0.23 (0.04) 0.23 (0.04) -- 
Salbutamol-Responders (n=2) 
VDP % (±SD) 9.0 (2.2) 7.0 (1.0) 5.7 (3.1) 
3He COV (±SD) 0.26 (0.04) 0.25 (0.03) 0.25 (0.02) 
2.3.3 Relationships between Imaging and other Measurements 
Table 2-5 shows the results of a forward stepwise multivariate regression model using 3He 
VDP as the dependent variable and all significant pulmonary function test measurements 
(obtained from the univariate analysis) as the independent variables.  FEV1%pred, IC%pred, 
and Raw%pred were shown to predict 45% of the variability in VDP (p=0.001), with 
FEV1%pred making the greatest contribution.  The univariate relationships are shown in 
Figure 2-4 including FEV1%pred (r
2=0.29, p<0.0001), Raw%pred (r
2=0.29, p<0.0001), and 
IC%pred (r
2=0.17, p=0.003).  There were no statistically significant relationships for VDP 
with CPET, dyspnea, or occupational exposure measurements.  It is important to note that 
three subjects had VDP ≥ 3SD of the mean and when these data were removed from the 
regression analysis, FEV1%pred (r
2=0.13, p=0.009) and IC%pred (r
2=0.17, p=0.003) was 
significantly related to VDP, and Raw%pred was not.   
Table 2-5 Univariate and Multivariate relationships for 3He MRI VDP with pulmonary 
function measurements 
  
Parameters Univariate Relationship VDP  
r2 (p value) 
Multivariate Model VDP 
β, r2, ∆r2 (p-value) 
FEV1 %pred  0.29 (<0.001) -0.541, 0.292, 0.292 (<0.001) 
Raw %pred 0.29 (<0.001) 0.359, 0.391, 0.099 (<0.001) 
IC %pred  0.17 (0.003) -0.265, 0.449, 0.058 (<0.001) 
FEV1/FVC %  0.17 (0.002) -0.147, 0.449, 0 (0.23)  
FVC %pred  0.24 (<0.002) 0.114, 0.449, 0 (0.68) 
RV/TLC %  0.15 (0.005) 0.105, 0.449, 0 (0.44) 
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Figure 2-4 Univariate Relationships for 3He MRI VDP 
Univariate correlations for VDP with: A) FEV1 %pred for all subjects (r
2=0.29, r=-0.54, 
p<0.0001), B) Raw %pred for all subjects (r
2=0.29, r=0.54, p<0.0001), and, C) IC %pred for 
all subjects (r2=0.17, r=-0.41, p=0.003). Grey circles show the subjects with VDP >3SD of 
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the mean.  Grey regression line shows the alternate regression line that resulted from when 
these subjects were excluded. 
2.4 Discussion 
To better understand the determinants and physiological consequences of ventilation 
defects in older never-smokers, we evaluated pulmonary function and CPET 
measurements, as well as occupational/second-hand smoke exposure in 52 older adults.  
We made a number of key observations including: 1) three quarters of older never-smokers 
had ventilation defects, the majority of whom showed no VDP response to either DI or 
salbutamol, 2) ventilation heterogeneity and VDP were significantly greater, and 
FEV1/FVC was significantly lower (p<0.05) for subjects with ventilation-defects 
responsive to DI/salbutamol compared to subjects without ventilation defects and subjects 
with ventilation-defects with no response to DI/salbutamol and, 3) in a multivariate model, 
FEV1, IC and Raw explained nearly 50% of the variability in 
3He VDP in these older never-
smokers.  
2.4.1 Ventilation Abnormalities in Older Never-Smokers 
In the 39 subjects with visually obvious ventilation defects, VDP was modest and lower 
than previously reported in COPD and asthma subjects; furthermore, only four subjects 
showed a change in VDP in response to DI.  This is consistent with previous findings that 
showed that the bronchodilatory effects of DI decrease with age,37 which may explain the 
low number of DI responders in this study.  Similar to previous observations in COPD38 
and asthma,26,28 two subjects showed an imaging response to salbutamol and this supports 
previous findings that reversible airflow limitation may be underappreciated in the elderly.  
Unexpectedly, the majority of older never-smokers with visually obvious ventilation 
defects (n=33/39, 85%) did not respond to DI or salbutamol.  This is consistent with the 
notion that in older never-smokers, small ventilation defects are related to irreversible 
airway narrowing or collapse, loss of elastic recoil and/or small peripheral regions that are 
slow filling.   
The majority of defects were observed along the periphery of the lung suggesting that 
terminal airway closure or narrowing may be a “normal” age-related pulmonary finding.  
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Relative peripheral VDP, 3He COV, VDP ∆PA, and VDP PA gradient were significantly 
greater in the imaging responders compared to the non-responder and no defect groups.  
Together these findings suggest that subjects who responded to DI or salbutamol also had 
greater ventilation heterogeneity (or patchiness) and greater posterior/peripheral 
ventilation defects.  The difference in ventilation heterogeneity between groups may reflect 
differences in lung filling related to airway lumen morphology, but this is yet to be 
determined.  Other potential mechanisms for ventilation heterogeneity have been suggested 
including the loss of parenchymal tethering forces due to alveolar collapse that alters 
airway diameters, differences in regional lung expansion due to diaphragm and ribcage 
motions, or gravity-dependent differences in lung expansion contributing to airway 
constriction in the gravity-dependent regions.39  Nevertheless, in these older never-smokers 
there appears to be a small, yet irreversible VDP component.  Finally, as might be expected 
based on the BOLD study,22 eight subjects showed spirometry evidence of COPD and 
another ten subjects exhibited 0.70<FEV1/FVC≤0.73 (0.73 accounts for FEV1 and FVC 
variability of 2-3%).35,36  Therefore, here, the proportion of subjects with undiagnosed 
airflow limitation was 35%, which is in agreement with the results of the BOLD study.22  
It is interesting to note that when the eight subjects with spirometry evidence of COPD 
were removed from the analysis, FEV1/FVC was no longer different across the three sub-
groups, however, VDP remained different.  For five subjects with an FEV1 response to 
salbutamol > 200ml, there were no significant changes in VDP, 3He COV or any of the 
ventilation clusters (C2-C5) post-salbutamol.  The discrepancy between FEV1 response 
and 3He MRI response may have been due to the effort-dependence of spirometry.  It is 
also important to note that all ventilation defects were peripherally located, near the distal 
airways, and this may also explain why salbutamol did not influence the size or magnitude 
of these ventilation defects. 
2.4.2 Relationships: Ventilation Defects with Exercise Capacity and 
Dyspnea 
In this study, the range of dyspnea scores and magnitude of ventilation defects observed 
were small as compared with recent findings in COPD and asthmatic subjects.24,26,28,38  For 
these reasons, we were not surprised that there were no differences in CPET or dyspnea 
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measurements between subjects with and without ventilation defects.  Further supporting 
this finding, O’Donnell and colleagues have shown that it is possible to have substantial 
ventilatory impairment during exercise without a corresponding effect on dyspnea.20  This 
is consistent with the notion that in healthy subjects, cardiovascular, and not respiratory 
factors provide the dominant contributions to exercise limitation.40,41  Furthermore, unlike 
previous work,7 there were no relationships between dyspnea and other pulmonary function 
or CPET measurements which could be due to the limited range of dyspnea scores reported.  
Subjects with ventilation defects had normal lung function and exercise capacity 
measurements for their age. 6,7,42   
2.4.3 Relationships: Ventilation Defects with Pulmonary Function and 
Volumes 
There were significant but weak univariate relationships for VDP with FEV1%pred, IC%pred 
and Raw%pred, although the relationship between VDP and Raw%pred was dominated by 
three subjects with relatively large VDP values (S3, S17, and S21).  S21 had occupational 
and environmental exposures, and both S3 and S17 had spirometry evidence of GOLD II 
COPD.  In a multivariate regression model, IC%pred, Raw%pred, and FEV1%pred all provided 
significant contributions to VDP, with FEV1%pred being the strongest predictor.  The 
negative correlation of IC%pred with VDP is concordant with previous results in COPD ex-
smokers which showed that abnormal IC is a marker of expiratory flow-limitation and a 
predictor of dynamic hyperinflation during exercise.43  An increase in dynamic 
hyperinflation results in an increased elastic load on the inspiratory muscles, thus 
increasing the work and cost of breathing.  This mechanical constraint can predispose 
individuals to fatigue and it has been shown that dynamic hyperinflation contributes to 
perceived exertional dyspnea in subjects with COPD.43-45  It is also interesting to note that 
resting IC can predict the peak symptom-limited VO2 in patients with expiratory flow-
limitation at rest.45   
2.4.4 Limitations 
We recognize a number of limitations that restrict the general applicability of our results.  
First, subjects were classified by viewing the grayscale images while the patients were still 
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in the scanner.  Offline, once the ventilation images were co-registered to the anatomical 
1H images, in two cases, previously classified ventilation defects could be directly related 
to anatomical bony structures and were unlikely to be ventilation abnormalities.  As a 
result, two subjects who were classified at the scanner as having ventilation defects, did 
not appear to have these once a full analysis was completed, although both completed DI 
and salbutamol inhalation.  One subject had ventilation defects that responded to DI (but 
not salbutamol) whereas the other subject had no ventilation defects and did not respond 
to DI or salbutamol.  We did not remove these subjects from the analysis and their inclusion 
did not alter the final overall results.  It should also be noted that since all subjects were 
imaged approximately 30 minutes after completion of CPET, ventilation defects and 
ventilation heterogeneity may have been influenced by exercise.  Previous studies have 
shown that during exercise athletes experience ventilation-perfusion mismatch and 
diffusion limitation.46  Other studies have evaluated the progression of ventilation-
perfusion mismatch after exercise and showed that some subjects don’t recover fully from 
ventilation-perfusion mismatch until 20 minutes post-exercise.47  Because of the time delay 
between imaging and CPET and the fact that in this study, VDP did not correlate with any 
CPET measurements, it is unlikely that prior exercise influenced the presence or absence 
of 3He MRI ventilation defects. 
2.4.5 Conclusions 
In summary, we evaluated hyperpolarized 3He MRI ventilation defects—a surrogate 
measurement of airway function—in the first, large imaging study of healthy older never-
smokers with no history of chronic heart or lung disease.  While a minority of subjects 
reported occupational exposures, most subjects had visually obvious ventilation defects 
that did not change after DI or salbutamol administration suggesting that terminal airway 
closure or narrowing may be a normal age-related lung finding.  While there were no 
differences in CPET or conventional pulmonary function measurements between subjects 
with and without ventilation defects, FEV1%pred in combination with IC%pred and Raw%pred 
predicted VDP in a multivariate regression model.  Taken together, these findings provide 
a better understanding of the nature of ventilation defects in healthy older never-smokers.  
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CHAPTER 3 
3 ULTRA-SHORT ECHO TIME PULMONARY 
MAGNETIC RESONANCE IMAGING: EVALUATION 
AND REPRODUCIBILITY IN COPD SUBJECTS WITH 
AND WITHOUT BRONCHIECTASIS 
To better understand the potential for ultra-short echo time MRI to provide quantitative 
COPD endpoints, we evaluated the reproducibility and consequences of signal-intensity in 
COPD subjects with and without bronchiectasis. We compared UTE MR measurements 
with CT measurements of radiodensity and pulmonary function test measurements. 
The contents of this chapter were previously published in the Journal of Magnetic 
Resonance Imaging: W Ma, K Sheikh, S Svenningsen, D Pike, F Guo, R Etemad-Rezai, J 
Leipsic, HO Coxson, DG McCormack, and G Parraga. J Magn Reson Imaging 2015; 
41(5):1465-1474.  Permission to reproduce this article was granted by John Wiley & Sons 
and is provided in Appendix A.  
3.1 Introduction 
Computed tomography (CT) provides the main anatomical/morphological measurements 
for research and clinical investigations in patients with chronic obstructive pulmonary 
disease (COPD).  Large multi-centre studies such as ECLIPSE,1 COPDGene2 and MESA3 
have highlighted the quantitative information that CT provides including structure-function 
phenotypes related to airway (including airway thickening and bronchiectasis) and 
parenchymal abnormalities that are regionally and heterogeneously distributed in 
obstructive lung disease.4  Cumulative radiation exposure related to thoracic CT imaging 
remains a concern5 and limits CT use in serial and longitudinal studies.    
MRI using short and ultra-short echo time (UTE) acquisition methods, was first proposed 
as a way to address the inherent challenges of pulmonary imaging stemming from low 
tissue and proton density.6  UTE MRI combines fast radiofrequency (RF) excitation pulses 
and efficient k-space sampling trajectories to minimize MR signal decay and motion 
artifacts.6  Pulmonary UTE methods have been used to estimate pulmonary emphysema in 
COPD patients7 lobar fissures and airways in pulmonary fibrosis8 as well as inflammation 
and peribronchial abnormalities in animal models of asthma.9   
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Before UTE measurements can be used in longitudinal clinical studies of respiratory 
disease or for monitoring treatment effects, it is critical to understand the inherent 
variability that can be attributed to image acquisition methods, including those related to 
the scanner (e.g. field strength and coils used) and subject compliance (e.g. breath-hold, 
motion, and position).  We hypothesized that rapid, single breath-hold UTE MRI could be 
optimized to reproducibly quantify abnormalities in COPD and that both low density 
parenchymal abnormalities and high density abnormalities such as airway thickening and 
mucous plugs could be quantified.  Therefore, our objective was to evaluate rapid 
pulmonary MRI using UTE methods with comparison to quantitative CT scan 
measurements and pulmonary function tests of subjects with COPD. 
3.2 Materials and Methods 
3.2.1 Study Logistics 
All subjects and healthy volunteers provided written informed consent to a protocol 
approved by a local research ethics board and Health Canada; the study was compliant with 
the Personal Information Protection and Electronic Documents Act (PIPEDA, Canada).  
MRI was performed 10 minutes after completion of spirometry and plethysmography that 
were performed using a MedGraphics Elite Series plethysmograph (MedGraphics, St. Paul, 
Minnesota, USA).  For seven subjects with COPD, (n=3 with emphysema; n=4 with 
emphysema and bronchiectasis) there was a three-week follow-up visit to determine UTE 
signal intensity and 3He apparent diffusion coefficients (ADC) reproducibility.  3He ADC 
reproducibility analysis was conducted as an internal control of reproducibility 
comparisons with the 1H UTE measurements. 
CT evidence of bronchiectasis was established by an experienced chest radiologist with 
>20 years experience (RER) and defined by an enlarged bronchial diameter, the failure of 
larger airways to taper while progressing to the lung periphery, bronchial wall thickening, 
mucous in the dilated airways, and tree-in-bud nodularity.10  All subjects had a clinical 
diagnosis of COPD with CT evidence of emphysema or both emphysema and 
bronchiectasis and were categorized according to the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) grades.11 
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3.2.2 Pulse Sequence 
A research prototype two-dimensional pulse sequence (Figure 3-1) with interleaved half-
pulse excitation and 2D radial k-space trajectories was used.6  There was no dephasing lobe 
after the slice-select gradient and two half-sinc excitations were required per slice to 
remove inter-slice cross-talk.   To decrease acquisition time, we adapted a compressed 
sensing algorithm that was previously described.12   
 
Figure 3-1 Pulse sequence diagram for 2D UTE with interleaved half-pulse excitation and 
2D radial k-space trajectories 
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3.2.3 Image Acquisition 
MRI was performed on a whole body 3T MR750 (General Electric Health Care [GEHC], 
Milwaukee, Wisconsin).  To ensure that the same location was imaged at baseline and 
follow-up, we used the same fiducial landmarks and values for each of the three plane 
localizer scans performed.  Briefly, using the sternum and spinal cord fiducials in the 
anterior-posterior direction, the scan space was divided into slices with slice 
thickness=15mm.  In this manner, the same centre slice could be imaged which was 
typically the fifth coronal slice from the posterior direction and the slice that allowed for 
visualization of the carina.  Centre slice 1H UTE MRI was obtained in the coronal plane 
using a 32-channel torso coil and the single channel body coil for comparison (GEHC) (13s 
acquisition time, repetition time (TR) /echo time (TE)/flip angle=13.0ms/0.05ms/10°, 
field-of-view (FOV)=40×40cm, matrix 256×511, number of excitations (NEX)=2, 15mm 
slice thickness) at a lung volume of functional residual capacity (FRC)+1L.  For 
comparison, coronal 1H MRI was performed with a 32-channel torso coil using a fast-
spoiled, gradient-recalled echo (FGRE) sequence (16s acquisition time, TR/TE/flip 
angle=4.7ms/1.2ms/30°, FOV=40×40cm, matrix 256×128, NEX=1, 14 slices, 15mm slice 
thickness).  Diffusion-weighted hyperpolarized 3He MRI was performed using a fast 
gradient-echo sequence with centric k-space sampling as previously described.13  In 
healthy volunteers, UTE MRI was acquired in the coronal plane at four different lung 
volumes (23s acquisition time, TR/TE/flip angle=13.0ms/0.05ms/10°, FOV=40×40cm, 
matrix 256×439, NEX=4, 15mm slice thickness): full expiration (FE), FRC, FRC+1L, and 
full inhalation (FI).  Thoracic CT was acquired in all COPD patients at FRC+1L, within 30 
minutes of MRI, using a 64-slice Lightspeed VCT scanner (GEHC) using a detector 
configuration of 64×0.625mm, 120kVp, 100 effective mA, tube rotation time of 500ms, 
and a pitch of 1.0. 
3.2.4 Image Analysis 
We adapted definitions of the normalized contrast-to-noise ratio (𝐶𝑅) and the apparent 
signal-to-noise ratio (𝑆𝑅) as previously described
8  where 𝑆𝐼𝑙𝑢𝑛𝑔 is the mean signal intensity 
of the lung, 𝑆𝐼𝑎𝑖𝑟 is the signal intensity of air outside of the subject, 𝑆𝐼𝑙𝑖𝑣𝑒𝑟 is the mean 
signal intensity of the liver, 𝑆𝐼𝑣𝑒𝑠𝑠𝑒𝑙 is the mean signal intensity of the aorta:   
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Equation 3-1 
𝐶𝑅 =
𝑆𝐼𝑙𝑢𝑛𝑔−𝑆𝐼𝑎𝑖𝑟
𝑆𝐼𝑣𝑒𝑠𝑠𝑒𝑙
. 
Equation 3-2 
                                                             𝑆𝑅 =
𝑆𝐼𝑙𝑢𝑛𝑔
𝑆𝐼𝑎𝑖𝑟
.                                                            
Absolute 1H signal intensity was normalized to the liver in the same images   
(𝑆𝐼 𝑆𝐼𝑙𝑖𝑣𝑒𝑟 × 100%⁄ ) to account for potential inter-scan variability in RF amplification and 
coil positioning.  The 1H SI coefficient of variation (COV) was calculated as the ratio of 
the standard deviation of the lung parenchyma signal intensity to the mean of the lung 
parenchyma signal intensity.  The 15th percentile of the signal intensity histogram (SI15) 
was compared with CT threshold measurements. 
For healthy volunteers, manually segmented FRC+1L images were registered to the other 
three lung volumes as previously described.14  3He MRI apparent diffusion coefficient 
(ADC) maps were generated using software, as previously described.13  For CT image 
analysis,  Pulmonary Workstation 2.0 (VIDA Diagnostics Inc., Iowa City, IA) was used to 
quantify tissue attenuation in Hounsfield units (HU) based on the relative area of the 
density histogram≤-950 HU (RA950), 15th percentile of the density histogram (HU15), mean 
radio-density, wall area percent (WA%), and lumen area (LA) for the segmental and 
subsegmental airways.15  Signal intensity and CT density histograms were generated by 
combining all the pixel values of the corresponding subgroup or lung volume together.  
Histograms were normalized to the area beneath the curve. 
3.2.5 Statistics 
Independent t-tests, the Shapiro-Wilk test for normality, analysis of variance (ANOVA) 
and post-hoc analysis using the Holm-Bonferroni correction were performed using IBM 
SPSS Statistics 21.0 (SPSS Inc., Chicago, IL, USA).  The data was normal and therefore 
parametric tests were used.  Univariate relationships were determined using linear 
regression (r2) and Pearson correlation coefficients (r) using Prism GraphPad version 6.00 
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(GraphPad Software, San Diego, CA).  To evaluate three-week reproducibility, a repeated 
measures analysis of variance (ANOVA) was used for UTE signal intensity and ADC using 
IBM SPSS Statistics 21.0 (SPSS Inc., Chicago, IL, USA).  Linear regression and Pearson 
correlation coefficients (r) were used to determine 3-week correlations and the relationship 
between UTE signal intensity and SR using GraphPad Prism version 6.00 (GraphPad 
Software Inc, San Diego, CA). The COV which is the ratio of the standard deviation of all 
measurements and the mean of repeated measurements was used to evaluate repeat imaging 
reproducibility.  A two-way mixed model intra-class correlation coefficient (ICC) analysis 
for absolute agreement was also used to determine reproducibility.  Fisher z-transformation 
was used to determine the significance of difference between Pearson correlation 
coefficients.  Results were considered significant when the probability of making a Type I 
error was less than 5% (p<0.05).   
3.3 Results 
3.3.1 Subject Demographics 
Twenty subjects were evaluated including five healthy volunteers and 15 subjects (60±39 
pack-years) with a clinical diagnosis of COPD, based on symptoms and GOLD criteria.  
For eight COPD subjects, there was qualitative CT evidence of emphysema only, whereas 
in seven COPD subjects, there was both emphysema and bronchiectasis.  Table 3-1 shows 
subject demographics and pulmonary function measurements for healthy volunteers, all 
COPD subjects and stratified into COPD subjects with emphysema, and subjects with both 
emphysema and bronchiectasis.   
3.3.2 Relationship between Lung Density and Signal Intensity 
Figure 3-2 shows the centre coronal slice for a healthy 22yr male using a conventional 
FGRE sequence and two different UTE imaging schemes.  The normalized lung 
parenchyma signal intensity increased from 6% to 27% using 32-channel UTE MRI with 
compressed sensing.  The bar graphs in the right panel show the significant improvements 
in signal intensity (p<0.001), SR (p=0.002), and CR (p<0.001) for the 32-channel UTE 
sequence as compared to the single-channel UTE and 32-channel FGRE approaches.  
Figure 3-3 shows UTE images acquired for a representative healthy volunteer at four 
 94 
 
different lung volumes and shows the qualitative differences in parenchymal signal 
intensity at full expiration compared to full inspiration.  Figure 3-3 also shows the strong 
and significant relationships of nominal lung mass-density with signal intensity using MRI-
derived (r2=0.98, r=0.99, p=0.007) and plethysmography-derived (r2=0.89, r=0.94, p=0.06) 
lung volumes for all healthy volunteers.  The relationship for signal intensity with MRI and 
plethysmography-derived volumes was not significantly different.  The frequency 
distribution of mean signal intensity for all four lung volumes is also shown in Figure 3-
3C, and shows a shift towards lower densities and narrowed distribution at higher lung 
volumes. 
Table 3-1 Subject demographic and pulmonary function test measurements 
Significance of difference (p<0.05) determined using an analysis of variance. H=healthy 
volunteer; E=CT evidence of emphysema only, E+B: CT evidence of emphysema and 
bronchiectasis; SD=standard deviation; BMI=body mass index; FEV1=forced expiratory 
in 1s; %pred=percent predicted; FVC=forced vital capacity; FRC=functional residual 
capacity; TLC=total lung capacity; RV=residual volume; DLCO=diffusing capacity of lung 
for carbon monoxide. 
 
  
COPD 
(n=15) 
GOLD Grade 
(n=15) 
Significant Difference 
 Healthy Emphysema 
Emphysema 
+Bronchiectasis 
GOLD I 
GOLD 
II 
GOLD 
III+IV 
H/E/E+B I/II/III+IV 
Mean (±SD) (n=5) (n=8) (n=7) (n=3) (n=6) (n=6) p p 
Age yrs 22(1) 67 (9) 65(8) 70 (9) 66 (8) 63 (9) <0.001 0.6 
Male Sex n 5 5 3 2 3 3   
BMI kg/m2 26(1) 28(4) 26(4) 28 (4) 29 (3) 25 (5) 0.5 0.2 
FEV1 %pred 101(14) 62(24) 54(19) 89 (8) 65 (9) 37 (8) 0.003 <0.001 
FVC %pred 99(14) 93(15) 82(26) 104 (7) 94 (22) 74 (17) 0.3 0.08 
FEV1/FVC % 85(3) 51(17) 49(12) 64 (11) 53 (11) 39 (10) <0.001 0.02 
TLC %pred 103(11) 123(11) 111(17) 118 (4) 109 (17) 126 (13) 0.05 0.4 
RV %pred 117(1) 174(52) 151(44) 142 (15) 129 (27) 208 (38) 0.1 0.002 
FRC %pred 101(16) 137(31) 134(36) 116 (13) 114 (24) 168 (15) 0.1 0.001 
DLCO %pred 132(18) 59(30) 58(19) 70 (38) 54 (4) 57 (32) <0.001 0.7 
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Figure 3-2 1H MRI of healthy volunteers 
Top panel: 32-channel FGRE MRI with mean normalized 1H SI=6%, SR=1.  Middle panel: 
single-channel UTE MRI with normalized mean 1H SI=11%, SR=3. Bottom panel: 32-
channel UTE MRI using compressed sensing (CS) with mean normalized 1H SI=27%, 
SR=7.  Right panel shows bar graphs with mean 
1H SI (normalized 1H signal intensity), 1H 
SR (apparent signal-to-noise ratio), and 
1H CR (normalized contrast-to-noise ratio) for all 
healthy volunteers (n=3 for signal channel UTE 1H measurements).  Significant differences 
between FGRE, signal-channel UTE, and 32-channel UTE MRI measurements shown by 
asterisks.  *p<0.01, **p<0.001. 
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Figure 3-3 Centre coronal slice MRI of a representative healthy volunteer 
A) UTE MR images of a 21 yr old male (FEV1=89%pred, FEV1/FVC=88%, 
DLCO=141%pred) at full expiration (FE), functional residual capacity (FRC), FRC+1L, and, 
full inspiration (FI) (from left to right); B) Normalized UTE signal intensity compared to 
lung mass-density derived from FGRE volumes in black (y=5.3x103x+6, r2=0.98, r=0.99, 
p=0.007) and with lung mass-density derived from plethysmography volumes in grey 
(y=3.2x103x+12, r2=0.89, r=0.94, p=0.06); C) Normalized UTE signal intensity histograms 
for mean of all healthy volunteers at four different lung volumes. 
3.3.3 Reproducibility 
Seven subjects with COPD (emphysema, n=3; emphysema with bronchiectasis, n=4) 
underwent a three-week follow-up visit.  Table 2 shows 1H and 3He MRI measurements at 
baseline and follow-up for seven subjects with COPD including COV, Pearson correlation 
coefficients, and ICC for 3-week re-scan measurements.  3He ADC measurements were 
used as an internal control for reproducibility comparisons with the 1H UTE measurements.  
There was no significant difference between baseline and 3-week 1H UTE signal intensity 
(Δ1H SI=0±2%, p=0.9), 1H SI SD (∆1H SI SD=0±1%, p=0.2), 1H SI COV (∆1H SI 
COV=2±4%, p=0.2), or 1H SI15 (Δ1H SI15=0±1%, p=0.6).  The COV for repeated 
measurements of 1H signal intensity and SI15 was 4% and 8%, respectively.  
Reproducibility is also shown in Figure 3-4 for a subject with emphysema and 
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bronchiectasis (Figure 3-4A) and for a subject with emphysema only (Figure 3-4B).  The 
corresponding histograms are shown for the baseline and three-week histograms for UTE 
signal intensity and ADC maps.  Figures 3-4C-4E show strong linear relationships for 
baseline and three-week normalized 1H signal intensity (r2=0.85, p=0.003), SI15 (r
2=0.67, 
p=0.02), and SR (r
2=0.74, p=0.01), respectively.  Figure 3-4F shows the strong linear 
relationship for baseline and three-week ADC measurements (r2=0.95, p=0.002).  There 
was no significant difference between 1H signal intensity and 3He ADC Pearson correlation 
coefficients (p=0.3).  Finally, there was no significant correlation between 1H signal 
intensity and SR (r
2=0.08, p=0.5). 
Table 3-2 Baseline and 3-week 1H and 3He measurements and reproducibility analysis 
*Including emphysema (n=3) and emphysema with bronchiectasis subjects (n=4). 1H 
SI=normalized centre slice signal intensity, 1H SI SD=standard deviation of the centre slice 
signal intensity, 1H SI COV=centre slice signal intensity coefficient of variation, 1H 
SI15=15
th percentile of the frequency distribution histogram of UTE signal intensities; 1H 
SR=centre slice apparent signal-to-noise ratio, 
1H CR=centre slice normalized contrast-to-
noise ratio, ADC=apparent diffusion coefficient, COV=coefficient of variation, ICC=intra-
class correlation coefficient. 
 
 COPD (n=7)* 
 
1H SI 
(%) 
1H SI SD 
(%) 
1H SI COV 
(%) 
1H SI15 
(%) 
1H SR 1H CR ADC 
(cm2/s) 
Measurements        
Baseline (±SD) 27(4) 3(2) 27(6) 19(3) 7(5) 0.19(0.05) 0.42(0.14) 
3-Week (±SD) 27(4) 3(1) 29(5) 19(2) 7(7) 0.17(0.07) 0.42(0.12) 
Reproducibility        
COV (%) 4 13 4 8 36 9 6 
Pearson r 0.87 0.84 0.85 0.82 0.85 0.09 0.97 
ICC 0.87 0.80 0.84 0.81 0.79 0.08 0.96 
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Figure 3-4 Baseline and 3-week images for two representative COPD subjects 
Baseline CT, baseline and 3-week UTE MRI signal intensity maps and 3He ADC maps 
with corresponding histograms. A) S20 is a 61 yr male with emphysema and 
bronchiectasis; B) S27 is a 51 yr male with emphysema. Shown below are linear 
regressions of inter-scan reproducibility for C) normalized 1H signal intensity (r2=0.85, 
r=0.87, p=0.003), D) SI15 (r
2=0.67, r=0.82, p=0.02), E) SR (r
2=0.74, r=0.85, p=0.01), and, 
F) ADC (r2=0.95, r=0.97, p=0.002). 
3.3.4 Quantitative Analysis 
Table 3-3 shows imaging measurements for healthy volunteers, COPD subjects with 
emphysema, and COPD subjects with both emphysema with bronchiectasis.  Independent 
t-tests showed significant signal intensity differences (p<0.05) for healthy volunteers as 
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compared to subjects with emphysema and subjects with both emphysema with 
bronchiectasis.  Healthy volunteers had significantly greater 1H signal intensity and 1H CR 
than subjects with emphysema and subjects with both emphysema with bronchiectasis.  
Healthy volunteers also had significantly greater 1H SI15 than the COPD subjects with 
emphysema, but this was not significantly different than subjects with both emphysema 
and bronchiectasis.  
Table 3-3 Imaging measurements for all subjects 
Significance of difference (p<0.05) determined using an analysis of variance. H=healthy 
volunteer; E=CT evidence of emphysema only, E+B: CT evidence of emphysema and 
bronchiectasis; SD=standard deviation; SI=normalized 1H signal intensity; SI15=15
th 
percentile of the frequency distribution histogram of UTE signal intensities; SR=apparent 
signal-to-noise ratio; CR=normalized contrast-to-noise ratio; ADC=apparent diffusion 
coefficients; RA950=relative area of the lung with attenuation values < -950 HU; 
HU15%=15
th percentile of the frequency distribution histogram in HU; LA=lumen area; 
BSA=body surface area; Pi10=airway wall thickness at an internal perimeter of 10mm. 
*Independent t-test shows significant difference between healthy volunteers (p<0.05). 
Figure 3-5 shows the MRI signal intensity maps, CT images and frequency distribution 
for MRI signal intensity and CT radio-density for two representative subjects with 
emphysema and two representative subjects with both emphysema and bronchiectasis.  The 
UTE signal intensity maps show regions of emphysema in blue and regions of 
inflammation, mucous, and other regions of increased lung density in yellow.  For the UTE 
signal intensity and CT radio-density there is evidence of regionally consistent 
  
COPD 
(n=15) 
GOLD Grade 
(n=15) 
Significant 
Difference 
 Healthy 
Emphysem
a 
Emphysema 
+Bronchiectasi
s 
GOLD I GOLD II 
GOLD 
III+IV 
H/E/E
+B 
I/II/III+
IV 
Mean (±SD) (n=5) (n=8) (n=7) (n=3) (n=6) (n=6) p p 
1H SI % 29(2) 23(3)* 24(4)* 27 (3) 23 (5) 22 (3) 0.07 0.3 
1H SI15 % 21(1) 18(3)* 18(4) 18 (4) 19 (4) 17 (2) 0.09 0.6 
1H SR 5.17(1.99) 4.82(2.02) 3.04(1.57) 6.12 (2.17) 3.55 (1.59) 3.37 (1.80) 0.1 0.1 
1H CR 0.22(0.03) 0.17(0.03)* 0.13(0.04)* 0.19 (0.03) 0.15 (0.04) 0.14 (0.03) 0.001 0.1 
ADC cm2/s 0.20(0.01) 0.46(0.14) 0.41(0.11) 0.39 (0.17) 0.41 (0.10) 0.48 (0.13) 0.003 0.4 
Radiodensity 
HU 
-- -855(35) -849(43) -831(26) -839(47) -874(27) 0.8 0.2 
RA950 % -- 17(15) 11(9) 9 (12) 11 (9) 19 (15) 0.3 0.4 
HU15% HU -- -942(37) -927(41) -921 (42) -923 (47) -950 (28) 0.5 0.3 
WA % -- 60(4) 59(4) 63 (3) 58 (4) 60 (4) 0.7 0.1 
LA mm2 -- 21(4) 27(14) 18 (6) 30 (13) 20 (4) 0.2 0.2 
LA/BSA 
mm2/m2 
-- 11(3) 15(6) 10 (3) 16 (6) 12 (3) 0.1 0.6 
Pi10 mm -- 4.23(0.15) 4.22(0.11) 4.31 (0.20) 4.24 (0.10) 4.17 (0.11) 0.9 0.3 
 100 
 
identification of corresponding abnormalities.  As shown in the signal intensity frequency 
distributions in Figure 3-5, there was a bi-modal distribution in S24 and with increasing 
COPD grade, the signal intensity distributions shifted towards lower signal intensities.  
This trend was also observed in the radio-density frequency distributions, where with 
increasing COPD grade, there was a shift towards the lower radio-densities. 
 
Figure 3-5 MRI and CT of COPD patients 
Normalized UTE signal intensity maps, CT images with relative area (RA) emphysema 
mask for 15th percentile of the HU (HU15, in blue), MRI signal intensity histograms, and 
CT radio-density histograms.  S24 is a 59 yr female with emphysema and bronchiectasis, 
FEV1=67%pred, FEV1/FVC=71%, DLCO=54%pred; S17 is a 77 yr male with emphysema and 
bronchiectasis and FEV1=79%pred, FEV1/FVC=42%, DLCO=50%pred;  S31 is a 75 yr female 
with GOLD III and FEV1=46%pred, FEV1/FVC=39%, DLCO=29%pred; S27 is a 51 yr male 
with GOLD IV and FEV1=28%pred, FEV1/FVC=22%, DLCO=32%pred.   
3.3.5 Correlations with Pulmonary Function Measurements and CT 
Table 3-4 summarizes the significant correlations for MRI signal intensity and pulmonary 
measurements for all COPD subjects.  For all subjects, there were significant correlations 
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for signal intensity with RA950 (r
2=0.50, p=0.005), FEV1/FVC (r
2=0.35, p=0.02), DLCO 
(r2=0.25, p=0.05), and mean radio-density (r2=0.85, p<0.001).  There was a significant but 
very modest correlation for SI15 and HU15 (r
2=0.38, p=0.01).  For subjects with only 
emphysema, significant relationships were observed for signal intensity with RA950 
(r2=0.90, p=0.002), HU15 (r
2=0.83, p=0.005), and mean radio-density (r2=0.90, p=0.001).  
For subjects with both emphysema and bronchiectasis, there were significant relationships 
were observed for signal intensity and RV (r
2=0.59, p=0.04), HU15 (r
2=0.76, p=0.01), Pi10 
(r2=0.62, p=0.04) and mean radio-density (r2=0.85, p=0.04).   
Table 3-4 UTE signal intensity correlations with 3He MRI ADC, CT and pulmonary 
function test measurements 
 
COPD 
(n=15) 
GOLD Grade 
(n=15) 
 Emphysema 
Emphysema+ 
Bronchiectasis 
GOLD I GOLD II 
GOLD 
III+IV 
  (n=8) (n=7) (n=3) (n=6) (n=6) 
 r p r p r p r p r p 
FEV1 %pred 0.50 NS 0.57 NS 0.78 NS 0.39 NS 0.30 NS 
FEV1/FVC % 0.50 NS 0.70 NS 0.91 NS 0.61 NS 0.37 NS 
FRC %pred -0.04 NS -0.64 NS -0.44 NS -0.46 NS -0.56 NS 
TLC %pred 0.31 NS -0.75 NS 0.99 NS -0.57 NS -0.16 NS 
RV %pred 0.19 NS -0.77 0.04 0.49 NS -0.58 NS 0.31 NS 
DLCO %pred 0.62 NS 0.32 NS 0.67 NS 0.09 NS 0.85 0.03 
ADC cm2/s -0.41 NS -0.61 NS -0.76 NS -0.30 NS -0.51 NS 
Radiodensity HU 0.95 0.001 0.92 0.004 0.99 0.04 0.93 0.02 0.82 0.04 
RA950 % -0.94 0.002 -0.60 NS -0.93 NS -0.49 NS -0.76 NS 
HU15% HU 0.91 0.005 0.87 0.01 0.87 NS 0.84 NS 0.86 0.03 
WA % 0.45 NS -0.09 NS 0.51 NS 0.19 NS -0.19 NS 
LA mm2 -0.60 NS 0.20 NS -0.75 NS 0.12 NS -0.01 NS 
LA/BSA mm2/m2 -0.70 0.05 -0.02 NS -0.87 NS 0.04 NS -0.57 NS 
Pi10 mm 0.38 NS 0.79 0.04 0.19 NS 0.41 NS 0.90 0.01 
r=Pearson correlation coefficient (p<0.05).  FEV1=forced expiratory in 1s; %pred=percent 
predicted; FVC=forced vital capacity; FRC=functional residual capacity; TLC=total lung 
capacity; RV=residual volume; DLCO=diffusing capacity of lung for carbon monoxide; 
ADC=apparent diffusion coefficient; RA950=relative area of the lung with attenuation 
values<-950 HU; HU15%=15
th percentile of the frequency distribution histogram in HU; 
LA=lumen area; BSA=body surface area; Pi10=airway wall thickness at an internal 
perimeter of 10mm 
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3.4 Discussion 
In recognition of some of the limitations of CT for longitudinal and serial evaluations of 
COPD, we are developing rapid pulmonary MRI methods to provide quantitative 
measurements of tissue density and airway abnormalities.  By utilizing compressed sensing 
and parallel imaging in combination with an ultra-short echo time, we showed: 1) 
significantly improved CR, SR, and signal intensity, 2) a significant and strong relationship 
for MR signal intensity and tissue density, 3) high three-week reproducibility for UTE 
signal intensity measurements, and, 4) spatial correlations for signal intensity with CT-
identified regions of emphysema, inflammation, and mucous plugging and quantitative 
correlations with pulmonary function and CT measurements. 
First, there was significantly improved signal intensity, SR, and CR using the 32-channel 
UTE approach as compared to the single channel UTE and 32-channel FGRE approaches.  
The improved signal intensity and SR was not surprising because of the geometry and 
number of elements in the 32-channel compared to the body coil.  Improvements in signal 
intensity, SR, and CR using the 32-channel UTE sequence were also expected because of 
the shorter echo-time and radial sampling.  Furthermore, for the UTE sequence, data 
acquisition began at the centre of k-space and extended radially, oversampling the centre 
of k-space and as a result, there was improved contrast at lower frequencies.   
Second, in healthy volunteers, pulmonary signal intensity was strongly related to the 
inverse of lung volume and because total lung mass was constant, this reduced to a strong 
linear relationship for signal intensity and nominal lung density.  Therefore, similar to 
CT,16 signal intensity directly reflected lung density, which suggests that UTE signal 
intensity can be used to quantify parenchymal tissue destruction and inflammation.  UTE 
signal intensity histograms shifted towards lower intensity values at higher lung volumes 
which is consistent with CT studies,16 and this is important, given that CT is universally 
recognized as the clinical non-invasive gold standard for lung density measurements. The 
increased heterogeneity at full expiration may be explained by the changing vascular 
portion at different lung volumes.16  UTE signal intensity maps showed similar regional 
information for both emphysema and inflammation/mucous deposition and these 
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preliminary qualitative results suggest that 1H MRI may provide a way to characterize the 
heterogeneous pathological processes of COPD and offer an alternative to CT 
measurements. 
We reported high UTE signal intensity reproducibility for three-week re-scan for COPD 
subjects which was consistent with high Pearson correlation coefficients, low COV and 
high ICC.  To further understand the relationship of reproducibility with image quality, we 
investigated whether differences in SR would influence UTE signal intensity, but did not 
find a significant relationship between them.  This suggests that noise did not influence the 
UTE signal intensity measurements.  Moreover, these results suggest that 2D UTE MRI 
provides a reproducible technique to monitor treatment response in longitudinal studies.  
We reported significant and moderate correlations for UTE signal intensity with pulmonary 
function, and CT measurements for COPD subjects.  These correlations are consistent with 
lung tissue destruction in emphysema leading to lung mass and density loss.  It is 
interesting to note that in subjects with emphysema only, in addition to significant 
relationships between RA950, HU15, and mean radio-density there was a significant 
correlation with lumen area normalized to body surface area.  It is also interesting to note 
that in subjects with both emphysema and bronchiectasis, there was a positive relationship 
between Pi10 and signal intensity, consistent with the notion that in bronchiectasis subjects, 
thickened airways resulted in increased signal intensity.  
Although this study provides promising preliminary results, several limitations must be 
acknowledged.  First, our analysis ignored the effect of pulmonary perfusion at different 
lung volumes in healthy volunteers.  As lung perfusion is dictated by the relationship 
between alveolar, pulmonary arterial, and pulmonary venous pressures - all of which vary 
at different lung volumes, it is expected that different lung volumes will change perfusion 
and subsequently change the UTE signal. Several potential mechanisms may explain 
pulmonary perfusion changes at different lung volumes (hypoxic vasoconstriction of the 
alveolar vessels, vessel branching pattern change, and the cavity pressure change) and its 
impact on UTE signal intensity.  Second, it is important to note that the impact of effective 
transverse decay time T2* on signal intensity at different lung volumes was ignored in 
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healthy volunteers for two reasons: 1) in human lungs, T2* variability was significantly 
smaller than other factors affecting SI across different lung volumes17 2) the echo-time of 
50µs was significantly smaller than the parenchymal T2* (500-800µs),7,17 which 
minimized the T2* weighting effect. Also, unlike CT, MRI signal intensity is influenced 
by hardware factors such as RF amplifications and the positioning of the RF coils, which 
introduce inter-scan variability.  While we corrected for absolute signal intensity 
quantification by normalizing acquired images to the liver, this is influenced by the 
precision of liver measurements.  In this regard, we note that the liver has minimal motion 
during the image acquisition and is relatively homogeneous despite inter-subject signal 
variability.  Finally, we acknowledge that the histopathological relationship between MRI 
signal intensity and CT radio-density measurements has not yet been established.  The 
quantification of emphysema using CT uses different threshold type analyses has been 
compared with histology,18 this has not yet been undertaken with parenchymal MRI signal 
intensity.   The comparison of mean MRI signal intensity to CT RA950 and HU15 is likely 
a conservative estimate of any direct relationships.  For this reason, the comparison of 
MRI-derived SI15 with CT-derived HU15 is likely a better estimate of the direct 
relationships of MRI signal intensity and CT radio-density measurements.   
Future studies will investigate three-dimensional UTE acquisition.  The three-dimensional 
UTE method would allow for more efficient RF excitation, isotropic spatial resolution, and 
reduced sensitivity to motion artifacts compared to 2D UTE.19   
In summary, we developed a 2D UTE MRI method to generate rapid measurements of 
pulmonary signal intensity that are strongly related to tissue density and in subjects with 
COPD is related to pulmonary function and CT measurements.  
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CHAPTER 4 
4 THREE DIMENSIONAL ULTRA-SHORT ECHO TIME 
MAGNETIC RESONANCE IMAGING OF ASTHMA 
To determine the underlying structural and clinical determinants of MRI signal-intensity 
in patients with asthma we generated novel ultra-short echo time (UTE) MRI biomarkers 
in asthmatics and directly compared these with structural CT and other clinical 
measurements.   
The contents of this chapter have been submitted to the Journal of Magnetic Resonance in 
Medicine: K Sheikh, F Guo, DPI Capaldi, A Ouriadov, RL Eddy, S Svenningsen, and G 
Parraga. Accepted for publication in J Magn Reson Imaging 2016 (in press).  
4.1 Introduction 
Asthma is a chronic inflammatory disease involving both the large and small airways.1,2  
Complex airway abnormalities including airway smooth muscle remodeling3,4 and 
inflammation4 are thought to be the source of shortness of breath, wheeze and chest 
tightness. These are also associated with gas-trapping5 and ventilation/perfusion 
abnormalities.6  Currently, asthma is diagnosed and monitored based on spirometry 
measurements of airflow made at the mouth.7  These measurements tend to over-estimate 
large airway constriction, under-estimate small airways disease8 and cannot provide 
regional information. 
Lung structural and functional abnormalities have also been measured in patients with 
asthma using chest computed tomography (CT),9 single photon emission computed 
tomography,10 positron emission tomography11 and magnetic resonance imaging (MRI) 
using inhaled gases.12,13  Because asthma often spans the lifetime of individual patients, 
the risk of cumulative radiation exposure certainly limits the use of x-ray based imaging 
for longitudinal and treatment response evaluations, especially in children.14   
A number of research teams have pioneered the use of inhaled gas MRI in asthmatics;12,15,16 
this previous work showed that ventilation abnormalities were heterogeneously 
distributed,17,18 reproducible,19 related to asthma severity12 and asthma control.17  Recently, 
zero echo time and ultra-short echo time (UTE) MRI have emerged as methods to minimize 
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MRI signal decay for the quantification of lung proton density.20-26  Previous UTE asthma 
studies showed the inflammatory response to allergen challenge in animal models27 and 
patients.28  This previous work demonstrated the potential and feasibility of 1H MRI 
methods for measuring the therapeutic efficacy of new asthma treatments.  Recent work 
also estimated regional ventilation deficits in asthmatics based on the change in signal-
intensity measured at different lung volumes using conventional 1H MR methods and echo-
times.29  However, it is well-understood that MRI signal-intensity is influenced by 
hardware factors such as RF amplification and RF coil positioning, which can introduce 
inter-scan variability.  Because of this, it is difficult to ascertain the physiological meaning 
of 1H MR signal-intensity changes especially in asthma where the underlying 
pathophysiology is complex.   
In an effort to better understand pulmonary MRI measurements, two-dimensional UTE 
MRI was recently evaluated in participants with COPD and bronchiectasis,30 patients that 
share some of the airway and inflammatory features common in asthmatics.31  Based on 
some of this previous work, we hypothesized that UTE-derived biomarkers could be 
generated across different lung volumes to capture evidence of ventilation abnormalities in 
patients with asthma and these measurements would be related to pulmonary function test 
measurements of gas-trapping and/or airflow obstruction.    Therefore, the objective of this 
proof-of-concept study was to generate novel UTE MRI biomarkers in asthmatics in whom 
CT structural and other clinical measurements could be directly compared.   
4.2 Materials and Methods 
4.2.1 Study Logistics 
All participants provided written informed consent to a study protocol approved by a local 
research ethics board and compliant with the Health Insurance Portability and 
Accountability Act (HIPAA, USA).  Healthy volunteers underwent pulmonary function 
tests and UTE MRI only.  All subjects with a diagnosis of asthma underwent pre- and post-
salbutamol pulmonary function tests, hyperpolarized noble gas MRI, UTE MRI and post-
salbutamol thoracic CT.  Methacholine challenge (MCh) was restricted to asthmatics 
according to ATS guidelines32 with testing halted at the PC20 which is the provocative 
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concentration resulting in a 20% decrease in forced expiratory volume in 1 second, or 
FEV1.  
Spirometry was used to measure FEV1, forced vital capacity (FVC), and their ratio 
(FEV1/FVC) according to American Thoracic Society (ATS) guidelines (MedGraphics 
Elite Series Plethysmograph, MedGraphics Corporation, St. Paul, Minnesota, USA).33  
Body plethysmography was also performed to measure lung volumes such as residual 
volume (RV), functional residual capacity (FRC), and total lung capacity (TLC).  
4.2.2 Image Acquisition 
MRI was acquired in the coronal plane using a whole body 3 Tesla Discovery MR750 
(General Electric Health Care [GEHC], Milwaukee, WI, USA) system with broadband 
imaging capability.  MRI was acquired pre- and post-salbutamol for all asthmatics and at 
PC20 in those asthmatics who underwent the methacholine challenge.  UTE MRI was 
obtained using a 32-channel torso coil (GEHC) and 3D cones UTE sequence (GEHC).  
Whole lung UTE images were acquired in the coronal plane with the following parameters 
in breath-hold: 15s acquisition time, echo time (TE)/repetition time (TR)/flip 
angle=0.03ms/3.5ms/5°, field-of-view (FOV)=40×40cm, bandwidth (BW)=125kHz, 
matrix=200×200, number of excitations (NEX)=1, and reconstructed to a 10mm slice 
thickness.  UTE MR images were acquired at four lung volumes including full expiration, 
FRC, FRC plus one liter, and full inspiration and this was completed in 5-10 minutes.  
Subjects were coached to achieve full expiration and full inspiration.  FRC was achieved 
at the end of passive expiration and FRC+1L was achieved by the inhalation of a 1L bag 
of N2.  The B1 field was mapped using a dual angle 3D Look-Locker pulse sequence (40s 
total data acquisition, TE/TR=0.3ms/1200ms, α/2α=5°/10°, FOV=48×48cm, 
BW=62.5kHz, matrix=32×32, 32 slices, 15mm slice thickness, 0 gap) using the 3T GE 
phantom model 2360049 (GEHC).34 
Polarization of 3He or 129Xe gas was achieved using commercial polarizer systems 
(Polarean, Durham, NC, USA).  Hyperpolarized 3He was diluted with medical-grade N2 
gas (Spectra Gases, New Jersey, USA) and 129Xe was diluted with 4He and administered 
in 1.0-L Tedlar® bags (Jensen Inert Products, Florida, USA).  Subjects were instructed to 
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inhale a gas mixture from the bag from FRC and image acquisition was performed under 
breath‐hold conditions.35  1H MRI was acquired with subjects in breath-hold using a whole-
body radiofrequency coil and a 1H fast spoiled gradient-recalled echo (FGRE) sequence 
with a partial echo (12s total data acquisition, TR/TE/flip angle=4.7ms/1.2ms/30°, 
FOV=40×40cm, BW=24.4kHz, matrix=128×80, number of slices=16, 15mm slice 
thickness, 0 gap), as previously described.35  3He static ventilation MRI was acquired using 
a 2D multi-slice fast gradient‐recalled echo sequence with a partial echo (total data 
acquisition time=10s, TR/TE/flip-angle=3.8ms/1.0ms/7°, FOV=40×40cm, BW=48.8kHz, 
matrix=128×80, NEX=1, number of slices=16, slice thickness=15mm) during breath-
hold.35  129Xe static ventilation MRI was also acquired in three subjects using methods 
previously described.36 
Thoracic CT was acquired post-salbutamol with subjects at inspiration (lung volume of 
FRC+1L) breath-hold (FRC+1L to allow for CT to MRI comparison) using a multi-
detector, 64-slice Lightspeed VCT scanner (GEHC, Milwaukee, WI) (64×0.625mm 
collimation, 120 kVp, 100 mA, tube rotation time=500ms, pitch=0.98).37  All subjects were 
coached prior to scanning with a practice bag; subjects were instructed to breath in and out 
through their nose and after a passive expiration the N2 gas was inhaled through the mouth 
from a 1 litre bag.  A spiral acquisition was used and images were reconstructed using a 
Standard reconstruction algorithm and reconstructed slice thickness of 1.25mm.37   
4.2.3 Image Analysis 
A B1 map was first applied to all UTE MR images to correct for flip angle inhomogeneities, 
which were then subsequently segmented using a multi-regional segmentation approach, 
previously described.38,39  Briefly, a single observer (F.G.) placed seeds on the left lung, 
right lung and the background.  These seeds were used to generate the probability 
distribution of signal intensities, which was used to generate the cost for assigning a 
corresponding label to a voxel.  The segmentation optimization problem was solved using 
primal-dual analysis and convex optimization techniques, resulting in the segmented lung.  
The mean UTE MRI signal-intensity for the whole lung was determined and normalized to 
the mean liver signal-intensity, as previously described.30  To determine signal-intensity 
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differences across the four different lung volumes, the images acquired at full-expiration, 
FRC, and full-inspiration were segmented and the extracted lung was registered to the lung 
acquired at FRC+1L (to ensure consistency with the noble gas and CT acquisitions) using 
an affine followed by a deformable registration approach provide by NiftyReg.40  Figure 
4-1 shows a schematic that summarizes how dynamic proton-density maps were generated.  
Dynamic proton-density maps reflect the change from full inspiration to full expiration of 
UTE signal intensity for each lung voxel in the map.  Each dynamic proton-density map 
required 15 minutes to generate (including the segmentation and registration time).   
Briefly, UTE MRI was acquired at four different lung volumes, and the magnitude of the 
slope of the line that described the signal intensity change across lung volumes was 
calculated on a voxel-by-voxel basis to generate the dynamic proton-density map.  UTE 
images were qualitatively evaluated based on visual evidence of diminished signal-
intensity at baseline, PC20, and post-salbutamol.  Dynamic proton-density maps with 
mainly warmer colours (e.g. orange, red) were classified as having diminished differences 
between full inspiration and full expiration signal-intensity.  Dynamic proton-density maps 
with mainly cool colours (e.g. blue, green) were classified as having greater differences 
between full inspiration and full expiration signal-intensity. 
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Figure 4-1 Schematic for generating Dynamic Proton-Density Maps 
A) Volume-time plot that shows lung volumes at which MRI was acquired: full expiration, 
passive expiration (functional residual capacity [FRC]), FRC+1L, and full inspiration, B) 
Centre slice UTE images in greyscale at four lung volumes with corresponding segmented 
and registered images.  Yellow box represents region-of-interest (ROI) and, C) Plot of ROI 
signal-intensity versus lung volume, where the slope of the line represents the dynamic 
proton-density value for each ROI or voxel that is used to generate a dynamic proton-
density map. 
 
Static ventilation images were segmented and co-registered with 1H FGRE MRI using 
custom software generated using MATLAB R2014a (Mathworks, Natick, Massachusetts, 
USA).41  Ventilation abnormalities were quantified using the ventilation defect percent 
(VDP) which represents the volume of ventilation defects (VDV) normalized to the 
thoracic cavity volume.  Briefly, static ventilation images were segmented by a single 
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observer (K.S.) using a k-means approach that classified voxel intensity values into five 
clusters ranging from signal void (cluster 1[C1] or VDV) and hypo-intense (cluster 2 [C2]) 
to hyper-intense signal (cluster 5 [C5]) to generate a gas distribution cluster-map.  For 
delineation of the ventilation defect boundaries, a seeded region-growing algorithm was 
used to segment the 1H FGRE MRI thoracic cavity for registration to the cluster-map, as 
previously described.41  Hyperpolarized noble gas images were qualitatively evaluated 
based on visual evidence of ventilation defects defined as any lung region of diminished 
signal-intensity but not including those areas of signal loss associated with the pulmonary 
vascular structures, heart, hilum, and mediastinum.  Homogeneous distribution of 
hyperpolarized noble gas was defined as static ventilation images without focal areas of 
diminished signal-intensity. When ventilation defects were visibly improved (signal-
intensity was greater) after the administration of salbutamol, they were deemed 
qualitatively diminished or improved. 
Pulmonary Workstation 2.0 (VIDA Diagnostics Inc., Coralville, Iowa, USA) was used to 
segment whole lung and pulmonary lobes from the CT images.  As previously described,30 
mean CT radio-density was determined using the CT pulmonary mask generated using 
VIDA.  A threshold of -856HU5 was not used to evaluate gas-trapping because images 
were not acquired at full expiration and instead, mean CT radio-density was used for direct 
comparison with mean UTE values across the entire lung and for individual lobes.  Using 
the CT pulmonary lobe masks, CT radio-density, UTE signal-intensity and VDP (by 
registering CT to hyperpolarized noble gas MRI42) were determined for each pulmonary 
lobe.  CT images were qualitatively evaluated and decreased lung density was described as 
a pulmonary hyperlucency or regions of hypoattenuation (i.e. low radio-density). 
4.2.4 Statistics 
Data were tested for normality using the Shapiro-Wilk normality test using SPSS 23.0 
(IBM, Armonk, NY, USA) and parametric tests were performed when the data satisfied 
normal distribution.  Univariate relationships were evaluated using linear regressions (r2) 
and Pearson correlations (r), and Spearman correlations (rs) (adjusted with Holm-
Bonferroni correction).   One-way analysis of variance (ANOVA) with a Holm-Bonferroni 
correction for multiple comparisons was used to compare measurements between healthy 
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volunteers and asthmatics.  Repeated measures ANOVA was performed to evaluate the 
difference between baseline, PC20, and post-salbutamol measurements.  All statistical tests 
were performed using SPSS 23.0 (IBM, Armonk, NY).  Results were considered 
significant when the probability of making a Type I error was less than 5% (p<.05). 
4.3 Results 
4.3.1 Study Subjects 
Thirty subjects were evaluated including 13 healthy volunteers (7M/6F, 25±5 years) with 
no history of chronic or acute respiratory disease and 17 asthmatics (7M/10F, 47±11 years).  
Fourteen asthmatics were clinically diagnosed with severe, uncontrolled disease, while 
three patients had mild-to-moderate asthma.  Table 4-1 shows subject demographics and 
pulmonary function test measurements for all participants pre-salbutamol.  Healthy 
volunteers were significantly younger and reported significantly greater FEV1 and 
FEV1/FVC as well as significantly lower RV/TLC than the asthmatics (p<.001).  
Table 4-1 Participant demographics 
*Significance of difference (p<.05) was determined using a one-way ANOVA with Holm-
Bonferroni correction to correct for multiple comparisons. SD=standard deviation; 
BMI=body mass index; FEV1=forced expiratory in 1s; FVC=forced vital capacity; 
TLC=total lung capacity; RV=residual volume, FRC=functional residual capacity; 
IC=inspiratory capacity. 
 Healthy 
Volunteers 
Asthma 
Significance of 
Difference 
Mean (±SD) n=13 n=17 p-value 
Male n 7 7 -- 
Age yrs 25 (5) 47 (11) <.001 
BMI kg/m2 24 (4) 28 (5) .09 
FEV1 %pred  102 (11) 69 (23) <.001 
FVC %pred 102 (11) 89 (17) .1 
FEV1/FVC % 85 (6) 78 (17) <.001 
RV %pred  128 (29) 148 (43) .7 
TLC %pred  110 (12) 110 (11) ~1 
RV/TLC % 28 (5) 42 (11) .002 
FRC %pred 112 (14) 116 (25) ~1 
IC %pred 104 (17) 103 (22) .9 
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4.3.2 UTE Signal Intensity and Dynamic Proton-density maps 
Figure 4-2 shows multi-volume UTE MRI and dynamic proton-density maps for a 
representative healthy volunteer and an asthmatic participant as well as the normalized 
signal-intensity values for the two subgroups at each lung volume.  For the healthy 
volunteer, there was qualitative evidence of homogeneously distributed low signal-
intensity at all lung volumes and a homogeneous dynamic proton-density map that 
reflected an approximate 10%/L difference in mean signal-intensity across lung volumes 
(with greater signal-intensity at smaller lung volumes).   For the representative asthmatic 
subject, there was qualitative evidence of low signal-intensity regions at all lung volumes, 
and a greater regional variability in the dynamic proton-density map reflecting regional 
heterogeneity in signal-intensity differences across the four lung volumes.  The dynamic 
proton-density map for the asthma patient was not only more heterogeneous but also 
reflected smaller differences in signal-intensity.  Quantitatively, there were significant 
differences between the healthy and asthmatic subgroup for signal-intensity at full 
expiration (healthy volunteers: 58±7%, asthmatics: 43±10%, p<.001) and FRC (healthy 
volunteers: 50±7%, asthmatics: 40±8%, p=.003).  Whole lung dynamic proton-density 
measurements were also significantly different (p<.001) for healthy volunteers 
(7.4±2.0%/L) and asthmatics (4.5±1.9%/L). 
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Figure 4-2 UTE MRI for Healthy Volunteers and Asthmatics 
Coronal UTE MRI at full expiration, FRC, FRC+1L, and full inspiration with 
corresponding dynamic proton-density maps for a representative healthy volunteer and 
asthmatic. The far right panel shows normalized signal intensity and dynamic proton-
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density values for the healthy volunteer and asthmatic subgroups. P-value determined using 
a one-way ANOVA with Holm-Bonferroni correction for multiple comparisons (*:p<.05, 
**:p<.01). 
For participants with asthma, we also evaluated qualitative and quantitative relationships 
for UTE signal-intensity and dynamic proton-density maps with biomarkers derived from 
CT, 3He MRI and pulmonary function tests.  As shown in Figure 4-3, for subject S19, there 
was a homogeneous distribution of hyperpolarized 3He gas and there were no visually 
obvious CT low attenuating regions or lucency.  For asthmatic subject S27, there were 
ventilation defects in the lower lobes which corresponded to regional CT lucency and 
smaller signal-intensity/volume differences in the dynamic proton-density maps.  In a 
similar manner for asthmatic subject S15, ventilation defects corresponded to regional CT 
lucency and small signal-intensity changes in the dynamic proton-density maps.   
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Figure 4-3 Pulmonary MRI and CT for Participants with Asthma 
Coronal centre slice 3He MRI, CT, UTE MRI at full expiration and full inspiration and 
dynamic proton-density maps for three representative asthmatic subjects.  S19: 39 year old 
female, FEV1=71%pred, RV/TLC=45%, mean whole lung CT radio-density=-792HU, full 
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expiration/full inspiration signal-intensity=46%/31%, VDP=2%, whole lung mean 
dynamic proton-density=5.06%/L; S27: 60 year old female, FEV1=52%pred, 
RV/TLC=54%, mean whole lung CT radio-density=-814HU, full expiration/full 
inspiration signal-intensity=34%/23%, VDP=10% whole lung mean dynamic proton-
density=4.80%/L; S15: 57 year old male, FEV1=36%pred, RV/TLC=48%, mean whole lung 
CT radio-density=-865HU, full expiration/full inspiration signal-intensity=31%/20%, 
VDP=32%, whole lung mean dynamic proton-density=2.65%/L. 
Quantitative results for asthmatics are provided in Figure 4-4 shows significant 
quantitative whole lung relationships for lung tissue CT radio-density with UTE signal-
intensity at full expiration (r2=0.67, r=0.82, p=.004) and FRC+1L (r2=0.69, r=0.83, 
p=.006).  There were similar findings for lobar relationships between CT radio-density and 
MRI signal-intensity at full expiration (r2=0.30, r=0.55, p=.003) and FRC+1L (r2=0.48, 
r=0.69, p=.004). Whole lung dynamic proton-density was also correlated with whole lung 
CT radio-density (r2=0.51, r=0.71, p=.01) and lobar results were very similar (r2=0.66, 
r=0.81, p=.003).  Finally, there were significant whole lung relationships for UTE signal-
intensity at full expiration with VDP (r2=0.45, r=-0.67, p=.006) and as well for UTE signal 
intensity at FRC+1L with VDP (r2=0.31, r=-0.56, p=.03).  The relationship of whole lung 
dynamic proton-density with whole lung VDP was on the threshold of significance 
(r2=0.26, r=-0.51, p=.05) while lobar signal-intensity at FRC+1L (r2=0.13, rs=-0.33, p=.02) 
and lobar dynamic proton-density (r2=0.14, rs=-0.47, p=.01) were both related to lobar 
VDP.  We note that in this evaluation, data for three subjects were based on 129Xe MRI 
VDP measurements.  Because previous work demonstrated 129Xe VDP was significantly 
greater than 3He VDP 43 in asthmatics, we evaluated all correlations without 129Xe VDP 
data and the relationships remained significant.  Previous work showed that lung inflation 
volume and CT lung density  44-47  are strongly related and that UTE signal-intensity also 
scales with lung volume 30, which is exactly what the dynamic proton-density maps show. 
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Figure 4-4 Relationships for UTE MRI Signal intensity and imaging measurements in 
asthmatics 
Linear correlations for A) whole lung radio-density with whole lung UTE signal intensity 
(SI) at full expiration (r2=0.67, r=0.82, p=.004) and FRC+1L (r2=0.69, r=0.83, p=.006), B) 
lobar radio-density and lobar UTE signal intensity at full expiration (r2=0.30, r=0.55, 
p=.003) and FRC+1L (r2=0.48, r=0.69, p=.004), C) whole lung VDP with whole lung UTE 
signal intensity at full expiration (r2=0.45, r=-0.67, p=.006) and FRC+1L (r2=0.31, r=-0.56, 
p=.03), D) lobar VDP with lobar UTE signal intensity at FRC+1L (r2=0.13, rs=-0.33, 
p=.02), E) whole lung radio-density and whole lung dynamic proton-density (r2=0.51, 
r=0.71, p=.01), F) lobar radio-density and lobar dynamic proton-density (r2=0.66, r=0.81, 
p=.003), and G) lobar VDP with lobar dynamic proton-density (r2=0.14, rs=-0.47, p=.01). 
Associations with pulmonary function test measurements and lung volumes are shown in 
Figure 4-5 for all subjects by subgroup.  In healthy volunteers, FEV1 %pred was 
significantly correlated with whole lung UTE signal-intensity at full expiration (r2=0.50, 
r=0.71, p=.03), while for the asthmatic subgroup, there were significant relationships for 
FEV1 %pred (r
2=0.50, r=0.71, p=.006), FEV1/FVC (r
2=0.53, r=0.73, p=.002) and RV/TLC 
(r2=0.32, r=-0.57, p=.02) with whole lung signal-intensity.  In asthma patients only, mean 
whole lung dynamic proton-density was related to FEV1 %pred (r
2=0.37, r=0.61, p=.02), 
FEV1/FVC (r
2=0.56, r=0.75, p=.003), and RV %pred (r
2=0.38, r=-0.62, p=.02).  Based on 
previous work,47 we performed linear regression analysis while controlling for TLC and 
the relationships for UTE and pulmonary function test measurements remained significant. 
 121 
 
 
Figure 4-5 Relationships for UTE MRI and pulmonary function measurements 
Signal intensity (SI) at full expiration associations with A) FEV1 (Healthy: r
2=0.50, r=0.71, 
p=.03; Asthma: r2=0.50, r=0.71, p=.006), B) FEV1/FVC (Healthy: r
2=0.14, r=0.37, p=.2; 
Asthma: r2=0.53, r=0.73, p=.002), C) RV/TLC (Healthy: r2=0.25, r=0.50, p=.2; Asthma: 
r2=0.32, r=-0.57, p=.02).  
Dynamic proton-density associations with D) FEV1 (Healthy: r
2=0.45, r=0.67, p=.4; 
Asthma: r2=0.37, r=0.61, p=.02), E) FEV1/FVC (Healthy: r
2=0.31, r=0.56, p=.2; Asthma: 
r2=0.56, r=0.75, p=.003) F) RV (Healthy: r2=0.06, r=-0.24, p=.4; Asthma: r2=0.38, r=-0.62, 
p=.02).  
4.3.3 Response to Bronchoconstriction and Bronchodilation 
Because of the quantitative relationships observed in Figures 4-4 and 4-5, we also 
qualitatively investigated the potential for UTE MRI biomarkers to reflect well-understood 
changes in asthma lung function that occur during methacholine challenge and after 
bronchodilator inhalation.  We note that based on international guidelines,32 the vast 
majority of asthmatics in this study were too severe to undertake a methacholine challenge 
and therefore results were limited to three subjects in whom methacholine challenge and 
therapy withholding could be safely undertaken.  Table 4-2 summarizes pulmonary 
function test and imaging results from the bronchodilator and bronchoconstrictor 
challenge.  There were significant differences in FEV1 and RV/TLC pre- and post- 
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salbutamol in all asthmatics.  There were no significant differences in imaging 
measurements in those subjects who only underwent tests pre- and post-salbutamol (n=14).  
In the three subjects that underwent the methacholine challenge, there were significant 
differences in signal-intensity at full expiration (p=.03).   
Table 4-2 Pre- and post-salbutamol pulmonary function test and imaging measurements 
for all asthmatics. 
*Significance of difference (p<.05) was determined using a repeated measures ANOVA.  
Figure 4-6 shows the results of a methacholine challenge and pre-to-post-salbutamol 
changes in two different representative asthmatics.  At PC20, for participant S14, MRI 
signal-intensity was qualitatively diminished and there were numerous 3He MRI 
ventilation defects, most of which resolved post-salbutamol.  In addition, dynamic proton-
density maps reflected diminished differences between full inspiration and full expiration 
signal-intensity as represented by the regions of warm colours.  After salbutamol 
administration, the lung signal-intensity was visually higher than at PC20 and the dynamic 
proton-density maps reflected greater differences between full inspiration and full 
expiration as represented by the regions of cool colours.  These images were visually 
similar to what was observed in the healthy volunteers.  For the individual patient S28 who 
was evaluated pre- and post-salbutamol, MRI signal-intensity was increased post-
 Baseline  
Post-
Salbutamol 
Significant 
Difference* 
Mean (±SD) n=14  n=14 p-value 
FEV1 %pred  64 (22)  72 (21) <.001 
FEV1/FVC % 58 (15)  63 (16) .001 
RV %pred  157 (41)  139 (29) .05 
RV/TLC % 44 (11)  40 (8) .03 
VDP % 10 (10)  8 (8) .1 
Full Expiration Signal-Intensity % 42 (10)  42 (8) .9 
Dynamic Proton Density %/L 4.4 (2.1)  4.3 (2.2) .8 
 Baseline PC20 
Post-
Salbutamol 
 
 n=3 n=3 n=3  
FEV1 %pred  92 (13) - 100 (15) .04 
FEV1/FVC % 74 (5) - 80 (9) .1 
RV %pred  103 (12) - 76 (6) .03 
RV/TLC % 33 (4) - 25 (3) .008 
VDP % 4 (2) 9 (6) 4 (3) .3 
Full Expiration Signal-Intensity % 49 (6) 40 (3) 48 (7) .03 
Dynamic Proton Density %/L 4.8 (0.6) 3.6 (0.2) 5.1 (1.6) .2 
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salbutamol and there was a concomitant reduction in 3He MRI ventilation defects.  
Concomitant with these post-salbutamol changes, dynamic proton-density maps showed 
that the difference between full inspiration and full expiration signal-intensity was greater 
and this is represented by the regions of cool colours.   
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Figure 4-6 Asthma Response to Bronchodilator 
MRI at baseline, PC20, and post-salbutamol.  For all subjects that underwent MCh (n=3), 
the mean VDP was: pre-/post-MCh=4±2%/9±6%, mean full expiration UTE signal-
intensity was: pre-/post-MCh=49±6%/40±3%, and UTE dynamic proton-density was: pre-
/post-MCh=4.8±0.5%/L/3.6±0.2%/L. S14: Asthmatic subject is 45 year old female with 
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pre-/post-salbutamol FEV1=103%pred/114%pred, RV/TLC=29%/23%. Baseline UTE at full 
expiration signal-intensity/VDP/Dynamic proton-density=56%/2%/4.8%/L, post-MCh 
UTE at full expiration signal-intensity/VDP/Dynamic proton-density=43%/16%/3.7%/L, 
post-salbutamol UTE at full expiration signal-intensity/VDP/Dynamic proton-
density=55%/2%/6.4%/L.  For subjects that underwent pre-/post-salbutamol only (n=14), 
the mean VDP pre-/post-Salbutamol was 10±10%/8±8%, the mean full expiration UTE 
signal-intensity pre-/post-Salbutamol was 42±10%/42±8%, and the mean dynamic proton-
density pre-/post-Salbutamol was 4.4±2.0/4.3±2.2%/L. S28: Asthmatic subject is 47 year 
old female with pre-/post-salbutamol FEV1=55%pred/74%pred, RV/TLC=50%/43%. 
Baseline UTE at full expiration signal-intensity/VDP/Dynamic proton-
density=46%/4%/6.7%/L, post-salbutamol UTE at full expiration signal-
intensity/VDP/Dynamic proton-density=48%/3%/7.6%/L. 
4.4 Discussion  
Inhaled gas MRI biomarkers of asthma lung function have been developed over the past 
decade and have disrupted our understanding about the regional heterogeneity of lung 
functional abnormalities in asthmatics.  While it has not been straightforward to replicate 
these findings using conventional 1H MRI, we sought to establish such an approach by 
developing multi-volume UTE lung biomarkers.  Therefore, in this proof-of-concept study 
in 30 participants, we investigated the potential of 3D UTE MRI as a practical way to 
measure and understand regional asthma lung function and observed: 1) UTE dynamic 
proton-density and signal-intensity measurements at full expiration and FRC were greater 
in healthy volunteers as compared to asthmatics, 2) in asthmatics, UTE biomarkers were 
significantly correlated with pulmonary function, CT radio-density and MRI VDP, and, 3) 
subsequent to methacholine inhalation, there were qualitative changes in signal-intensity 
and dynamic proton-density that resolved post-salbutamol. 
First, we observed significantly greater normalized signal-intensity measurements in 
healthy volunteers as compared to asthmatics.  These findings were similar to previously 
published work using CT that showed significantly lower radio-density in asthmatics than 
in healthy volunteers.48  Diminished signal-intensity in the asthmatic lung may reflect gas-
trapping which is certainly plausible given that in these patients there is often premature 
closure of peripheral airways toward the end of full expiration.  In asthmatic lungs, small 
airways also close at higher lung volumes than in healthy subjects -a result of increased 
smooth muscle tone, edema, and or inflammation of the airway walls.  In addition to 
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diminished signal-intensity, there was also diminished dynamic proton-density in the 
asthmatic subgroup.  This was consistent with previous work using conventional 1H MR 
that showed there was a larger change in signal-intensity across lung volumes in healthy 
volunteers than in asthmatics29 which may be reflective of reduced lung compliance or 
decreased compressibility due to gas-trapping in asthmatics.  
Second, in the participants with asthma, we observed moderate-to-strong correlations for 
UTE measurements with pulmonary function and CT measurements.  Signal-intensity at 
full expiration and dynamic proton-density were both significantly correlated with FEV1 
and FEV1/FVC suggesting relationships with airflow obstruction.  Signal-intensity at full 
expiration was also correlated with RV/TLC which is consistent with the notion that gas-
trapping is responsible for signal-intensity differences in asthmatics.  Similar findings were 
previously reported using CT, where gas-trapping score was related to pulmonary function 
tests.49   
Whole lung and regional UTE signal-intensity and dynamic proton-density measurements 
were also related to whole lung and regional CT radio-density.  These findings are in 
agreement with previous work in COPD patients.30  Similar to previous work in asthmatics 
in which focal lucency was spatially correlated with 3He MRI ventilation defects,16 here 
we also observed significant correlations for regional VDP and regional UTE 
measurements.  These relationships were weak-to-modest, perhaps reflective of asthma 
heterogeneity and the relatively small sample size or that UTE measurements necessarily 
include signal from the vasculature. 
Finally, we also observed visually obvious changes in UTE images after methacholine and 
salbutamol administration.    To provide context, these results are similar to previous work 
using diffusion-weighted 3He MRI to evaluate gas-trapping post-MCh.50  This previous 
work demonstrated larger apparent diffusion coefficients (ADC) post-methacholine, 
suggesting an increase in airspace size or gas-trapping.  Here, using UTE methods, the 
decrease in signal-intensity at PC20 suggests an increase in airspace size due to retained air 
(i.e. gas-trapping) resulting in lower proton density per voxel.  These results hold promise 
for future studies attempting to evaluate treatment response in patients with asthma because 
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these regions of low signal-intensity and low magnitude of dynamic proton-density may 
provide potential targets for therapy.  
Although this study provides promising preliminary results, we must point out a number 
of study limitations.    We acknowledge that CT was not acquired at full expiration and this 
limited our ability to ascertain the etiology of CT lucency.  Therefore, while we observed 
a relationship for UTE signal-intensity and CT radio-density, this was not in itself 
definitive for regional gas-trapping.  However, signal-intensity at full expiration and 
dynamic proton-density measurements were related to RV and to RV/TLC (both reflective 
of gas-trapping) and to MRI ventilation defects.  Previous studies have demonstrated the 
relationship of expiratory CT lucency and 3He MRI ventilation abnormalities which is also 
supportive of a relationship between gas-trapping and ventilation defects in asthma.16  
There was a significant age difference between healthy volunteers and asthmatics which 
may have biased some of the results.  We should also stress that for three asthmatics, only 
129Xe MRI was performed, which based on previous work, would be expected to be greater 
than 3He VDP.43  Importantly however, when these data were removed from the analysis, 
the correlations with VDP were not significantly different which may also be attributed to 
a small sample size.  Finally, it should be noted that three subjects underwent the 
methacholine challenge. Although there were significant differences in signal-intensity at 
full expiration, caution must be taken when extrapolating these results to a larger sample 
size. 
In conclusion, we developed UTE MRI signal-intensity and dynamic proton-density 
biomarkers of asthma that were related to pulmonary function and hyperpolarized noble 
gas MR measurements of ventilation defects.  These MRI measurements made using 
conventional equipment suggested that UTE MRI may reflect ventilation heterogeneity 
and/or gas-trapping in asthmatics, making this approach amenable for clinical use.   
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CHAPTER 5 
5 CONCLUSIONS AND FUTURE DIRECTIONS 
In this final chapter, an overview and summary are provided in addition to the important 
findings and conclusions of Chapters 2-4.  The study specific limitations and general 
limitations are also provided with some potential solutions.  Finally, based on these 
findings, an outline is provided for future pulmonary MRI studies. 
5.1 Overview and Research Questions 
Obstructive lung diseases, including COPD and asthma, affect over six million Canadians.  
By 2030, it is projected that the current economic burden will double if no further 
improvements (including drug development) are made in dealing with obstructive lung 
disease.1  Despite decades of research, therapies that modify obstructive lung disease 
progression and control are lacking.2,3  This is in part because the diagnosis and monitoring 
of these patients and their response to therapy are currently made using airflow 
measurements.  These measurements, while important, cannot account for inter-subject 
variability or be used to regionally evaluate pathologies.  One goal of obstructive lung 
disease research is to develop ways to identify patients with specific underlying 
pathological phenotypes with the hope that this will improve patient care and outcomes.  
In this regard, imaging methods such as thoracic CT and MRI have the potential to provide 
regional and quantitative biomarkers of obstructive lung disease.  As the first step to 
identify patients with specific underlying pathological phenotypes, it is important to 
understand the physiological and clinical consequences of these imaging derived 
measurements. 
In response to the need for a better understanding of imaging-derived biomarkers, studies 
have evaluated the clinical significance of hyperpolarized noble gas MR biomarkers in 
obstructive lung disease.4-6  Work using hyperpolarized noble gas MRI in aging has shown 
that with increasing age there is a relationship with increased ventilation defects7 and 
increased lung microstructure measured using 3He ADC.8  But this work did not ascertain 
the clinical consequences of these biomarkers in older never-smokers.   This understanding 
is important to appreciate the pulmonary consequences associated with obstructive lung 
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disease.  Furthermore, hyperpolarized noble gas MRI has yet to find acceptance in the 
clinic.  Dose limiting advances in CT, limited availability of the necessary hardware for 
polarizing and imaging hyperpolarized noble gases, and the identification of clinical 
applications that will benefit from this have made clinical translation difficult.  With this 
in mind, there has been growing motivation for the development and implementation of 
non-contrast enhanced pulmonary MRI to overcome the challenges of ionizing radiation 
and resource accessibility. 
Non-contrast enhanced pulmonary UTE MRI has been proposed as a way to address the 
inherent challenges of pulmonary imaging that stem from low tissue and 1H density without 
the use of specialized equipment or personnel.  Recent studies using pulmonary UTE MRI 
have quantified parenchymal signal-intensity as a function of lung volume or gravity 
dependence in healthy volunteers.9  In mouse models, UTE MRI has been used to evaluate 
inflammation and peribronchial abnormalities in animal models of asthma.10  Studies have 
also used UTE MRI to produce T2* maps in murine models
11 and healthy volunteers,12 and 
have shown that this biomarker is related to smoking history in COPD.13   Previous work 
using this technique provides a strong foundation for its use in obstructive lung disease 
research and patient care; however, a major drawback is that the reproducibility and clinical 
and physiological meaning of UTE-derived measurements in obstructive lung disease are 
poorly understood.  Thus, a clear understanding of UTE-derived biomarkers (including 
reproducibility and clinical meaning) is necessary prior to widespread clinical translation.  
The overarching objective of this thesis was to develop and evaluate lung structure and 
function measurements using multi-nuclear MRI in aging and obstructive lung disease to 
provide an understanding of the physiological and clinical consequences of these MR-
derived measurements.  The specific research questions addressed were: 1) What are the 
physiological and clinical consequences of MR-derived biomarkers in normal aging? 
(CHAPTER 2); 2) Can non-contrast enhanced UTE MRI measurements be developed to 
have high reproducibility (comparable to that of 3He derived measurements), and are these 
measurements related to pulmonary function tests and CT measurements of emphysema in 
obstructive lung disease (i.e. COPD)? (CHAPTER 3); and, 3) Can we extend the method 
in Chapter 3 and merge different lung volume information to capture evidence of gas-
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trapping and ventilation heterogeneity in patients with obstructive lung disease (i.e. 
asthma)? (CHAPTER 4) 
5.2 Summary and Conclusions 
In Chapter 2 we determined the physiological consequences and potential relevance of 
ventilation abnormalities in older never-smokers.  We also evaluated the relationship of 
ventilation defects with occupational exposures, pulmonary function, and exercise 
capacity.  We found that majority of older never-smokers (39/52) had ventilation defects 
and 33 of these subjects had ventilation defects that did not resolve after bronchodilation.  
The six older never-smokers that did respond to bronchodilation had significantly worse 
baseline pulmonary function test measurements.  However, most of these older never-
smokers had normal pulmonary function test measurements, but with peripheral ventilation 
defects that were not reversible by bronchodilation.  Ventilation defects were related to 
pulmonary function tests, however, dyspnea and exercise capacity were not.  This study 
builds the foundation of pulmonary abnormalities observed with aging.  Obstructive lung 
disease, such as COPD, tends to occur in elderly individuals and thus it will be important 
in future studies to quantify lung function using MRI to differentiate between normal aging 
and both aging and obstructive lung disease in this elderly diseased population. 
We then developed and evaluated reproducibility of a non-contrast enhanced UTE MR 
method in patients with COPD in Chapter 3.  We tested the hypothesis that the signal-
intensity derived from UTE MRI has high short-term reproducibility in COPD and is 
related to CT radio-density and pulmonary function test measurements.  In healthy 
subjects, signal-intensity correlated with the inverse of lung volume (r=0.99, p=.007).  The 
coefficient of variation for 3-week repeated measurements was 4%.  There were significant 
correlations for signal-intensity with RA950 (r=-0.71, p=.005), FEV1/FVC (r=0.59, p=.02), 
and for SI15 with HU15 (r=0.62, p=.01).  We developed a UTE MRI method to generate 
measurements of pulmonary signal-intensity that are strongly related to tissue density and 
in subjects with COPD are related to pulmonary function and CT measurements. 
In Chapter 4 of this thesis, we developed and utilized UTE MRI biomarkers of asthma lung 
function.  The mean signal-intensity at four lung volumes (full expiration, FRC, FRC+1L, 
 135 
 
and full inspiration) was quantified.  The difference in MRI signal-intensity across four 
lung volumes was also determined on a voxel-by-voxel basis to generate dynamic proton-
density maps.  The mean whole lung signal-intensity at full expiration and magnitude of 
the dynamic proton density maps were significantly greater (p=.001) in healthy volunteers 
than asthmatics.  Mean signal-intensity at full expiration (p<.01), FRC (p<.05) and 
dynamic proton-density (p<.01) were greater in healthy-volunteers compared to 
asthmatics.  In asthmatics, UTE signal-intensity at full expiration and dynamic proton-
density were correlated with FEV1/FVC (signal-intensity r=0.73/p=.002; dynamic proton-
density r=0.75/p=.003), RV/TLC (signal-intensity r=-0.57/p=.02) or RV (dynamic proton-
density r=-0.62/p=.02), CT radio-density (signal-intensity r=0.83/p=.006; dynamic proton-
density r=0.71/p=.01) and lobar VDP (signal-intensity rs=-0.33/p=.02; dynamic proton-
density rs=-0.47/p=.01).  This work demonstrated that in patients with asthma, UTE MR 
signal-intensity measurements were correlated with pulmonary function test measurements 
of gas-trapping and airflow obstruction, provided information about regional ventilation 
deficits and provided similar information as CT.  Taken together, UTE MR measurements 
may provide a surrogate measurement for ventilation heterogeneity and/or gas-trapping in 
patients with asthma. 
In summary, we have provided: 1) evidence that in a majority of older never-smokers there 
are age-related changes in pulmonary ventilation that are not reversible by bronchodilation 
and are related to pulmonary function test measurements, but not dyspnea or exercise 
capacity; 2) a new and reproducible non-contrast enhanced MR method to evaluate 
pulmonary abnormalities in patients with obstructive lung disease; and, 3) evidence that 
the measurements derived from non-contrast enhanced MR are related to tissue density 
measurements (evaluated using CT) and pulmonary function test measurements. 
5.3 Limitations 
In this section the most significant limitations from Chapters 2-4 will be discussed.  It 
should be noted that the study specific limitations are also presented in the Discussion 
section of each respective Chapter.  
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5.3.1 Study Specific Limitations 
Pulmonary ventilation defects in older never-smokers (Chapter 2) 
In Chapter 2, we sought to better understand the physiological consequences and potential 
relevance of 3He MRI ventilation defects in older never-smokers.  We did not acquire CT 
images which limited our understanding of age-related airway changes and their 
relationship to ventilation defects.  Our results, therefore, could not be directly compared 
to more established CT measurements, such as the percentage of low attenuation pixels as 
a measurement of the extent of senile emphysema or WA% as a measurement of airway 
wall thickness.  A direct comparison of CT and hyperpolarized 3He MRI measurements in 
the same subjects would allow for a better understanding of the etiology of the ventilation 
defects observed in older never-smokers. 
Another limitation of this study was that subjects were classified by viewing the gray-scale 
images, while the patients were still in the scanner.  In two cases, once the ventilation 
images were co-registered to the anatomical 1H images, offline, previously classified 
ventilation defects could be directly related to anatomical bony structures and were 
unlikely to be ventilation abnormalities.  As a result, the two subjects, who were classified 
at the scanner as having ventilation defects did not appear to have these once a full analysis 
was completed.  Ideally, all subjects should have undergone deep inspiration and 
salbutamol administration and image analysis should have been used to evaluate 
bronchodilator response.   
Finally, 129Xe and UTE MRI were not acquired in the older never-smokers.  The high cost 
of 3He gas has restricted translation of this imaging method beyond specialized MRI 
centres.  As previously discussed, this shortage is forcing the noble gas MRI community 
to transition to 129Xe gas, a less expensive and more readily available contrast agent, and 
non-contrast enhanced methods such as UTE MRI.  One can hypothesize that ventilation 
defects may be more prominent and obvious using 129Xe MRI since previous work has 
shown the increased sensitivity of 129Xe gas compared to 3He gas in OLD.14,15  One can 
also hypothesize that UTE MR signal-intensity measurements would be lower in older 
individuals than younger individuals due to increased resting lung volumes in older 
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subjects.  Regardless, future studies should aim to image older never-smokers using 129Xe 
and UTE MRI to better understand the age-related changes in these imaging measurements. 
Ultra-short echo-time pulmonary MRI: evaluation and reproducibility in COPD subjects 
with and without bronchiectasis (Chapter 3) 
In the study presented in Chapter 3, a reproducible UTE MRI method was developed and 
an understanding of the physiological determinants of UTE signal-intensity in patients with 
COPD was determined.  First, we acquired single slice images rather than whole-lung 
images.  This limited our understanding of this measurement in the anterior and posterior 
regions of the lung.       
Second, it is important to note that the impact of effective transverse decay time T2* on 
signal-intensity at different lung volumes was ignored in healthy volunteers for two 
reasons: 1) in human lungs, T2* variability was significantly smaller than other factors 
affecting signal-intensity across different lung volumes 2) the echo-time of 0.05ms was 
significantly smaller than the parenchymal T2* (0.5-0.8ms), which minimized T2* 
weighting.  Also, unlike CT, MRI signal-intensity is influenced by hardware factors such 
as the positioning of the RF coils, which introduce inter-scan variability.  While we 
corrected for absolute signal intensity quantification by normalizing acquired images to the 
liver, this is influenced by the precision of liver measurements.  In this regard, we note that 
the liver has minimal motion during the image acquisition and is relatively homogeneous 
despite inter-subject signal variability.   
Finally, we acknowledge that the histopathological relationship between UTE MRI signal-
intensity and CT radio-density measurements has not yet been established.  The 
quantification of emphysema using CT uses different threshold type analyses has been 
compared and validated with histology, yet this has not been undertaken with parenchymal 
MRI signal intensity.   The comparison of mean MRI signal-intensity to CT RA950 and 
HU15 is likely a conservative estimate of any direct relationships.  For this reason, the 
comparison of MRI-derived SI15 with CT-derived HU15 is likely a better estimate of the 
direct relationships of MRI signal-intensity and CT radio-density measurements.   
Ultra-short Echo Time Magnetic Resonance Imaging Biomarkers of Asthma (Chapter 4) 
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In Chapter 4 we developed a whole lung breath-hold UTE MRI protocol and evaluated 
asthmatics and healthy volunteers.   There was a significant age difference between healthy 
volunteers and asthmatics which may have biased our results.     
Another limitation of this study was that CT was not acquired at full expiration.  Chest CT 
at full expiration allows for the evaluation of gas-trapping.  The extent of the gas-trapping 
can be evaluated using a threshold type measurements (i.e. the relative area under -856HU, 
RA856).
16  Unfortunately, this threshold is only appropriate when CT is acquired at a lung 
volume of full expiration and this limited our understanding of regional gas-trapping.  
Consequently, the mean whole lung radio-density was used for direct comparison with 
mean whole lung signal-intensity.  It should be noted that not only does the mean 
measurement not capture the extent of low signal-intensity, but the lack of expiratory CT 
limits our understanding of regional gas-trapping and our ability to ascertain the etiology 
of CT lucency.  Although we can comment on the relationship of UTE signal-intensity and 
CT radio-density, it is difficult to conclude that the signal-intensity at full expiration was 
reflective of regional gas-trapping.  We can conclude, however, that signal-intensity at full 
expiration and dynamic proton-density measurements are related to pulmonary function 
test measurements of gas-trapping such as residual volume and the ratio of residual volume 
to total lung capacity.  It is also important to note that UTE signal-intensity measurements 
were related to hyperpolarized noble gas ventilation defects.  Previous studies have 
demonstrated the relationship of CT lucency and 3He MRI which suggest the relationship 
between gas-trapping and ventilation defects in asthma.17   
Finally, for three asthmatics, only 129Xe MRI was performed, which based on previous 
work, would be expected to be greater than 3He VDP.14  Importantly, however, when these 
data were removed from the analysis, the correlations with VDP were not significantly 
different. It should also be noted that three subjects underwent the methacholine challenge. 
Although there were significant differences in signal-intensity at full expiration, caution 
must be taken when extrapolating these results to a larger sample size. 
 139 
 
5.3.2 General Limitations 
In Chapters 2-4, we used mean whole lung measurements of ventilation defects and signal-
intensity to evaluate the extent of pulmonary abnormalities.  Mean measurements tend to 
disregard the heterogeneity of lung disease.  Threshold based measurements, such as VDP 
and SI15, also do not capture the heterogeneity of obstructive lung disease.  Moreover, these 
measurements ignore the regions of signal hyper-intensity since VDP is dependent on the 
noble gas signal that is of the lowest intensity and SI15 is dependent on the low signal-
intensity.  Limitations with single threshold methods also include the over or under-
estimation of the disease, where a lower threshold differentiates more severe diseased 
regions18 disregarding regions of mild disease and a higher threshold identifies regions of 
mild disease.19  As a result, methods that diverge from single threshold measurements (e.g. 
principal component analysis and texture analysis) have emerged20-22 to evaluate lung 
disease.  Automated evaluation of the CT density histogram using principal component 
analysis21 has been used to generate a principal component score based on each frequency–
HU pair.21  The strength of this approach relates to the fact that a broad frequency 
distribution of pixel intensities across a wide range of Hounsfield unit values is evaluated 
to generate a single score.  This measurement is strongly related to pulmonary function 
tests and expert radiologist emphysema scores.21  In future studies, it will be important to 
investigate pulmonary MR measurements that incorporate all signal-intensities to evaluate 
obstructive lung disease.    
An important limitation of this work is that we still do not understand the etiology of MR 
ventilation defects in aging or UTE signal-intensity in obstructive lung disease.  To truly 
understand the cause of the MR-derived biomarkers presented in this thesis it is important 
to determine the relationship between MRI measurements and histology and inflammatory 
markers.  Although it can be speculated that these pulmonary imaging abnormalities are 
related to airway narrowing or wall thickening in older never-smokers, and emphysema or 
gas-trapping in patients with obstructive lung disease, it is difficult to ascertain the cause 
without histological specimen or other clinical biomarkers.  Studies in mouse models of 
asthma10,23 and emphysema11 have demonstrated the relationship between histology and 
1H MR-derived measurements.  Studies have also shown differences in eosinophil 
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percentages of bronchoalveolar lavage fluid that correspond to proton MR measurements 
in patients with asthma that have undergone an allergy challenge.24  However, future 
studies still need to investigate the etiology of MR-derived biomarkers for us to fully 
understand what these measurements represent in patients with obstructive lung disease.  
Another important limitation to this work is the limited availability of 3He gas.  It should 
be noted that Chapters 2-4 used 3He MRI to evaluate static ventilation and/or apparent 
diffusion coefficients.  The high cost of 3He gas has restricted translation of this imaging 
method beyond specialized MRI centres.  As previously discussed, this shortage is forcing 
the noble gas MRI community to transition to 129Xe gas, a less expensive and more readily 
available inhaled gas.  Studies have shown increased sensitivity to ventilation defects in 
COPD and asthma using 129Xe MRI.14,15  If Chapters 2 and 4 were to be done using 129Xe, 
one may hypothesize that the extent of ventilation defects may be of greater magnitude 
than the values reported. Regardless of this speculation, future 129Xe MRI studies are 
required to validate the results presented here using 3He MRI.  Moreover, future research 
and potential clinical applications of noble gas MRI will most definitely utilize 129Xe gas. 
Finally, for clinical translation of the presented methods it is important to understand their 
reproducibility and feasibility across a number of centres and in a clinically relevant 
population.  As stated before, MR measurements are influenced by hardware factors such 
as RF amplifications and the positioning of the RF coils, which introduce inter-scan 
variability.  An important application for the MR methods presented is pediatric imaging 
(e.g. survivors of preterm birth and those with bronchopulmonary dysplasia) and those 
subjects who require longitudinal monitoring (e.g. those with hereditary disorders such as 
alpha-1 antitrypsin deficiency).  These populations are vulnerable to the radiation burden 
associated with CT based methods.  To better understand these biomarkers in pediatric 
populations, one might want to image a younger cohort.  Thus, future studies should aim 
to evaluate these MR methods across several sites and in a pediatric cohort. 
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5.4 Future Directions 
5.4.1 Ultra-short echo time MRI Measurements of Tissue Density using 
Principal Component Analysis  
In Chapters 3 and 4, we evaluated obstructive lung disease using mean signal-intensity of 
the UTE images.  Pulmonary emphysema has been quantified using mean signal-intensity 
and T2* measurements enabled by UTE MRI.
25  Previous work also showed the utility of 
a single MRI signal-intensity threshold based on thoracic CT emphysema thresholds.26  
Thoracic CT threshold-based emphysema measurements are correlated to pulmonary 
function tests, 27 and both microscopic and macroscopic measurements of emphysema,28,29 
but there is no consensus regarding an optimal threshold.  Recent work has used principal 
component analysis (PCA) of CT radio-density histograms to assess emphysema.  This 
method uses a broad frequency distribution of pixel intensities across a wide range of 
density values to produce a single score and measurements derived from this method have 
been shown to correlate with pulmonary function tests and expert radiologist emphysema 
scores.21   
We have performed preliminary analysis in a small proof-of-concept study in which PCA 
was used to evaluate the UTE signal-intensity histograms to generate principal components 
based on each frequency-signal intensity pair.  We wanted to evaluate and compare the 
performance of the UTE signal-intensity PCA score with CT measurements. 
Frequency histograms of MR signal-intensity and CT radio-density (Hounsfield Units, 
HU) were generated and PCA was performed on the relative area under the histogram curve 
for each signal-intensity and HU value.  Principal components (PC) were generated based 
on the variation between input variables.  The first two PCs with the highest eigenvalues 
were selected and the density histogram principal component score (DHPCS) and signal-
intensity histogram principal component score (SHPCS) were determined, as previously 
described:21  
Equation 5-1     𝑆𝐻𝑃𝐶𝑆 = ∑ 𝑅𝐴𝑖𝑃𝐶𝑖
50
0  
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Where RA is the relative area under the histogram curve for each signal-intensity value 
and PC is the principal component value calculated from PCA analysis. 
In this preliminary work in 10 COPD ex-smokers (68±8yrs) with CT evidence of 
emphysema, UTE signal-intensity histogram PC scores were determined.  Figure 5-1 
shows mean signal-intensity, CT radio-density histograms and corresponding principal 
components. SHPCS was significantly correlated with DHPCS (r
2=0.49, p=.02).  As shown 
in Figure 5-2, SHPCS significantly correlated with RA950 (r
2=0.43, p=.04) and FEV1/FVC 
(r2=0.50, p=.02), but not HU15 (r
2=0.34, p=.08), DLCO (r
2=0.08, p=.5) or six minute walk 
distance (6MWD) (r2=0.14, p=.3).  SI15 was not significantly correlated with RA950 
(r2=0.05, p=.5), HU15 (r
2=0.08, p=.4), FEV1/FVC (r
2=0.09, p=.4), DLCO (r
2=0.0004, p=.9) 
or 6MWD (r2=0.34, p=.06).  We speculate that in a larger population of COPD subjects, 
PCA can be used to derive a UTE MRI score that is related to CT measurements of 
emphysema and gas-trapping.  Accordingly, the next steps require a similar but larger-scale 
validation study of UTE PCA in COPD. 
 
Figure 5-1 UTE signal-intensity and CT radio-density histograms and corresponding 
principal components generated by PCA with sum of the first and second principal 
components. 
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Figure 5-2 Relationships between UTE PCA score (SHPCS-defined as the summation of 
the relative frequency multiplied by the principal component value) and CT and pulmonary 
function test measurements. 
5.4.2 The Etiology of Ultra-short echo time MRI Signal-Intensity  
In this thesis, we demonstrated that UTE MR measurements are reproducible and related 
to CT measurements of tissue density.  However, unlike CT measurements, MRI signal-
intensity is dependent on four parameters that include the proton density, T1 relaxation, T2 
relaxation, and flow.  Briefly, proton density is the concentration of protons in the tissue in 
the form of water, fats, or proteins (i.e. macromolecules), T1 and T2 define the way the 
protons revert back to their resting states after excitation, and flow effects are due to the 
loss of signal due to arterial blood flow.  UTE measurements of signal-intensity have the 
potential to be novel biomarkers of tissue density (e.g. parenchymal loss due to emphysema 
or regions of inflammation) in longitudinal studies of lung disease.  But before this goal 
can be achieved, the etiology of regions of low UTE signal-intensity and high signal-
intensity need to be determined. 
To determine the etiology of UTE signal-intensity, there are various potential studies that 
could be performed.  The most concrete evidence would be provided by histological 
evidence to determine the underlying pathology leading to regions of either high or low 
signal-intensity.  Previous work in mouse models of asthma10,23 and emphysema11 have 
demonstrated the relationship between histology and 1H MR-derived measurements.  To 
evaluate the cause of these regions of low signal-intensity, a study following a similar 
protocol, but with a human population undergoing lung transplantation should be 
considered.  Sampling the areas within the regions of low signal-intensity would allow for 
the evaluation of the parenchyma in the region of the low signal-intensity to determine 
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whether or not bullae or gas-trapping were present that may have contributed to the region 
of low signal.  The area of the lungs that precede the ventilation defect should also be 
sampled to determine what lead to these regions of low signal.   
In patients with asthma who have undergone an allergy challenge, studies have shown 
differences in eosinophil percentages of bronchoalveolar lavage fluid that correspond to 
increased regions of high signal-intensity.24  Similar work could be done to evaluate the 
etiology of high signal-intensity regions where inflammation biomarkers are acquired to 
determine whether or not the high signal-intensity corresponds to inflammation, edema, or 
other pathologies that can potentially increase tissue density. 
5.4.3 Ultra-short echo time MRI of Emphysema in Adults with Alpha-1-
Antitrypsin Deficiency 
Alpha-1-Antitrypsin Deficiency (AATD) is a hereditary disorder caused by a mutation in 
the SERPINA1 gene,  which leads to a dysregulation in neutrophil elastase.30  This disease 
affects approximately 1/5000 North Americans.31,32  One of the hallmark findings of this 
chronic and progressive disease is panlobular emphysema which is mainly located in the 
lower lobes of the lung.  This under-recognized genetic condition increases the risk of 
COPD.33 Similar to smoking-related emphysema, AATD related emphysema has no cure.  
Therapies do exist, however, to slow the progression of alveolar destruction (e.g. 
exogenous alpha-1 antitrypsin augmentation therapy). 
Current tools available to longitudinally monitor and evaluate therapy response in AATD 
include pulmonary function tests and imaging methods such as thoracic CT.  However, 
pulmonary function tests do not provide regional information.  Studies have shown the CT 
is more sensitive at monitoring emphysema progression in patients with AATD.34-36  CT 
has also been used to monitor therapy response from augmentation therapy.37 
Unfortunately, x-ray based imaging methods pose radiation concerns especially in these 
patients where serial monitoring is important.  Hyperpolarized noble gas MRI offers highly 
reproducible measurements of lung microstructure and may serve as a sensitive tool to 
evaluate disease progression.  However, the translation of this method to clinic is limited 
due to advances in CT and limited availability of the necessary hardware for polarizing and 
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imaging hyperpolarized noble gases.  UTE MRI provides a non-contrast enhanced and non-
ionizing alternative to pulmonary imaging with reproducible measurements of tissue 
density (Chapter 3).  UTE MR-derived measurements may serve as sensitive biomarkers 
to evaluate disease progression and response to potential AATD therapies.  
Figure 5-3 shows coronal CT, UTE MR, and hyperpolarized noble gas images of three 
AATD patients with decreasing lung function.  The signal intensity in the UTE images 
becomes visually lower from S1 to S3.  In S2 (smoking history<0.5 pack-years) there are 
regions of visually obvious low signal intensity in the lower lobes of the UTE images that 
spatially correspond to the regions of ventilation defects and low radiodensity.  Similarly, 
in S3 (smoking history=43 pack years), there are regions of low signal-intensity that 
visually correspond to regions of low radiodensity and ventilation defects.  In this case, 
these regions are apparent in both the upper and lower lobes indicative of perhaps 
panlobular and centrilobular emphysema. 
 146 
 
 
Figure 5-3 Pulmonary MR and CT of AATD. 
Thoracic CT, UTE MRI at full expiration and FRC+1L, and 3He MR static ventilation 
images shown for AATD subjects with decreasing lung function (S1: FEV1=77%pred, S2: 
FEV1=55%pred, S3: FEV1=32%pred). 
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Initial investigations should focus on qualitatively and quantitatively comparing CT and 
UTE MR images in a larger cohort of AATD.  Future work should aim to answer the 
following research questions: 
1) Can UTE MRI provide similar information to that of CT in patients with AATD? 
2) Are there regional structural and functional relationships between UTE MRI and 
hyperpolarized noble gas MRI? 
3) What are the relationships between UTE MR signal-intensity measurements and 
pulmonary function test measurements in patients with AATD? 
4) Can UTE MRI be used to monitor treatment response in AATD? 
5.4.4 From Neonatal Chronic Lung Disease to Early Onset Adult COPD: 
Ultra-short echo time MRI of Bronchopulmonary Dysplasia 
Bronchopulmonary dysplasia (BPD) is a chronic lung disease resulting from oxygen 
therapy, mechanical-ventilation, and/or surfactant deficiency in premature infants who 
require oxygen 36 weeks post-menstrual age.38  Studies in infants39 with BPD have 
consistently demonstrated abnormalities in the peripheral lung, including failed 
alveolarization with a decreased number of large and simplified alveoli.38  Although well-
described in children, the long-term respiratory consequences of BPD in adults are not 
well-understood, although it is hypothesized that the risk of chronic lung disease and 
emphysema are increased.40  Consequently, there is growing interest in risk factors beyond 
smoking given the development of emphysema and COPD in non-smokers.41  Equipped 
with the knowledge of how the normal lung ages (Chapter 2) and the pulmonary MRI 
abnormalities that result in obstructive lung disease (Chapters 3 and 4), we can evaluate 
patients who are at risk of developing COPD with age.  More importantly, we can evaluate 
regional structural and functional information using MRI without the use of ionizing 
radiation. 
Individuals born extremely preterm, especially with BPD, share many clinical features with 
COPD patients.  Prematurity-related morbidities are quite substantial and impact on 
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patient’s health status such as seen in COPD patients.42  Airflow obstruction is only 
partially reversible following administration of bronchodilators.43  In fact, studies have 
shown that over 70% of children with BPD do not respond to bronchodilators as 
demonstrated by lack of significant increase in FEV1.
44  Not only is there is no cure for 
BPD,45 there are no evidence-based or consensus-based guidelines for its treatment in 
adults.45  Stem cell therapies aimed at regenerating damaged lung tissue are now being 
developed, yet there are few tools that allow for longitudinal measures of treatment 
efficacy.46  Moreover, our understanding of the morphological alterations of lung structure 
in patients with BPD is limited due to the difficulty of obtaining lung tissue from living 
individuals.  Proton and inhaled hyperpolarized noble gas MRI provide ways to visualize 
functional and structural pulmonary information.   
We have performed preliminary analysis in a single young adult (a survivor of extreme 
prematurity of birth) with bronchopulmonary dysplasia.  She was born at 27 weeks 
gestation and was mechanically ventilated and in the neonatal intensive care unit for six 
weeks without surfactant therapy.   She underwent pulmonary function tests, chest x-ray, 
hyperpolarized 3He and UTE MRI, both pre- and post-salbutamol.  As shown in Figure 5-
4, cyst-like regions of low UTE signal-intensity were similar to previous MRI findings in 
infants47 and previous CT findings in adults.48  These regions of low UTE signal-intensity 
likely reflected gas-trapping and/or emphysema and have been hypothesized to be 
associated with prolonged mechanical-ventilation47 often injurious to immature, surfactant 
deficient lungs.49  3He ventilation defects were clearly abnormal and irreversible and 
spatially related to regions of low signal-intensity and elevated lung microstructure 
measurements, reflective of enlarged airspaces.  Abnormal ADC (whole-lung mean 
ADC=0.36cm2/s) were also heterogeneously distributed throughout the lung.  These results 
demonstrate the feasibility of pulmonary MRI in BPD patients and showed the potential 
for MRI biomarkers to provide a better understanding of underlying pathophysiology 
responsible for symptoms and disease worsening in BPD patients. 
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Figure 5-4 Pulmonary MR Images of a young adult with BPD. 
Ultra-short echo time (UTE) MR images at full expiration and full inspiration shown for 
the posterior, centre, and anterior slices.  Hyperpolarized 3He static ventilation (cyan) 
images overlaid on FGRE anatomical images (greyscale) and ADC maps shown for 
posterior to anterior slices (from left to right). 
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In a study currently underway, we aim to use UTE and noble gas MRI to evaluate preterm 
young adults with and without BPD.  We hypothesize that young adults born preterm have 
imaging abnormalities that can be used to evaluate the risk of developing COPD with age.  
This knowledge will help provide opportunities for early disease interventions.  The 
overarching objective of this work is to characterize the structural and functional 
pulmonary changes following preterm birth in young adults.  This study will address the 
following research questions: 
1) Are there differences in UTE MR images of young adults born preterm with and 
without BPD and term-born controls? 
2) What are the relationships between UTE MR signal-intensity measurements and 
pulmonary function test measurements in young adults born preterm with and 
without BPD and term born controls? 
3) Can UTE MRI be used to longitudinally evaluate young adults born preterm with 
and without BPD to better understand the natural history of BPD? Are longitudinal 
changes in UTE MRI measurements in young adults born preterm similar to those 
young adults born at term?  
5.5 Significance and Impact 
Obstructive lung disease affects over six million Canadians and costs the economy $12 
billion per year in direct and indirect expenditures.  These diseases affect individuals of all 
ages and can start from birth lasting until the end of life.  Despite years of research, 
obstructive lung disease continues to takes its toll on our healthcare system and economy.  
More importantly, the quality of life of patients and families facing a life-long battle with 
lung disease is severely burdened.  For many patients, current therapies do not modify 
disease progression or control requiring the need for hospitalizations or emergency 
department visits which lead to days lost at school or work.  Pulmonary function tests are 
the gold standard for the diagnosis, monitoring, and evaluation of response to therapy in 
patients with obstructive lung disease.  These measurements, while important, conceal the 
regional contributions of underlying pathologies.  Accordingly, a necessary goal of 
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obstructive lung disease research is to develop ways to identify patients with specific 
underlying pathological phenotypes to further personalize medicine with the hopes to 
improve patient care and outcomes.  Imaging methods such as thoracic CT and MRI have 
the potential to provide regional and quantitative biomarkers of obstructive lung disease.  
Until now, pulmonary MRI has focused on hyperpolarized noble gas MRI.  These inhaled 
gas MR methods have yet to find wide-ranging acceptance in the clinic.  Advances in low 
dose CT, limited availability of the necessary hardware for polarizing and imaging 
hyperpolarized noble gases, and the determination of clinically-relevant applications have 
made clinical translation difficult.  However for clinical trials, especially those including a 
placebo cohort, repeated exposure to ionizing radiation must be considered given that there 
may be no clinical benefit to monitoring these subjects. 
In this thesis we have evaluated pulmonary MR biomarkers in aging and disease to better 
understand their physiological and clinical consequences.  Not only have we provided a 
basis for imaging abnormalities associated with pulmonary aging, we have introduced a 
novel method for quantifying lung tissue density without the use of ionizing radiation or 
inhaled gas contrast.  UTE signal-intensity measurements have high reproducibility and 
are related to pulmonary function test and CT measurements in obstructive lung disease.  
These methods can be used on clinically available MR scanners without additional 
specialized equipment or personnel and have the potential to longitudinally evaluate 
emphysema/gas-trapping for exploratory research or drug-development.   
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09/10 Canadian Interuniversity Sport Academic All-Canadian 
Awarded to a student-athlete who has maintained an 80% average 
while competing as a varsity athlete. 
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National 
 
09/10 Recognition of Achievement Bursary 
Awarded to students on OSAP assistance who have maintained an 
80% or higher average 
Provincial 
$1000 
 
09/10 Blue and Gold Scholarship, The University of Windsor 
Awarded to a student-athlete who has excelled at his/her sport. 
Institutional 
$200 
 
09/08-09/09 Outstanding Scholars Scholarship 
Awarded upon admission to Windsor students who have an admission 
average of 85% or more. 
Institutional  
$1500 
 
09/08  Interfaculty Physics Scholarship 
Awarded upon admission to the top five Honours Physics students 
who have the highest admission average 
Institutional 
$1000 
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A. Refereed Journal Manuscripts (14 published, 4 submitted) 
 
Published (14) 
 
1. K Sheikh, F Guo, A Ouriadov, DPI Capaldi, RL Eddy, S Svenningsen, G Parraga.  Ultra-
short Echo Time Magnetic Resonance Imaging Biomarkers of Asthma. Submitted to 
Journal of Magnetic Resonance Imaging (MS # JMRI-16-0866R1 in press). 
 
2. F Guo, S Svenningsen, RL Eddy, DPI Capaldi, K Sheikh, J Yuan, A Fenster, G Parraga.  
Anatomical Pulmonary Magnetic Resonance Imaging Segmentation for Regional 
Structure-Function Measurements of Asthma. Medical Physics (MS #16-156R in press). 
 
3. C Davis, K Sheikh, D Pike, S Svenningsen, DG McCormack, D O’Donnell, JA Neder, G 
Parraga.  Ventilation Heterogeneity in Never-Smokers and COPD: Comparison of 
Pulmonary Functional Magnetic Resonance Imaging with the Poorly Communicating 
Fraction Derived from Plethysmography.  Academic Radiology. 2016 Apr;23(4):398-405. 
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4. GA Paulin, A Ouriadov, E Lessard, K Sheikh, NAM Paterson, DG McCormack, G 
Parraga.  Non-Invasive Quantification of Alveolar Morphometry in Older Never-Smokers.  
Physiological Reports 2015 Oct; 3(10): e12583. 
 
5. K Sheikh, HO Coxson, G Parraga. This is What COPD Looks Like. Respirology 2016 
Feb; 21(2):224-236. Cover of Journal. 
 
6. K Sheikh, DPI Capaldi, DA Hoover, DA Palma, BP Yaremko, G Parraga.  Magnetic 
Resonance Imaging Biomarkers of Chronic Obstructive Pulmonary Disease prior to 
Radiation Therapy for Non-Small Cell Lung Cancer.  European Journal of Radiology 
Open. 2015 May 26; 2: 81-89. 
 
7. F Guo, J Yuan, M Rajchl, S Svenningsen, DPI Capaldi, K Sheikh, A Fenster, G Parraga.  
Globally optimal joint segmentation of three-dimensional pulmonary 1H and 
hyperpolarized 3He MRI with spatial consistence prior.  Medical Image Analysis. 2015 Apr 
17; 23(1):43-55. 
 
8. S Svenningsen, GA Paulin, K Sheikh, F Guo, A Hasany, M Kirby, J Suggett, R Etemad-
Rezai, G Parraga, DG McCormack. Oscillatory Positive Expiratory Pressure in Chronic 
Obstructive Pulmonary Disease. Journal of Chronic Obstructive Pulmonary Disease. 2016 
Feb;13(1):66-74.  
 
9. DA Hoover, DPI Capaldi, K Sheikh, DA Palma, GB Rodrigues, R Dar, E Yu, M Landis, 
B Dingle, W Kocha, MS Sanatani, MD Vincent, J Younus, S Kuruvilla, S Gaede, G 
Parraga, BP Yaremko.  Functional lung avoidance for individualized radiotherapy 
(FLAIR): Study protocol for a randomized, double-blind clinical trial.  BMC Cancer. 2014 
Dec 11; 14:934. 
 
10. DPI Capaldi, K Sheikh, F Guo, S Svenningsen, R Etemad-Rezai, HO Coxson. JA Leipsic, 
DG McCormack, G Parraga.  Free-breathing pulmonary 1H and hyperpolarized 3He MRI: 
comparison in COPD and bronchiectasis.  Academic Radiology. 2015 Mar; 22(3):320-329. 
 
11. W Ma, K Sheikh, S Svenningsen, D Pike, F Guo, R Etemad-Rezai, J Leipsic, HO Coxson, 
DG McCormack, G Parraga. Ultra-short echo-time Pulmonary MRI: Evaluation and 
Reproducibility in COPD subjects with and without Bronchiectasis. Journal of Magnetic 
Resonance Imaging. 2015 May; 41(3):1465-1474. 
 
12. D Pike, M Kirby, TJ Lindenmaier, K Sheikh, CE Neron, DG Hackam, JD Spence, A 
Fenster, NA Paterson, DD Sin, HO Coxson, DG McCormack, G Parraga.  Pulmonary 
abnormalities and carotid atherosclerosis in ex-smokers without airflow limitation.  
Journal of Chronic Obstructive Pulmonary Disease. 2015 Feb; 12(1):62-70. 
 
13. K Sheikh, GA Paulin, S Svenningsen, M Kirby, NA Paterson, DG McCormack, G Parraga.  
Pulmonary ventilation defects in older never-smokers.  Journal of Applied Physiology. 
2014; 117(3): 297-306. 
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14. QI Mohaidat, K Sheikh, S Palchaudhuri, SJ Rehse. Pathogen identification with laser-
induced breakdown spectroscopy: the effect of bacterial and biofluid specimen 
contamination. Applied Optics. 2012; 51: B99-B107.   
 
Submitted (4) 
 
1. A Bhalla, E Lessard, D Pike, K Sheikh, DG McCormack, A Ouriadov, G Parraga. Cross-
sectional and Longitudinal Pulmonary Magnetic Resonance Imaging Biomarkers of Alpha-
1 Antitrypsin Deficiency. Submitted to Journal of Chronic Obstructive Pulmonary 
Disease. 
 
2. K Sheikh, A Ouriadov, HM Young, C Yamashita, TM Luu, SL Katz, G Parraga.  Multi-
Spectral Pulmonary Magnetic Resonance Imaging of Bronchopulmonary Dysplasia. 
Submitted to Journal of Chronic Obstructive Pulmonary Disease. 
 
3. F Guo, S Svenningsen, M Kirby, DPI Capaldi, K Sheikh, A Fenster, G Parraga. CT-1H/3He 
MRI Co-Registration for Regional Pulmonary Structure-Function Measurements of 
Chronic Lung Disease. Submitted to Medical Image Analysis. 
 
4. A Ouriadov, E Lessard, K Sheikh, A Bhalla, GA Paulin, M Kirby, G Parraga. Chronic 
Obstructive Pulmonary Disease and Alpha-one Antitrypsin Deficiency: Non-invasive MRI 
Biomarkers of Airspace Enlargement and Emphysema. Submitted to Radiology. 
B.  Published Refereed Conference Papers (1) 
 
1. TJ Lindenmaier, K Sheikh, E Bluemke, I Gyacskov, M Mura, C Licskai, L Mielniczuk, A 
Fenster, IA Cunningham, G Parraga.  Three-Dimensional Segmentation of Pulmonary 
Artery Volume from Thoracic Computed Tomography Imaging.  Proc SPIE 2015 Vol. 
8320, 9417-99.  
C. Peer Reviewed Published Conference Abstracts (28) 
 
1. K Sheikh, DPI Capaldi, DA Hoover, DA Palma, BP Yaremko, G Parraga, Pulmonary 
Functional imaging Biomarkers of NSCLC to Guide and Optimize Functional Lung 
Avoidance Radiotherapy. American Association of Physicists in Medicine Annual Meeting 
2016 Washington, District of Columbia, July 31-August 4, 2016. 
 
2. K Sheikh, F Guo, A Ouriadov, DPI Capaldi, S Svenningsen, M Kirby, DG McCormack, 
HO Coxson, G Parraga, Ventilation Estimates in Severe Uncontrolled Asthma using 3D 
Single breath-hold Ultra-short Echo Time MRI.  International Society of Magnetic 
Resonance in Medicine Annual Scientific Meeting 2016 Singapore, Singapore May 7-13, 
2016. 
 
3. DPI Capaldi, A Lausch, K Sheikh, F Guo, DG McCormack, G Parraga, Pulmonary 
Imaging Biomarkers of COPD for Personalized Treatment and Better Outcomes.  
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International Society of Magnetic Resonance in Medicine Annual Scientific Meeting 2016 
Singapore, Singapore May 7-13, 2016. 
 
4. F Guo, K Sheikh, RL Eddy, DPI Capaldi, DG McCormack, A Fenster, G Parraga, A 
Segmentation Pipeline for Measuring Pulmonary Ventilation Suitable for Clinical 
Workflows and Decision-making.  International Society of Magnetic Resonance in 
Medicine Annual Scientific Meeting 2016 Singapore, Singapore May 7-13, 2016. 
 
5. M Fennema, N Zha, D Pike, K Sheikh, S Svenningsen, DG McCormack, G Parraga, MRI 
Ventilation Texture Measurements as an Intermediate Endpoint of Asthma.  International 
Society of Magnetic Resonance in Medicine Annual Scientific Meeting 2016 Singapore, 
Singapore May 7-13, 2016. 
 
6. K Sheikh, F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG McCormack, 
G Parraga, What does Magnetic Resonance Imaging Signal-Intensity mean in Asthma?  
American Thoracic Society Annual Scientific Meeting 2016 San Francisco, California 
May 13-18, 2016. 
 
7. RL Eddy, D Pike, K Sheikh, GA Paulin, M Kirby, DG McCormack, G Parraga, Testing 
the Fletcher-Peto Assumptions using Pulmonary Imaging Biomarker Longitudinal 
Measurements.  American Thoracic Society Annual Scientific Meeting 2016 San 
Francisco, California May 13-18, 2016. 
 
8. M Fennema, DPI Capaldi, K Sheikh, S Svenningsen, RL Eddy, C Licskai, DG 
McCormack, G Parraga, The Abnormal Airways that Dominate Asthma Attack: New clues 
using ventilation MRI during Exercise- and Methacholine-Challenge. American Thoracic 
Society Annual Scientific Meeting 2016 San Francisco, California May 13-18, 2016. 
 
9. DPI Capaldi, K Sheikh, S Svenningsen, M Kirby, HO Coxson, DG McCormack, G 
Parraga.  Measurement of Asthma Treatment Response using Free-breathing 1H 
Ventilation MRI.  American Thoracic Society Annual Scientific Meeting 2016 San 
Francisco, California May 13-18, 2016. 
 
10. B Yaremko, DA Palma, G Parraga, DPI Capaldi, K Sheikh, G Rodrigues, AR Dar, AV 
Louie, E Yu, S Gaede, D Hoover, Functional Lung Avoidance Radiation Therapy for Stage 
III Non-Small Cell Lung Cancer: A Double-Blind Randomized Phase 2 Trial.  American 
Society for Radiation Oncology Annual Scientific Meeting 2015 San Antonio, Texas 
October 18-21, 2015. 
 
11. K Sheikh, A Ouriadov, F Guo, DPI Capaldi, DG McCormack, G Parraga. Structure-
Function Magnetic Resonance Imaging of Bronchopulmonary Dysplasia as an alternative 
to pulmonary CT. International Workshop for Pulmonary Functional Imaging Edinburgh, 
United Kingdom September 28-30, 2015. 
 
12. DPI Capaldi, K Sheikh, DA Hoover, DA Palma, BP Yaremko, G Parraga. Fourier-
decomposition Pulmonary Magnetic Resonance Imaging Ventilation and Perfusion 
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Defects in Non-Small Cell Lung Cancer Patients prior to Radiotherapy: Comparison with 
3He Ventilation Defects and Smoking History. International Workshop for Pulmonary 
Functional Imaging Edinburgh, United Kingdom September 28-30, 2015. 
 
13. DPI Capaldi, K Sheikh, S Svenningsen, D Pike, D McCormack, G Parraga. MRI 
Measurements of Regional Ventilation Heterogeneity: Ventilation Defect Clusters. 
International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto, Canada 
June 1-5, 2015. 
 
14. DPI Capaldi, N Zha, D Pike, K Sheikh, D McCormack, G Parraga. 3He MRI and CT 
Parametric Response Mapping of Small Airways Disease: The Battle-Ground for Ground 
Truth. International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto, 
Canada June 1-5, 2015.  
 
15. GA Paulin, A Ouriadov, K Sheikh, DG McCormack, G Parraga. What can multiple b-
value 3He MRI tell us about lung micro-structure in healthy elderly never-smokers? 
International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto, Canada 
June 1-5, 2015. 
 
16. K Sheikh, DPI Capaldi, S Svenningsen, DG McCormack, G Parraga. Ultra-short Echo 
Time MRI Measurements of Emphysema using Principal Component Analysis. 
International Society of Magnetic Resonance in Medicine Meeting 2015, Toronto, Canada 
June 1-5, 2015. 
 
17. GA Paulin, K Sheikh, DG McCormack, G Parraga. Differences in Pulmonary Structure 
and Function in Healthy Elderly Never-smokers after Two Years. American Thoracic 
Society Annual Scientific Meeting 2015, Denver, Colorado May 16-20 2015. 
 
18. E Bluemke, S Svenningsen, K Sheikh, GA Paulin, DG McCormack, G Parraga.  
Relationship of Ventilation Heterogeneity in the Conducting and Acinar Airway Zones 
with 3He MRI in Elderly Never-Smokers. American Thoracic Society Annual Scientific 
Meeting 2015, Denver, Colorado May 16-20 2015. 
 
19. S Svenningsen, DPI Capaldi, E Bluemke, GA Paulin, C Davis, K Sheikh, DG McCormack, 
G Parraga.  Lung Clearance Index and Hyperpolarized 3He MRI Ventilation Heterogeneity 
Measurements in non-CF Bronchiectasis and COPD. American Thoracic Society Annual 
Scientific Meeting 2015, Denver, Colorado May 16-20 2015. 
 
20. K Sheikh, GA Paulin, S Svenningsen, DG McCormack, JA Neder, G Parraga. How do 
Exercise Responses Relate to 3He Magnetic Resonance Imaging Apparent Diffusion 
Coefficients in Older Never-Smokers? American Thoracic Society Annual Scientific 
Meeting 2015, Denver, Colorado May 16-20 2015. 
 
21. DPI Capaldi, K Sheikh, GA Paulin, S Svenningsen, HO Coxson, DG McCormack, G 
Parraga. Conventional non-contrast MRI of Ventilation Abnormalities in Bronchiectasis: 
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New Tools and Measurements for an Old Disease. American Thoracic Society Annual 
Scientific Meeting 2014, San Diego, California May 17-21 2015. 
 
22. W Ma, K Sheikh, D Pike, S Svenningsen, HO Coxson, DG McCormack, G Parraga.  
Conventional Pulmonary MRI and CT of Bronchiectasis and Emphysema: Tissue density 
measurements and relationship to pulmonary function tests. American Thoracic Society 
Annual Scientific Meeting 2014, San Diego, California May 17-21 2015. 
 
23. K Sheikh, W Ma, F Guo, S Svenningsen, TM Peters, HO Coxson, DG McCormack,  R 
Etemad-Rezai, G Parraga. Two Dimensional Radial Pulmonary Ultra-short time 1H MRI: 
Reproducibility in COPD and Bronchiectasis. International Society of Magnetic 
Resonance in Medicine Meeting 2014, Milan, Italy May 10-16, 2014. 
 
24. DPI Capaldi, F Guo, S Svenningsen, W Ma, K Sheikh, R Etemad-Rezai, J Leipsic,  HO 
Coxson, DG McCormack, G Parraga. Comparison of Pulmonary 1H non-contrast and 
Hyperpolarized 3He MRI Ventilation Abnormalities in Bronchiectasis and COPD. 
International Society of Magnetic Resonance in Medicine Meeting 2014, Milan, Italy May 
10-16, 2014. 
 
25. W Ma, K Sheikh, J Leipsic, HO Coxson, DG McCormack, R Etemad-Rezai, G Parraga. 
Pulmonary Ultra-short Echo-time (UTE) Two-dimensional Radial Acquisition with 
Compressed Sensing: Preliminary Quantitative Results with Comparison to Thoracic CT. 
International Society of Magnetic Resonance in Medicine Meeting 2014, Milan, Italy May 
10-16, 2014. 
 
26. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM Paterson, HO 
Coxson, DG McCormack, G Parraga.  Airways Disease in Asymptomatic Ex-smokers 
without Airflow Limitation: Relationship to Carotid Atherosclerosis.  American Thoracic 
Society Annual Scientific Meeting 2013, Philadelphia, Pennsylvania May 18-22, 2013. 
 
27. K Sheikh, S Svenningsen, M Kirby, NAM Paterson, A Wheatley, DG McCormack, G 
Parraga.  What is the Relationship between Hyperpolarized 3He MRI Measurements, 
Airborne Toxin Exposure, and Exercise Capacity in Healthy Elderly Never-Smokers?  
American Thoracic Society Annual Scientific Meeting 2013, Philadelphia, Pennsylvania 
May 18-22, 2013. 
 
28. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga. Hyperpolarized 3He MRI 
Ventilation Defects in Healthy Elderly Never-Smokers: Response to Deep Inspiration and 
Salbutamol. American Thoracic Society Annual Scientific Meeting 2013, Philadelphia, 
Pennsylvania May 18-22, 2013. 
 
29. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga.  Hyperpolarized 3He 
Magnetic Resonance Imaging ADC Gradients in Healthy Elderly Never-Smokers. 
International Society of Magnetic Resonance in Medicine Meeting 2013, Salt Lake City, 
Utah April 20-26, 2013. 
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C. Peer Reviewed Oral Presentations (12)  
 
1. K Sheikh, DPI Capaldi, DA Hoover, DA Palma, BP Yaremko, G Parraga, Pulmonary 
Functional imaging Biomarkers of NSCLC to Guide and Optimize Functional Lung 
Avoidance Radiotherapy. American Association of Physicists in Medicine Annual Meeting 
2016 Washington, District of Columbia, (08/16). 
 
2. K Sheikh, F Guo, A Ouriadov, DPI Capaldi, S Svenningsen, M Kirby, DG McCormack, 
HO Coxson, G Parraga, Ventilation Estimates in Severe Uncontrolled Asthma using 3D 
Single breath-hold Ultra-short Echo Time MRI.  International Society of Magnetic 
Resonance in Medicine Annual Scientific Meeting 2016 Singapore, Singapore (05/16) 
 
3. K Sheikh, F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG McCormack, 
G Parraga, What does Magnetic Resonance Imaging Signal-Intensity mean in Asthma?  
American Thoracic Society Annual Scientific Meeting 2016 San Francisco, California 
(05/16). 
 
4. RL Eddy, D Pike, K Sheikh, GA Paulin, M Kirby, DG McCormack, G Parraga, Testing 
the Fletcher-Peto Assumptions using Pulmonary Imaging Biomarker Longitudinal 
Measurements.  American Thoracic Society Annual Scientific Meeting 2016 San 
Francisco, California (05/16).  
 
5. DPI Capaldi, K Sheikh, S Svenningsen, M Kirby, HO Coxson, DG McCormack, G 
Parraga.  Measurement of Asthma Treatment Response using Free-breathing 1H 
Ventilation MRI.  American Thoracic Society Annual Scientific Meeting 2016 San 
Francisco, California May (05/16).  
 
6. K Sheikh, F Guo, S Svenningsen, A Ouriadov, DPI Capaldi, RL Eddy, DG McCormack, 
G Parraga, What does Magnetic Resonance Imaging Signal-Intensity mean in Asthma?  
London Health Research Day (Top 32), London, Ontario (03/16). 
 
7. B Yaremko, DA Palma, G Parraga, DPI Capaldi, K Sheikh, G Rodrigues, AR Dar, AV 
Louie, E Yu, S Gaede, D Hoover, Functional Lung Avoidance Radiation Therapy for Stage 
III Non-Small Cell Lung Cancer: A Double-Blind Randomized Phase 2 Trial.  American 
Society for Radiation Oncology Annual Scientific Meeting 2015, San Antonio, Texas 
(10/15). 
 
8. DPI Capaldi, N Zha, D Pike, K Sheikh, D McCormack, G Parraga. 3He MRI and CT 
Parametric Response Mapping of Small Airways Disease: The Battle-Ground for Ground 
Truth. International Society of Magnetic Resonance in Medicine Annual Scientific 
Meeting, Toronto, Canada (05/15). 
 
9. K Sheikh, GA Paulin, S Svenningsen, DG McCormack, JA Neder, G Parraga. How do 
Exercise Responses Relate to 3He Magnetic Resonance Imaging Apparent Diffusion 
Coefficients in Older Never-Smokers? Imaging Network of Ontario Symposium, Toronto, 
Canada (03/15). 
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10. DPI Capaldi, K Sheikh, F Guo, S Svenningsen, DG McCormack, G Parraga. Fourier-
decomposition Pulmonary Magnetic Resonance Imaging Ventilation Defects in Ex-
smokers: Relationship to Emphysema and 3He ventilation defects. Radiological Society of 
North America Conference, Chicago, Illinois (12/14). 
 
11. W Ma, K Sheikh, J Leipsic, HO Coxson, DG McCormack, R Etemad-Rezai, G Parraga. 
Pulmonary Ultra-short Echo-time (UTE) Two-dimensional Radial Acquisition with 
Compressed Sensing: Preliminary Quantitative Results with Comparison to Thoracic CT. 
Imaging Network Ontario Symposium, Toronto, Canada (03/14). 
 
12. K Sheikh, S Svenningsen, M Kirby, D.G. McCormack, G Parraga. Hyperpolarized 3He 
MRI Ventilation Defects in Healthy Elderly Never-Smokers: Response to Deep Inspiration 
and Salbutamol. Imaging Network Ontario Symposium, Toronto, Canada (02/13). 
 
D. Peer Reviewed Poster Presentations (23)  
 
1. DPI Capaldi, A Lausch, K Sheikh, F Guo, DG McCormack, G Parraga, Pulmonary 
Imaging Biomarkers of COPD for Personalized Treatment and Better Outcomes.  
International Society of Magnetic Resonance in Medicine Annual Scientific Meeting 2016 
Singapore, Singapore May 7-13, 2016. (Accepted February 1, 2016) 
 
2. F Guo, K Sheikh, RL Eddy, DPI Capaldi, DG McCormack, A Fenster, G Parraga, A 
Segmentation Pipeline for Measuring Pulmonary Ventilation Suitable for Clinical 
Workflows and Decision-making.  International Society of Magnetic Resonance in 
Medicine Annual Scientific Meeting 2016 Singapore, Singapore May 7-13, 2016. 
(Accepted February 1, 2016) 
 
3. M Fennema, DPI Capaldi, K Sheikh, S Svenningsen, RL Eddy, C Licskai, DG 
McCormack, G Parraga, The Abnormal Airways that Dominate Asthma Attack: New clues 
using ventilation MRI during Exercise- and Methacholine-Challenge. American Thoracic 
Society Annual Scientific Meeting 2016 San Francisco, California May 13-18, 2016. 
(Accepted January 20, 2016) 
 
4. K Sheikh, A Ouriadov, F Guo, DPI Capaldi, DG McCormack, G Parraga. Structure-
Function Magnetic Resonance Imaging of Bronchopulmonary Dysplasia as an alternative 
to pulmonary CT. International Workshop for Pulmonary Functional Imaging Edinburgh, 
United Kingdom (09/15). 
 
5. DPI Capaldi, K Sheikh, S Svenningsen, D Pike, D McCormack, G Parraga. MRI 
Measurements of Regional Ventilation Heterogeneity: Ventilation Defect Clusters. 
International Society of Magnetic Resonance in Medicine 2015, Toronto, Canada (05/15). 
 
6. GA Paulin, A Ouriadov, K Sheikh, DG McCormack, G Parraga. What can multiple b-
value 3He MRI tell us about lung micro-structure in healthy elderly never-smokers? 
International Society for Magnetic Resonance in Medicine 2015, Toronto, Canada (05/15). 
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American Thoracic Society Annual Scientific Meeting (05/13). 
 
18. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga. Hyperpolarized 3He MRI 
Ventilation Defects in Healthy Elderly Never-Smokers: Response to Deep Inspiration and 
Salbutamol. American Thoracic Society Annual Scientific Meeting (05/13). 
 
19. K Sheikh, S Svenningsen, M Kirby, DG McCormack, G Parraga.  Hyperpolarized 3He 
Magnetic Resonance Imaging ADC Gradients in Healthy Elderly Never-Smokers. The 
International Society for Magnetic Resonance in Medicine (04/13). 
 
20. K Sheikh, S Svenningsen, M Kirby, NAM Paterson, A Wheatley, DG McCormack, G 
Parraga.  Relationship between Hyperpolarized 3He MRI Measurements and Exercise 
Capacity in Healthy Elderly.  Imaging Network Ontario Symposium (02/13). 
 
21. D Pike, M Kirby, K Sheikh, D Buchanan, C Neron, JD Spence, NAM Paterson, HO 
Coxson, DG McCormack, G Parraga.  Airways Disease in Asymptomatic Ex-smokers 
without Airflow Limitation: Relationship to Carotid Atherosclerosis.  American Thoracic 
Society (05/13). 
 
22. K Sheikh, A Daabous, R Putnam, SJ Rehse. Chemometric Data Analysis Strategies for 
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